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CHAPTER 1
________________________________________________________________
Introduction and aim of this thesis
bw-de hooge\50  30-08-2004  15:44  Pagina 7
1.1 Rheumatoid arthritis and osteoarthritis
1.1.1 Rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic and chronic inflammatory disease that affects
multiple joints. Approximately 1% of the population will develop RA. Although the dis-
ease itself is not lethal, RA patients have a lower quality of life and also a lower life
expectancy1. Patients suffer from painful, swollen joints and can become disabled by
destruction of the articular bone and cartilage. In the chronic phase of RA relatively quiet
periods alternate with flare-ups of the disease. 
Normal joints are encapsulated by the synovial lining (see figure 1). This thin layer
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Figure 1 Normal and arthritic joint. During arthritis inflammatory cells enter the joint. These cells
(black dots) are present in the joint cavity as an inflammatory exudate and infiltrate the synovium.
The synovium furthermore thickens by hypertrophy and hyperplasia of the synovial cells. These syn-
ovial changes can lead to the formation of an erosive pannus tissue that can destroy the articular car-
tilage (shown in right figure).
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consists of the so-called synoviocytes, macrophages and fibroblasts-like cells. During RA,
the lining becomes thickened by hypertrophy and hyperplasia of the synovial cells and by
infiltration with inflammatory cells. These changes in the lining can lead to the forma-
tion of pannus: a vascularized granulation tissue that is rich in fibroblasts, lymphocytes
and macrophages. The pannus overgrows the weight-bearing surface of the joint and can
finally contribute to destruction of the articular surface (see figure 1). Besides inflamma-
tory infiltration of the lining, also an exudate of inflammatory cells can be found in the
joint cavity.
The exact cause of RA is still unknown, but it is generally believed to be an autoim-
mune disease. During the last decades there has been much debate on which cell type is
primarily responsible for the joint inflammation and destruction in RA. The presence of
T cells in the rheumatoid synovium and the linkage of RA to certain MHC class II mol-
ecules have suggested involvement of T cells (reviewed in2). The last years, involvement
of other cell types has come into focus. Involvement of activated macrophages and
fibroblast-like synoviocytes in perpetuation of inflammation and development of joint
destruction has been implicated3;4. Involvement of B cells came into focus again after
development of the KRxN model. Mice that express the transgene encoded KRN T cell
receptor and the IAg7 MHC class II allele develop spontaneous arthritis5. These trans-
genic T cells can respond to IAg7 MHC class II molecules that are loaded with a peptide
fragment from the ubiquitous glucose-6-phosphate isomerase (GPI). Transfer of anti-
bodies against GPI could induce arthritis in recipient mice6. Transfer of these antibodies
to mast cell deficient mice did not induce arthritis suggesting involvement of mast cells
in development of arthritis7. In a systemic and complex disease like RA, however, more
than one cell type might be responsible for initiating the disease.
Cytokines are proteins that play an important role in the communication between cells.
Cytokine stimulation of cells can influence their growth, metabolism or gene expression.
In this way cytokines seem to play an important role in RA (reviewed in8). The inflamed
synovium is a rich source of pro-inflammatory cytokines and other pro-inflammatory and
destructive mediators like chemokines and matrix-metalloproteases. IL-1 and TNF-α have
been found to be key pro-inflammatory cytokines in RA. The role of both cytokines has
been extensively studied in animal RA models9-11 and inhibitory therapies against IL-1 and
TNF-α have made it to the clinic12;13. The immuno-modulatory effects of long-term sys-
temic inhibition of cytokines like TNF-α, however, can have its drawbacks as shown by the
development of infections after anti- TNF-α therapy14. Not only pro-inflammatory and
destructive, but also anti-inflammatory cytokines are produced in inflamed joints.
Cytokines can even have both pro- as well as anti-inflammatory effects depending on the
Introduction and aim 9
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cell type that is stimulated. The balance between these pro- and anti-inflammatory signals
could therefore contribute to the final outcome in RA.
Another cytokine that is highly produced in inflamed joints of RA patients is
Interleukin-6 (IL-6)15. Just as for IL-1 and TNF-α, blocking therapies have been devel-
oped against IL-6 and the first clinical data show beneficial effects of anti-IL-6 therapy16.
A more extensive introduction on IL-6 and its role in RA is given in section 1.2 as it is
the focus of this thesis.
1.1.2 Osteoarthritis
Osteoarthritis (OA) is the most common of all joint disorders. Its incidence increases
with age and in people over 60 years old 60 percent have OA in one or more joints. The
loss of joint function that accompanies OA makes it a disabling disease. The cause of OA
is not known but several mechanisms could be involved17;18. Genetic alterations that are
found in extracellular matrix components could impair the normal strength and func-
tion of the cartilage. These mutations also suggest that OA has a large genetic compo-
nent17. Also biomechanical overloading or an imbalance in synovial homeostasis could
contribute to its etiology.
The disease is characterized by breakdown of the cartilage matrix followed by devel-
opment of fibrillations, fissures and finally complete loss of articular cartilage.  Besides
the articular cartilage, also the subchondral bone is involved. Thickening of the sub-
chondral bone occurs in OA, leading to increased stiffness and reduced shock absorbing
capacity of the bone. Whether changes in the bone cause cartilage pathology or are a con-
sequence of it is still a matter of debate19. Another complication related to bone is the
formation of osteophytes in OA joints.
A third component of the joint that could be involved is the synovial lining. Joint
inflammation can occur in OA, although it is less prominent than in RA. Production of
proteases and other destructive mediators by the inflamed synovial lining could con-
tribute to OA pathology.
The production of both anabolic and catabolic factors like cytokines and growth fac-
tors by the articular chondrocytes and synovial lining cells could contribute to the coex-
istense of repair and destructive processes in OA joints (reviewed in20;21). Anabolic fac-
tors include TGFβ and the bone morphogenetic proteins. Catabolic factors that are pro-
duced in the joint include IL-1 and TNFα. The balance between anabolic factors, cata-
bolic factors and their inhibitors could therefore contribute to the final outcome in OA. 
10 CHAPTER 1
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1.2 Interleukin-6
1.2.1 IL-6 family members, their receptors and signal transduction
Interleukin-6 (IL-6) is a 26 kd protein that gives its name to the IL-6 cytokine family.
Also Oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1),
ciliary neurotrophic factor (CNTF), IL-1122;23 and the recently described neurotrophin-
1/ B cell stimulating factor-324 belong to this family. These cytokines share a similar 3-
dimensional structure, can display functional redundancy and stimulate cells through
receptor complexes that have the receptor glycoprotein130 (gp130) in common
(reviewed in23;25). 
The receptor complex for the IL-6 family members consists of gp130 and at least one
other receptor (Table I) (reviewed in25;26). Homo- or heterodimerization of gp130 is
necessary for inducing signal transduction. The fact that all IL-6 family members contain
gp130 in their receptor complex could at least partly explain the functional redundancy
that is observed for these cytokines. Signal transduction by IL-6 starts with binding of 
IL-6 to gp80, the IL-6 specific receptor. GP80 does not induce signal transduction by
itself but instead binds together with IL-6 to the gp130 receptor. Subsequently, a hexam-
eric complex of two IL-6, gp80 and gp130 molecules is formed 27 and signaling proceeds
in the cell. 
Not only a membrane-bound form of gp80 exists but also two soluble forms. These can
be generated either by differential splicing28 or by shedding29. In contrast to most solu-
ble receptors does the soluble gp80 function as an agonistic instead as an antagonistic
Table I Receptor complexes of the IL-6 family
The IL-6 family members and their receptors can be divided in two groups. IL-6 and IL-11 only use
GP130 for their signal transduction. Receptor complexes for the other members contain a second
receptor that can give signal transduction, the LIF receptor. Leukemia Inhibitory Factor (LIF),
Oncostatin M (OSM), Ciliary Neurotrophic Factor (CNTF), Cardiotrophin-1 (CT-1), Cardiotrophin-
like cytokine/novel neurotrophin-1 (CLC/NN-1), receptor (R). Based on Bravo and Heath, 2000 26.
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Only GP130 as signaling receptor GP130 and LIFR as signaling receptor
Cytokine Receptor complex Cytokine Receptor complex
IL-6 GP130/GP80 LIF GP130/LIFR
IL-11 GP130/IL-11R OSM GP130/OSMR or LIFR
CNTF GP130/LIFR/CNTFR
CT-1 GP130/LIFR
CLC/NN-1 GP130/LIFR
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receptor. Cells that express gp130, but not membrane-bound gp80, can still respond to
IL-6 in the presence of soluble gp80. In this way the range of cells that can respond to IL-
6 is greatly expanded.
An important pathway for signal transduction of the IL-6 family members is the Janus
Kinase/ Signal Transducer and Activator of Transcription (JAK/STAT) pathway
(reviewed in30). JAK family tyrosine kinases are associated intracellularly with gp130 and
become transphosphorylated in response to binding of the cytokine to the receptor com-
plex. The activated JAKs, in turn, phosphorylate specific tyrosine residues in gp130,
thereby creating docking sites for STAT proteins. STATs are transcription factors that are
present in the cytoplasm in a latent state. They can bind to the phosphorylated STAT
12 CHAPTER 1
Figure 2 JAK/STAT signaling by IL-6. Upon binding of IL-6 to the gp 80/gp130 receptor complex the
GP 130 becomes phosphorylated by Jak kinases. STAT 1 or STAT 3 molecules that are present in the
cytoplasm are recruited to the activated GP 130 and become themselves phosphorylated by the JAK
kinase. Two activated STAT molecules form a homo- or heterodimer (STAT 3/3, STAT 3/1, STAT
1/1) and translocate to the nucleus. In the nucleus they start transcription of STAT responsive genes.
Based on Levy and Darnell (2002)30.
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docking sites and become themselves phosphorylated on specific tyrosine residues by the
JAKs. The activated STATs form homo- or heterodimers that translocate to the nucleus
where they start transcription of STAT responsive genes. Figure 2 illustrates the
JAK/STAT signaling as it is induced by IL-6. In addition to tyrosine phosphorylation,
STAT1 and STAT3 can also become phosphorylated on a serine residue and this could
increase the transcriptional activity31.
JAK1 is the main JAK kinase that is involved in signaling by IL-632. STAT3 is the main
STAT protein that becomes activated but also STAT1 can become activated in response
to IL-625;33. Therefore not only STAT3/STAT3 homodimers but also STAT3/STAT1 het-
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Figure 3 Regulation of JAK/STAT signaling. There are different ways to control and terminate signal-
ing by the JAK/STAT pathway. Phosphatases can remove phosphate groups from GP 130 or from acti-
vated STAT proteins. In this way phosphatases can deactivate GP 130 or STAT proteins (1 and 5).
SOCS proteins can inhibit signaling by binding to the JAK or to STAT-bindingsites on GP 130 (2 and
3). PIAS proteins can interact with STAT homo- or heterodimers and prevent them for binding to the
DNA (4).  Naturally occurring short forms of STAT proteins can act as dominant negative regulators
by forming inactive dimers with full-length STATs (6). Based on Levy and Darnell (2002)30.
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erodimers or STAT1/STAT1 homodimers can be found in IL-6 stimulated cells. Pivotal
roles for STAT3 in the regulation of cell growth, differentiation and survival have been
found (reviewed in25;30). STAT1 in contrast is more linked to growth control and apop-
tosis (reviewed in34). STAT5 activation in response to IL-6 has also been reported35 but
its role in the biological effects of IL-6 has been less well studied compared to STAT3 and
STAT1. 
There exist several ways to control signaling by the JAK/STAT pathway (figure 3). In
this way, negative effects of prolonged STAT-induced gene expression are prevented
(reviewed in30;36). Cytoplasmic tyrosine phosphatases dephosphorylate receptors or
kinases and prevent further signaling. Naturally occurring truncated STATs can act as
dominant-negative regulators of the full-length STATs and prevent, upon binding to a
full-length STAT, the formation of a functional dimer. Another class of inhibitors con-
sists of the Protein Inhibitor of Activated STAT (PIAS) proteins. They block transcrip-
tional activity of STAT dimers in the nucleus. Activated STATs induce expression of
members of the Suppressor of Cytokine Signaling (SOCS) protein family. Until now 8
members of this family (SOCS1-7 and CIS1) have been described37. These proteins
either inhibit the JAK kinase or mask STAT docking sites on the receptor. In this way, a
negative feedback loop is created.
IL-6 family members can, besides by the JAK/STAT pathway, also signal through the
RAS-MAP kinase pathway25. Upon receptor stimulation tyrosine residue 759 of GP130
becomes phosphorylated. This residue is the binding site for the src homology 2 domain-
bearing protein tyrosine phosphatase (SHP)-2. This SHP-2 in turn becomes activated
and leads to activation of the RAS-MAP kinase pathway. Subsequent ERK activation has
been suggested to play a negative regulatory role in STAT3 signal transduction38.
Several groups have made mice with mutations in the GP130 receptor that affect
either the JAK-STAT or RAS-MAP kinase pathway. Ernst et al39 made a mutant mouse
with a truncated GP130 (GP130∆STAT/∆STAT). GP130 induced STAT activation but not
SHP-2/RAS/ERK activation was inhibited in these mice. These mice showed a reduced
humoral and mucosal immune response and a reduced acute phase response in the liver.
They also developed gastrointestinal ulcerations and severe joint disease. IL-6 induced
SOCS1 mRNA expression was almost completely absent in GP130∆STAT/∆STAT livers and
synovial cells. SOCS3 mRNA expression was also reduced. These results led to the con-
clusion that the joint disease was a consequence from the disturbance of the balance
between GP130 induced JAK/STAT and SHP-2/RAS/ERK signaling.
Researchers from the Hirano laboratory obtained contrasting results. Both STAT3 sig-
nal-deficient (GP130FXXQ/FXXQ) and GP130 deficient (GP130D/D) mice died perinatally.
14 CHAPTER 1
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Mice with a mutated Tyr-759 residue (GP130F759/F759) are born normal but develop
splenomegaly, lymphadenopathy and show an enhanced acute phase response 40. An
increased GP130 mediated STAT3 activation was observed in these mice. They further-
more found evidence that STAT3 signaling directed T cell development towards the Th1
type. SHP-2 mediated signaling in contrast seemed involved in Th2 development. When
the GP130F759/F759 mice grow older they develop joint disease in an autoimmune manner
that involves T cell immunity41. This was linked to augmented STAT3 activation. In con-
trast to the mice by Ernst et al.39 do these mice only have a point mutation in GP130 and
not a large deletion. How this deletion affects the signaling by GP130 and if this could
explain the opposite results of Ernst et al. and Atsumi et al.41 is not completely clear. 
Negative regulation by SOCS proteins could also be involved in the GP130F759/F759
mice. Tyr-759 of GP130 is also the binding site for SOCS342;43. SOCS3 mRNA expres-
sion was enhanced in the GP130F759/F759 mice. Inhibition of STAT3 activation, howev-
er, was not possible because of the Tyr-759 mutation. Reduced STAT3 inhibition by
SOCS3 could therefore be involved in the observed phenotype of GP130F759/F759 mice.
An alternative possibility is that the enhanced expression of SOCS3 leads to interference
with signaling pathways other than the GP130 induced signaling.
The results with the GP130 mutant mice demonstrate the complexity of establishing
the in vivo role of the GP130 induced signaling pathways. They furthermore point at an
important role for negative regulators like the SOCS proteins in determining the effects
of cytokine signaling. The final outcome of IL-6 induced signaling in a given cell might
be determined by the expression of the involved signaling molecules and their inhibitors.
Furthermore, cross talk between different signaling pathways generated by IL-6 or by
other cytokines can either positively or negatively influence the final outcome of stimu-
lation in a given cell type40;44;45.
1.2.2 IL-6 and inflammation 
IL-6 was originally named B-cell stimulatory factor 2 because of its ability to induce B
cells to produce immunoglobulins46. A variety of cells have been shown to produce IL-
6. This includes T and B cells, monocytes, endothelial cells and different tumor cells22.
Since its discovery as a B cell stimulatory factor, IL-6 has been shown to be a pleiotropic
cytokine with a wide range of biological activities. After in vivo administration, leukocy-
tosis and fever are induced by IL-647;48. IL-6 plays an important role in the maturation
of B cells into antibody secreting plasma cells 46, the differentiation of osteoclasts49 and
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macrophages50, and it has a co-stimulatory role in T cell activation51;52. In vitro, IL-6
could rescue resting mouse T cells from apoptosis pointing at an important role for IL-
6 in T cell survival53. The effect of IL-6 on T cell differentiation has been controversial.
IL-6 has been described as an inducer of Th2 differentiation54. Other researchers, in con-
trast, found augmentation of naive, Th1 and Th2 effector CD4 T cell responses by IL-6
but no induction of Th2 differentiation55. Furthermore, IL-6 plays a role in differentia-
tion and activity of cytotoxic T cells56;57 and potentiates the activity of natural killer
cells58. The influence of IL-6 on T and B cell activity can contribute to a good host
response against bacterial and viral infections. 
Not only pro-inflammatory, but also anti-inflammatory properties have been found
for IL-6. The induction by IL-6 of IL-1 receptor antagonist and soluble TNF receptor
expression has been reported59;60. Induction of this IL-1 respectively TNF-α inhibitor
could down regulate inflammation and reduce tissue damage due to inflammation. IL-6
also can reduce TNF-α production61. IL-6 plays an important role in generating an acute-
phase response in the liver62-64. During this response acute phase proteins are produced
that are thought to participate in the defense against tissue damage and infection.
The dual face of IL-6 as a pro- and anti-inflammatory protein is also reflected by stud-
ies in IL-6 gene knock out (IL-6-/-) mice. IL-6-/- mice are viable and develop normally65.
They fail, however, to mount a good immune response against vaccinia, Listeria mono-
cytogenes65 and Candida albicans infections66. Furthermore, the inflammatory acute-
phase response after tissue damage or infection was severely compromised65;67. The local
inflammatory response against turpentine was impaired in IL-6-/- mice while systemic
inflammatory reactions on LPS were not67. Xing et al.68 in contrast found increased
inflammatory reactions in endotoxic lung or during endotoxemia in IL-6-/- mice and
proposed an anti-inflammatory role for IL-6 during acute infection. Similarly, enhanced
inflammation was found in experimental pancreatitis induced in IL-6-/- mice69.
Together these results demonstrate that the effect of IL-6 deficiency at least partly
depends on the localization and type of inflammatory stimuli. 
1.2.3 IL-6 and arthritis
Increased levels of IL-6 have been found in serum and synovial fluid of RA patients.
Especially in the synovial fluid several 1000 pg/ml of IL-6 can be measured15;70 and syn-
ovial fluid levels correlated with clinical parameters of inflammation71. Also in systemic
Juvenile Idiopathic Arthritis are the serum and synovial fluid levels of IL-6 significantly
16 CHAPTER 1
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enhanced72. Many cell types, including T and B cells, fibroblasts, macrophages and chon-
drocytes can produce IL-670;73. There have been significant correlations found between
serum levels of IL-6 and acute phase proteins74 and between synovial IL-6, IgG and
Rheumatoid Factor levels75;76. The positive role of IL-6 in developing antibody-secreting
plasma cells could contribute to the latter correlation.
Through its role in activation and survival of T cells, IL-6 could contribute to T cell
activity in RA and other autoimmune diseases. Anti-IL-6 receptor antibodies induced
apoptosis of T cells in a murine colitis model and ameliorated this disease77. IL-6 could
also contribute to development of auto-immunity in other ways. High IL-6 levels can
lead to the processing and presentation of cryptic epitopes by dendritic cells78. In this
way IL-6 might contribute to development of T cell immunity against self-antigens.
Recently, IL-6 was found to play a major role in the control of T regulatory cells79. High
IL-6 concentrations could inhibit T regulatory cells and this might contribute to the gen-
eration of auto-reactive T cell immunity.
Other cell types in the joint, besides T and B cells, could be influenced by IL-6. The
combination of IL-6 and the soluble IL-6 receptor can activate endothelial cells and
hence stimulate the inflammatory response of these cells80. IL-6 has also been reported
to induce synovial fibroblast proliferation81;82 but the opposite result, inhibition, has
also been found83. The combination of IL-6 with its soluble receptor can induce osteo-
clast formation49;84 and, in this way, IL-6 could contribute to bone erosion in RA.
IL-6 could not only have negative but also positive effects for RA as is shown in table II.
Induction of IL-1 receptor antagonist and soluble TNF receptor expression by IL-6 59;60
could downregulate the inflammatory and destructive effects of IL-1 and TNF-α. Several
reports suggest a protective role for IL-6 in cartilage pathology. In our laboratory we have
found increased cartilage proteoglycan depletion in IL-6 deficient mice in the early phase
of zymosan-induced arthritis (ZIA)85. During this phase inflammation did not differ
Table II The negative and positive roles that IL-6 could play during RA.
Negative and positive properties that have been described for IL-6 and that make its role in RA unclear.
For references see 1.2.2 and 1.2.3.
Introduction and aim 17
Negative role by Positive role by
Maturation plasma cells Induction IL-1 Ra
Activation and survival T cells Induction soluble TNF receptor
Differentiation T cells Induction TIMP’s
Differentiation osteoclasts Reduction TNF production
Systemic acute phase response Local acute phase response
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between wildtype and IL-6 deficient mice. Intra-articular injection of IL-6 ameliorated
the cartilage destruction in IL-6 deficient mice. Addition of IL-6 to human chondrocytes
induced expression of the proteinase inhibitor α1-antitrypsin suggesting induction of a
protective acute phase response in these cells86. Murine anti-human IL-6 antibodies
showed a transient clinical improvement in RA patients87. Surprisingly, serum IL-6 lev-
els increased in these patients making it unclear what exactly caused the improvement.
The exact role of IL-6 in RA therefore needs to be investigated further as well as the pos-
sibility to separate the positive from the negative effects of IL-6 in joint pathology.
1.2.4 IL-6 and osteoarthritis
Increased expression of IL-6 in the joint is not only found in RA but also in OA. IL-6 pro-
duction has been found in chondrocytes from OA cartilage and IL-1 was found to be an
important inducer of IL-6 in these cells88. The exact function of IL-6 in OA is not clear.
Different effects of IL-6 on chondrocytes have been described. Recombinant human IL-
6 did not induce proliferation of bovine chondrocytes neither did it influence proteogly-
can production89. Proliferation and proteoglycan synthesis in rabbit articular chondro-
cytes were, however, both inhibited by human IL-690. Most likely species differences are
related to these opposing results. Guerne et al.91 have reported that the combination of
IL-6 and soluble gp80 inhibits proteoglycan synthesis in human articular chondrocytes.
Proteoglycan synthesis, however, was measured with an Elisa that detected soluble pro-
teoglycans. It can therefore not be excluded that proteoglycan breakdown but not syn-
thesis was influenced by IL-6. The induction of α1-antitrypsin86 and TIMP-192 in human
chondrocytes suggests a protective role for IL-6 against cartilage pathology.
IL-6 has also been studied in experimental or spontaneous OA models in animals.
Synovial IL-6 levels increased after naturally acquired or experimentally induced cranial
cruciate ligament rupture in dogs93. In this study lower IL-6 concentrations were found
in dogs with higher radiographic OA scores. Sectioning the anterior cruciate ligament in
dogs likewise increased IL-6 levels94. In these dogs IL-6 expression correlated positively
with increased PG synthesis.
Increased IL-6 mRNA expression was found in cartilage of C57 black mice with early
stages of spontaneous OA95. IL-6 expression, however, did not correlate with histologi-
cal changes. Male STR/ort mice develop osteoarthritic lesions of the knee joint by 35
weeks of age. In situ hybridisation studies showed increased IL-6 mRNA expression in
cartilage at the site of the lesions96. It is, however, not clear if this IL-6 expression plays
a role in developing cartilage damage in mice.
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1.3 Oncostatin M and arthritis
Oncostatin M (OSM) is a 28 kd glycoprotein that belongs to the IL-6 family97. Like the
other IL-6 family members, OSM was found to be a multifunctional cytokine. OSM can for
example stimulate an acute-phase response in liver cells98 and enhance expression of tissue
inhibitor of metalloproteinase 199 and of adhesion molecules like ICAM-1100. Just as for
IL-6, both pro- and anti-inflammatory effects of OSM have been described100;101.
Elevated levels of OSM (up to several 100 pg/ml) can be detected in the synovial fluid
of RA patients and synovial macrophages are the source of this OSM102;103. Unlike its
family member IL-6, OSM was not detected in the serum of RA patients102. This suggests
a local rather than a systemic role for OSM in RA. Circumstantial evidence for a local role
is the positive correlation found between concentrations of OSM and cartilage degrada-
tion markers in synovial fluid104. Injection of recombinant human OSM in the joints of
goats induced inflammation105. Similarly, an adenoviral vector expressing murine OSM
induced joint inflammation in mice106. These results further support a local and pro-
inflammatory role for OSM in joint pathology. Recently, intraperitoneal administration
of blocking antibodies to OSM ameliorated experimental arthritis in mice107, demon-
strating a pro-inflammatory role for OSM in murine arthritis. A systemic effect of block-
ing OSM can, however, not be excluded under these experimental conditions. 
OSM is a strong inducer of IL-6 and could contribute to the local IL-6 expression in
RA. OSM furthermore has been shown to synergize with or enhance the activity of other
cytokines. OSM was the first cytokine that, in combination with IL-1β, could induce col-
lagen release from human cartilage103. A similar synergy in collagen breakdown was
found for the combination of OSM and IL-17 on explants of bovine nasal cartilage108.
OSM could therefore contribute to joint pathology by enhancing the effects of other pro-
inflammatory and destructive cytokines.
OSM was detected at low frequency (4/32) and at low concentrations (mean of 7.9
pg/ml) in synovial fluid of OA patients103. By in situ hybridisation, OSM mRNA was
detected in OA femoral heads109. Alone or in combination  with other cytokines, OSM
could influence cartilage and bone metabolism and integrity. It is therefore possible that
OSM contributes to OA pathology but further investigation on this is beyond the scope
of this thesis.
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Aim of this thesis
The basis for the research described in this thesis was the interesting finding that IL-6 had
a cartilage protective role during the acute phase of zymosan-induced arthritis. Although
IL-6 is generally seen as a pro-inflammatory cytokine, these results demonstrated that IL-
6 might also exert positive effects at the inflammatory site in RA patients. This ambigu-
ity on the involvement of IL-6 in RA is also reflected in the title of this research project:
Role of IL-6 in chronic arthritis: good or bad guy?  In the first part of this thesis the
good and bad roles of IL-6 will be further investigated in murine models for RA and for
osteoarthritis (OA), another major joint disease. 
Elevated levels of IL-6 have been found in synovial fluid of affected joints from OA
patients. Based on the cartilage protective role of IL-6 found in experimental arthritis
( the good guy ) we extended this study to murine models of osteoarthritis. In chapter 2,
knee joints of old wildtype (WT) and IL-6-/- mice were compared histologically for signs
of OA-like pathology. Old IL-6-/- male mice showed a higher incidence of major OA-like
changes as proteoglycan deposition and bone formation in the ligaments and complete
cartilage erosion. Cartilage PG production and breakdown were reduced in old IL-6-/-
male mice compared to old WT mice. Similar to its protective role in experimental RA,
these results suggest a protective role against connective tissue damage for IL-6 in OA.
IL-6 is seen as a bad guy  in RA because of its pro-inflammatory properties. The
influence of IL-6 on development of immunity is well known. IL-6 could therefore play
a role in development of auto-immunity during RA. The pro-inflammatory role of IL-6
could, however, not only rely on immune development because IL-6 can also directly
stimulate resident cells of the synovium like synovial fibroblasts and endothelial cells.
Previous studies showed reduced cellular and humoral immunity in IL-6-/- mice during
experimental arthritis but failed to discriminate between immune and non-immune
effects of IL-6. In chapter 3 the role of immune and non-immune mechanisms in the
pro-inflammatory properties of IL-6 is investigated. WT and IL-6-/- mice were compared
in different arthritis models: antigen-, immune-complex - and zymosan-induced arthri-
tis. These experiments confirmed the importance of IL-6 for development of antigen-
specific humoral and cellular immunity. However, transfer of WT lymphocytes to 
IL-6-/- mice could enhance the acute inflammatory phase of the AIA but did not lead to
a chronic arthritis in these mice. Similarly, IL-6-/- mice developed an acute inflammation
during the ZIA but failed to develop into a chronic synovitis. Together these results indi-
cate an important role for IL-6 in propagation of joint inflammation, potentially inde-
pendent of its role in immunity. 
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STAT proteins play an important role in the signaling by IL-6. STAT3 and, to a lesser
extend, STAT1 become activated in response to stimulation by IL-6. The relation
between STAT activation, IL-6 and development of chronic synovitis is investigated in
chapter 4. STAT3 activation in the synovial tissue occurred directly at the onset of the
arthritis and continued during the chronic phase of ZIA. This activation was IL-6 depen-
dent. STAT1 became only activated during chronic arthritis. Severe enhancement of
inflammation, but not of cartilage damage, in STAT1-/- mice suggests that STAT1-regu-
lated genes protect or control the inflammation in arthritis. STAT3 activation was not
impaired in these mice. Manipulation of the IL-6 induced signal transduction in the syn-
ovium could become a way to separate the pro-inflammatory effects of IL-6 from its car-
tilage protective properties.
In the second part of this thesis, the role of the IL-6 family member Oncostatin M (OSM)
in joint pathology was investigated. OSM is produced in inflamed joints, is a strong
inducer of IL-6 and can activate both STAT3 and STAT1. Adenoviral overexpression of
murine OSM induces joint inflammation in both WT and IL-6-/- mice as shown in chap-
ter 5. During this inflammation, the periosteum became activated and bone apposition
occurred. In vitro experiments showed that OSM enhanced the bone morphogenetic
protein-2 induced differentiation of C2C12 cells towards the osteoblastic lineage as mea-
sured by increased alkaline phosphatase activity. This suggests that enhancement of
BMP-2 induced osteoblast differentiation or activity by OSM could be a mechanism that
contributed to the observed bone apposition in vivo. 
In chapter 6 we show that OSM overexpression also leads to cartilage damage. This
cartilage damage was mediated in part by IL-1 but was not counteracted by IL-6. Also the
growth plate became affected by OSM. Expression of OSM during juvenile idiopathic
arthritis could possibly be involved in growth plate damage during this disease. We
found that OSM is expressed in most of the joints of JIA patients that we examined.
Together chapter 5 and 6 show that both OSM and IL-6 have inflammatory properties
but differ in their effects on bone and cartilage, respectively.  
In the third part of this thesis we describe a spin off from our IL-6 research. The chap-
ters 3 and 4 showed an important role for IL-6 in development of chronic arthritis.
Furthermore, IL-6 is a general marker of disease activity. In chapter 7 we describe an
inflammation-inducible adenoviral expression system based on the IL-6 promoter. This
expression system made it possible to achieve repeatable and disease-dependent gene
expression in vivo. This system was not dependent on the presence of IL-6 and might
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therefore become a useful tool to obtain disease-regulated expression of biologicals (e.g.
IL-6 inhibitors) to tackle arthritis locally by gene-therapy. 
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Abstract
Objective: Interleukin-6 (IL-6) is expressed in osteoarthritic joints but its function in
osteoarthritis (OA) is unknown. To study this, spontaneous and experimental OA were
evaluated in IL-6 deficient (IL-6-/-) mice.
Design: Histology of knees of 18-23 months old wild type (wt) and IL-6-/- mice was
compared for signs of OA. Cartilage proteoglycan (PG) density was measured by image
analysis on safranin-O stained whole knee sections. Chondrocyte PG synthesis was mea-
sured ex vivo by 35S-sulfate incorporation. Knee bone mineral density (BMD) was mea-
sured by dual x-ray absorptiometry (DEXA). In young mice (3 months), OA was
induced by intra-articular injection of collagenase. 
Results: The incidence of extensive cartilage loss at both lateral - and medial sides was
markedly higher in old IL-6-/- males, but not females, as compared to their wild-type
controls. Compared to age-matched wt mice, reduced ex vivo PG synthesis was found
during aging in IL-6-/- males, without affecting their cartilage PG density. IL-6-/- males
showed more extensive extracellular matrix deposition in the collateral ligaments and
subchondral bone sclerosis, predominantly at the medial side. Total knee BMD
decreased more in IL-6-/- (-23%) than in wt (-10%) males during aging. Collagenase-
induced OA showed a similar degree of joint pathology in both strains, implying that OA
susceptibility was not different at younger age. 
Conclusions: Upon aging IL-6-/- male mice developed more severe spontaneous OA.
Reduced PG synthesis and BMD values might be indicative for an impaired repair
response in IL-6-/- mice. This suggests a protective role for IL-6 in age-related OA.
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Introduction
Osteoarthritis, the most common of all joint disorders, is a disabling disease whose inci-
dence increases with age. The cause of OA is unknown but several mechanisms could be
involved1 including genetic/age-related alterations in extracellular matrix components,
biomechanical stress or an imbalance in synovial homeostasis. The disease is character-
ized by breakdown of the cartilage matrix followed by development of fibrillations, fis-
sures and this ultimately can lead to complete loss of articular cartilage. Another charac-
teristic of OA is hypertrophy of the bone. Thickening of the subchondral bone can lead
to increased stiffness and reduced shock absorbing capacity of the bone. Another com-
plication related to bone is the formation of osteophytes in OA joints. Whether changes
in the bone cause cartilage pathology or vice versa is still a matter of debate2;3. 
The production of both anabolic and catabolic cytokines and growth factors by the
articular chondrocytes and synovial lining cells could contribute to the coexistense of
repair and destructive processes in OA joints reviewed in van der Kraan and van den
Berg, 20004; van den Berg, 20015. Increased experimental OA in IL-1β deficient mice
suggested recently that catabolic cytokines could also have beneficial effects and could
contribute to joint homeostasis in OA6. One other cytokine whose expression is
increased in affected joints of OA patients is the multifunctional cytokine interleukin-6
(IL-6). IL-6 production has been found in chondrocytes from OA cartilage7 but its exact
function in this disease is not clear. IL-6 could reduce PG synthesis in vitro8 but this was
investigated with normal and not with OA cartilage. IL-6, in contrast, had no effect on
PG metabolism itself but depressed IL-1β induced PG breakdown in OA chondrocytes
in vitro9. The induction by IL-6 of α1-antitrypsin10 and Timp-111 in human chondro-
cytes also suggests a protective role against cartilage pathology. Previously we had found
a cartilage protective role for IL-6 during the onset of zymosan-induced arthritis (ZIA)
in mice12. IL-6 deficient mice had higher articular cartilage PG loss during onset of ZIA.
This PG loss could be normalized by intra-articular injection of IL-6.  Furthermore, IL-
6 injections in naive mice could stimulate PG synthesis moderately13.
IL-6 also has properties that could have a negative effect in the joint e.g. in the pres-
ence of the soluble IL-6 receptor IL-6 contributes to osteoclast development14, and this
links it to bone erosion. Furthermore, IL-6 plays a role in development of chronic joint
inflammation15;16, and might therefore be involved in osteoarthritis-associated joint
inflammation.
Investigations on the role of IL-6 in murine OA are limited. Increased IL-6 mRNA
expression was found in cartilage of C57 black mice with early stages of spontaneous OA17.
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IL-6 expression, however, did not correlate with histological changes. Male STR/ort mice
develop osteoarthritic lesions of the knee joint by 35 weeks of age. In situ hybridisation
studies showed increased IL-6 mRNA expression in cartilage at the site of the lesions18.
It is, however, not clear if this IL-6 expression plays a role in developing cartilage dam-
age in mice. Recently, it was shown that young STR/ort females had a higher expression
of IL-6 in their cartilage than males19. Because in the STR/ort strain female mice devel-
op less OA than males, it was of interest to include both male and female mice in our
study.
In the present study we have investigated both spontaneously developed age-related
OA as well as experimentally induced OA in wt and IL-6 deficient mice.
Materials and methods
Spontaneous and experimental osteoarthritis
Wildtype C57Bl6 (Charles River, Sulzfeld, Germany) and IL-6 deficient mice20, back-
crossed for 8 times into C57Bl6, were used in the experiments. Breeding pairs of the 
IL-6 deficient mice were a kind gift of dr. Manfred Kopf. (Basel, Switzerland). During a
period of four years, groups of healthy mice were followed for the spontaneous develop-
ment of OA. Knee joints of male and female mice were isolated when they had reached
the age of 18 months or older. The mean age in months ± sd for the different groups was
19.8 ± 0.6 wt male, 20.0 ± 2.1 IL-6-/- male, 19.6 ± 2.2 wt female and 19.6 ± 1.7 IL-6-/-
female. Isolated knee joints were fixed in formalin and processed for histological evalua-
tion. Male C57Bl6 wt and IL-6-/- mice were used for experimental OA at the age of 3-4
months. Experimental OA was induced by injecting 6 µl of physiological saline contain-
ing 1 unit of collagenase (from Clostridium histolyticum, type VII, Sigma, St. Louise,
MO) in the knee joint of mice. The injection was repeated once at day 2 after the first
injection. At day 42 after the start of the experiment, knee joints were isolated, formalin
fixed and processed for histological evaluation. All mice were housed in filter-top cages
under standard pathogen free conditions and a standard diet and water were provided ad
libitum. Experiments were performed according to national and institutional regulations
for animal use.
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Histological evaluation of knee joints
Histological signs of OA were scored in a blindfolded manner on 5 semi-serial sections
of the joint. Cartilage erosion was scored on a scale from 0-3: 0 no cartilage erosion, 1
superficial ruffling, 2 surface erosion and/or fissures, 3 complete loss of cartilage.
Proteoglycan deposition (red color in saf O stained sections) and bone formation in the
ligaments were scored on a scale from 0-3: 0 no changes, 1 moderate red staining, 2
extensive red staining, 3 extensive red staining and bone formation in the ligament.
Incidence of mice with erosion and/or PG deposition was expressed as a percentage of
the total number of mice in that group. The incidence of mice with the highest score (3)
is used as a marker for development of severe OA in the different groups. The joint sec-
tions were furthermore evaluated for the presence or absence of dislocation of the patel-
la, subchondral bone sclerosis, joint inflammation, osteophyte formation and bone
apposition.
Chondrocyte PG synthesis
Proteoglycan synthesis was assessed by 35S-sulfate incorporation in patellar cartilage.
Patellae were dissected, with a minimum amount of surrounding synovium, under ster-
ile conditions. The ex vivo synthesis assays were performed in RPMI/penicillin 100 U/ml
and streptomycin 100 µg/ml/ 1 mmol/l pyruvate/ 5% fetal calf serum (Life Technologies,
Breda, The Netherlands). The patellae were placed separately in 200 µl medium con-
taining 4 µCi 35S-sulfate and incubated for three hours at 37°C and 5% CO2. After
labelling, the patellae were washed twice with physiological saline and fixed overnight in
100% ethanol. Patellae were decalcified in 5% formic acid for 4 hours at room tempera-
ture. Thereafter, the articular cartilage was stripped from the underlying bone and dis-
solved O/N in 0,25 ml lumasolve at 60°C (Lumac, Groningen, The Netherlands). After
addition of 1 ml lipoluma (Lumac, Groningen, The Netherlands), the 35S-sulfate content
of each patella was measured by liquid scintillation counting in a Trilux 1450 MicroBeta
(Perkin-Elmer Wallac, Turku, Finland).
IL-6 knock out mice and OA 33
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Cartilage PG breakdown
Patellae were isolated and labelled with 35S-sulfate as described for the ex vivo PG syn-
thesis. Part of the patellae was fixed after labelling (t = 0). The rest was, after washing,
further incubated for 48 hours at 37°C and 5% CO2 in medium without 35S-sulfate.
Medium was changed after the first 24 hours. After 48 hours incubation the patellae were
washed, fixed and processed as described for the ex vivo synthesis. 
Assessment of PG density in patellar cartilage
Patellar PG density was quantified by image analysis on histological slides as described
previously by van der Kraan et al, 199421. Images of safranin-O-stained sections were
captured using a JVC 3-CCD color video camera (Victor Company of Japan Ltd., Tokyo,
Japan) and displayed on a computer monitor. Patellar cartilage was selected and the
amount of red staining was measured using the Qwin image analysis system (Leica
Imaging Systems Ltd., Cambridge, UK). Of each mouse three sections were measured. 
Measurement of knee bone mineral density
Bone mineral density (BMD) of murine knee joints was determined by dual energy x-ray
absorptiometry (DEXA). Knee joints were scanned with a Norland bone densitometer
XR-46 (Norland Medical Systems, Inc. fort Atkinson, WI). Calibration of the densito-
meter was performed with a calibration phantom before measurement. Scans were per-
formed at a speed of 60 mm/s with a resolution of 0,5 x 0,5 mm and included the femoral
condyles, patella and tibial plateau. The BMD is expressed as mg/cm2
Statistical analysis
Statistical analysis between groups was performed with Student’s t-test. Distribution of
maximal OA scores was analyzed by a Chi-square test with a 95% confidence interval.
Values of p<0.05 were considered significant in both tests.
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Results
Osteoarthritis related pathology in old mice
Knee joints were isolated from wt and IL-6-/- mice of both sexes at the age of 18 months
or older. At the femoral-tibial junction, cartilage surface became affected varying from
superficial ruffling to complete erosion of the cartilage layer. PG deposition and, in more
advanced cases, bone apposition occurred in the collateral ligaments. Subchondral bone
sclerosis was also frequently observed.  Inflammation was not observed in females, 1 out
of 36 wt males had an inflamed joint while 3 out of 39 IL-6-/- males showed signs of pre-
vious joint inflammation. Dislocation of the patella was not observed in these old mice. 
Higher incidence and more substantiated cartilage damage found 
in old IL-6-/- males
Female mice of both strains had only moderate signs of OA with mild cartilage erosion
and only in exceptional cases complete cartilage loss (Table 1, Figure 1A and B). Male wt
mice also developed OA at the same incidence and with comparable degree of OA
pathology as the females.  However, significantly more IL-6-/- male mice showed severe
OA with complete cartilage erosion at both medial and lateral side (Table1, Figure 1 C
and D). Further experiments were therefore focused on male mice. 
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Table I Spontaneous cartilage erosion in old wt and IL-6-/- mice
Cartilage erosion of old wt and IL-6-/- mice (18-23 months). Scoring ranged from 0-3 as described in
materials and methods. For each mouse the maximum score, either medial or lateral or equal on both
sides, is indicated. This means that the other side could have lower or no signs of cartilage erosion.
Incidence is calculated as the percentage of mice with a positive score of 1, 2 or 3. a The number between
brackets represents the percentage of mice showing the highest score. b Distribution of the maximal score
(either 1, 2 or 3) for cartilage damage over the medial (M) and lateral (L) side of the knee joint. In case
the score is equal for both sides than that joint is counted for medial as well as lateral. The number
between brackets indicates the number of joints with maximal damage score 3 at that side. 
Distribution of maximal cartilage erosion scores as compared to wt male or female mice was analyzed
by a Chi-square test with a 95% confidence interval. *p<0.05, ** p<0.005, ns not significant.
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Fig. 1. Spontaneous OA in old wt and IL-6-/- mice.
WT (A, 23 months) and IL-6-/- (B, 22 months) female mice with PG deposition in the collateral ligament
(arrow in A and B) but without cartilage erosion. Mild surface erosion (arrow) in the tibial cartilage of an
old wt male (C, 20 months). Severe OA as seen in an old IL-6-/- male (D, 19 months). Severe cartilage
erosion occurs in both femur and tibia. Bone sclerosis is seen under the affected cartilage.  Bone apposi-
tion (arrows) and PG deposition occur in the collateral ligament. The normal ligament structure as seen
in the wt male (E) and bone formation in the ligament of the IL-6-/- male (F) are shown in more detail. F
= femur, L = ligament, T = tibia. Safranin-O staining. Original magnification A-D 50x, E and F 500x.
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The cartilage erosion occurred in absence of cartilage PG depletion. Image analysis per-
formed on safranin-O stained histological sections showed no significant difference
(Student’s t-test) between the wt and IL-6-/- male mice in the PG density of patellar car-
tilage (260+/-116 (n=16) respectively 246+/-95 (n =14) mean ± sd). However, already at
12 months a marked reduction was found in patellar chondrocyte PG synthesis in IL-6-/-
males in comparison to age-matched wt mice (Table 2).  This difference in PG synthesis
with aging does not lead to reduced PG density but could be indicative for diminished
chondrocyte function. As a consequence the cartilage may become more vulnerable and
the repair response against osteoarthritic insults may be hampered in IL-6-/- mice. This
is illustrated by increased inhibition of PG synthesis when patellae of 12-13 months old
mice were incubated in vitro for 24 hours with 1ng/ml IL-1β (wt 42% inhibition, IL-6-/-
57% inhibition, n = 6).
Increased subchondral bone sclerosis in old IL-6-/- males
Differences in the bone mineral density (BMD) between OA patients and healthy age-
matched controls have been reported. An increase in BMD is thought to cause stiffness
of bone, which leads to increased pressure and ultimately damage to the overlaying car-
tilage. The BMD of murine knee joints was measured by the DEXA technique. Young
male mice (3 months) of both strains did not differ in their BMD value (IL-6-/- 63.2 +/-
7.7 mg/cm2, n = 12; wt 68.9 +/- 10.2 mg/cm2, n = 13. mean ± sd). IL-6-/- males at 20
months of age, in contrast, had a significantly reduced BMD value as compared to age-
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Table 2 Ex vivo cartilage PG synthesis and breakdown in 4 and 12 months old male wt and IL-6-/-
mice
Ex vivo PG synthesis and breakdown in patellae from 4 and 12 months old wt and IL-6-/- mice. Ex
vivo PG synthesis is shown by the 35S incorporation directly after labeling (t = 0). PG breakdown was
determined by comparing incorporation at t = 0 and the amount of 35S that is still present in the car-
tilage after 48h incubation in 35S-free medium. n = 6 per group. One of two experiments with similar
results is shown. mean ± sd, ** p < 0.005 IL-6-/- mice compared to wt mice of the same age. Student’s
t-test. ns not significant.
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matched wt mice (48.7 +/- 5.3 mg/cm2 (n = 13) respectively 61.8 +/- 6.1 mg/cm2 (n =
12), mean ± sd, p < 0.001, Student’s t-test). The reduction in the mean BMD was also
greater for IL-6-/- males as for wt males (-23% versus -10%) in the period from 3 to 20
months. Histology, however, showed subchondral bone sclerosis in the tibial plateaus,
which occurred more frequently at the medial side and had the highest incidence (49%)
in old IL-6-/- males (Table 3, Figure 1D). Although bone sclerosis was found in 11 of the
14 IL-6-/- males with complete cartilage loss, it did not co-localize with cartilage erosion
in general (compare Table 1 and 3). 
Osteophyte formation, another bone related change during OA, was observed less fre-
quently in both females (wt 2 of 24; IL-6-/- 4 of 27) and males (wt 1 of 36; IL-6-/- 7 of 39). 
Enhanced PG and bone apposition in collateral ligaments of old IL-6-/- male mice
Changes in collateral ligaments may jeopardize joint stability and are implicated in the
osteoarthritic process. In both sexes of each strain, the apposition of PG and bone in the
collateral ligaments occurred mainly at the medial side (Table 4, figure 1A and B).  A sig-
nificant higher incidence and more severe PG and bone deposition in the collateral liga-
ments was found in the IL-6-/- males as compared to their wt controls (Table 4, figure 1
C-F). In 9 of the 10 IL-6-/- males with maximal apposition in the ligament (score 3), car-
tilage erosion was also maximal at the same medial side.
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Table 3 Bone sclerosis in old wt and IL-6-/- mice
Distribution of subchondral bone sclerosis over the medial and lateral side of the joint in old wt and
IL-6-/- mice. a The incidence is calculated as the percentage of mice that have bone sclerosis either
medial, lateral or at both sides. b Distribution of bone sclerosis over the medial and lateral side of the
knee joint. In case bone sclerosis is present at both sides than that joint is counted for medial as well
as lateral.
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Similar pathology of experimental OA in wt and IL-6-/- mice at young age
Analysis of the spontaneous OA showed a clear difference between old wt and IL-6-/-
male mice. To investigate if IL-6-/- mice are already at younger age more prone to devel-
op OA-like changes we compared young (3 months) wt and IL-6-/- male mice in the col-
lagenase induced OA. Ligaments and cartilage were severely affected in both strains (fig
2A and B, table 5). PG deposition and bone formation in the ligaments was mostly
observed at the medial side in both strains. Cartilage damage occurred mostly on the
medial side. Subchondral bone sclerosis was scarce and was found only at the medial part
in 3 mice of each group. Patellar dislocation was observed in four wt mice but not in IL-
6-/- mice. Bone apposition and osteophyte formation, in contrast, were observed fre-
quently in both groups (9 of 12 in wt and 9 of 11 in IL-6-/- mice). 
These results suggest that during aging IL-6-/- male mice start to differ from their wt
counterparts in the osteoarthritic response. Intriguingly, chondrocyte PG synthesis
(Table 2) and BMD also did not differ between young (3-4 months) wt and IL-6-/- mice. 
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Table 4 Spontaneous extracellular matrix deposition in ligaments of old wt and IL-6-/- mice
PG and bone deposition (extracellular matrix, EM) in the ligaments of old wt and IL-6-/- mice (18-23
months). Scoring ranged from 0-3 as described in materials and methods. For each mouse the maxi-
mum score, either medial or lateral or equal on both sides, is indicated. This means that the other side
could have lower or no signs of EM deposition. Incidence is calculated as the percentage of mice with
a positive score of 1, 2 or 3. a The number between brackets represents the percentage of mice show-
ing the highest score. b Distribution of the maximal score (either 1, 2 or 3) for ligament PG deposi-
tion/bone formation over the medial (M) and lateral (L) side of the knee joint. In case the score is
equal for both sides than that joint is counted for medial as well as lateral. The number between
brackets indicates the number of joints with maximal damage score 3 at that side. 
Distribution of maximal EM deposition scores as compared to wt male or female mice was analyzed
by a Chi-square test with a 95% confidence interval. *p<0.05, ** p<0.005, ns not significant. 
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Discussion 
Expression of the pleiotropic cytokine interleukin-6 is increased in the joints of OA
patients. Chondrocytes, osteoblasts, osteoclasts as well as synoviocytes can respond to 
IL-6 and the final outcome of IL-6 expression in OA is therefore unclear. Our present
study on spontaneous OA in IL6-/- and wt mice suggests that especially in males IL-6
could have a beneficial effect on joint pathology during OA.
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Figure 2 Collagenase induced OA in wt and IL-6-/- male mice
Severe OA at day 42 after the first collagenase injection in both wt (A) and IL-6-/- (B) male mice.
Complete cartilage erosion is seen at the femur. Osteophytes are formed at the tibia and femur. PG depo-
sition is seen in the collateral ligament. F = femur, L = ligament, T = tibia, O = osteophyte, M = menis-
cus. Safranin-O staining. Original magnification 50x.
Table 5 Cartilage erosion and PG deposition in the ligaments of male mice with collagenase induced
osteoarthritis
A) Cartilage erosion and B) PG and bone deposition in the ligaments was scored on day 42 after the first 
injection with collagenase. a, b Score for cartilage and ligament damage and medial/lateral distribution
are presented as in table 1 and 4. Distribution of maximal OA scores was analyzed by a Chi-square test
with a 95% confidence interval but did not differ significantly between wt and IL-6-/- mice.
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Depending on the affected joint, human OA occurs either more in females or is equal-
ly present in both sexes. In our study wt male and female mice did not differ significant-
ly in cartilage erosion and ligament PG deposition. A gender difference, in contrast, was
seen in the IL6-/- mice where males, but not females, developed significantly more severe
OA when compared to age-matched wt mice. Androgens have been shown to reduce IL-
6 production and androgen receptors have been found in bone22 and ligaments23.
Dihydrotestosterone reduced in vitro IL-6 production in human osteoblasts and, in com-
bination with mechanical strain, shifted bone metabolism from high turnover into an
osteoanabolic state24. It is therefore possible that under influence of androgens, joint
metabolism in response to mechanical strain or damage is switched into an enhanced
anabolic mode in our IL6-/- males. This could then contribute to development of sub-
chondral bone sclerosis and ligament ossification.
Future studies should address the relation between IL-6 expression, OA development
and sex hormones in mice of different age. Our present study showed that young IL-6-/-
male mice were not yet more susceptible to experimental OA suggesting IL-6 involve-
ment only upon aging. We can, however, not rule out that presence or absence of IL-6
expression at younger age already has an effect on development of OA.
Based on the increase of severe cartilage damage in old IL-6 deficient male mice, our
present study suggests a modifying or protective role for IL-6 against cartilage pathology in
OA. Proteoglycans form an important component of the cartilage matrix and, by retaining
water, contribute to the shock absorbing capacity of the cartilage. These PG’s are continu-
ously synthesized and degraded. In line with previous results25, young IL6-/- male mice did
not differ from wt mice in ex vivo cartilage PG synthesis. When these mice got older (12
months), however, PG synthesis decreased in IL6-/- but not in wt mice. This suggests a pos-
itive relation between IL-6 and PG synthesis similar to the positive correlation between IL-
6 and cartilage PG synthesis in dogs with experimentally induced OA26. Preliminary results
showed that 24-hour incubation of 12 months old IL6-/- patellae in IGF supplemented
medium restored PG synthesis to wt levels (data not shown). This suggests presence of
lower levels of chondrocyte stimulating factors in older IL6-/- mice, which should be sub-
ject of further investigation. Histological measurement of cartilage PG’s revealed no differ-
ence in net PG density of old IL6-/- and wt patellar cartilage. This will most likely be caused
by decreased PG turnover in IL6-/- mice. Although a reduced PG synthesis in old IL6-/-
mice does not affect the patella, it might impair the recovery or repair of cartilage and, in
this way, could make it more prone to develop OA lesions. 
The collateral and cruciate ligaments contribute to stability of the joint. We had pre-
viously found a positive relation between ligament damage and cartilage loss at the medi-
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al side in wt mice with collagenase-induced OA27. A similar positive relation between
calcification and ossification of the medial collateral ligament (MCL) and the develop-
ment of OA lesions has been found in STR/ort mice28. In our present study we found
more intense PG deposition and bone formation in the MCL of old IL6-/- male mice.
Deposition of this so-called fibrocartilage and subsequent ligament stiffening could con-
tribute to cartilage damage and bone sclerosis by altering the load distribution in the
joint. Increased stiffness of the MCLs is also found in OA patients when compared to
age-matched healthy people29. Heterotopic osteogenesis of human ligaments has been
most studied in the spine where ligament fibroblasts can differentiate into chondrocytes
in response to bone morphogenetic protein-2 (BMP-2)30. IL-6 can inhibit BMP-2
mRNA expression31 and it is therefore possible that increased expression of BMP-2 or
related growth factors contributes to the ligament damage in the IL-6-/- males. 
Alternatively to being a cause, fibrocartilage deposition in and stiffening of ligaments
might also be a consequence of other remodeling processes that occurred earlier in the
joint. Increased collagen remodeling was measured in the anterior cruciate ligament
(ACL) of STR/ort mice before radiological signs of OA were detected and the ACL was
also weaker than in control mice32. Similarly, a reduced strength and stiffness of the ACL
was found in people over 50 years of age when compared to young adults33. Weaker lig-
aments could contribute to greater joint instability and in this way might increase the
risk of development and progression of knee OA34. Ligament lesions in either cruciate or
collateral ligaments are frequently found in patients with advanced OA35. During pro-
gression of OA and as a response to increased joint laxity, the ligaments might subse-
quently become stiffer by development of fibrocartilage. 
In vitro cultures of pig MCL fibroblasts showed that collagen production is positively
correlated with IL-6 production36. This suggests that absence of IL-6 in our study might
reduce the MCL collagen content, which might lead to a weaker ligament or impaired
response to damage. Experimental ligament damage was induced by collagenase injec-
tion. The equal OA development that was observed in wt and IL-6-/- mice with collage-
nase-induced OA could indicate that during aging under normal conditions IL-6 plays
an important role in maintaining ligament function.
Subchondral bone sclerosis can occur in human OA and was also in our study the
most prominent bone-related change. Subchondral bone sclerosis could lead to a
reduced shock absorbing capacity that finally leads to cartilage erosion. In vitro IL-6
expression could divide human OA osteoblasts in normal and high IL-6 producers37.
This study, however, could not relate IL-6 expression to pathological findings. In osteo-
phytes, IL-6 mRNA has been detected in active osteoblasts38. In trabecular OA bone,
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decreased IL-6 mRNA expression was associated with enhanced mRNA expression for
the bone formation marker osteocalcin39. The increased bone sclerosis in the old IL6-/-
males could be in line with these last results. 
Although the resolution of the bone densitometer did not allow us to evaluate the
subchondral bone in detail due to the small size of the murine joint, DEXA measure-
ments revealed a reduced BMD in knees of old, but not young, IL-6-/- male mice when
compared to wt mice. Our data, therefore, suggest a BMD preserving role for IL-6. The
reduced BMD might seem conflicting with the increased sclerosis in the IL-6-/- males but
studies on human OA suggest it is not. Although bone volumes can increase in OA, the
subchondral bone of these patients is less mineralized than normal bone (reviewed in
Hunter and Spector, 200340). Different reports showed a reduced BMD in OA subchon-
dral bone38;41;42. Longitudinal studies relating BMD and OA development showed that
high BMD at non-joint sites is associated with increased risk of OA. Once people have
OA, in contrast, a low BMD and high bone turnover appear associated with enhanced
progression of the disease (reviewed in Hunter and Spector, 200340). This could explain
the coexistence of reduced BMD, bone sclerosis and enhanced OA development in 
IL-6-/- males.
In our old wt and IL-6-/- males bone sclerosis, ligament ossification and complete car-
tilage erosion coincided in the most severe cases but only at the medial side. Bone scle-
rosis and ligament ossification were almost completely restricted to the medial side in all
groups. Cartilage erosion, in contrast, occurred at both sides and had the highest inci-
dence of all pathological changes. Together with the reduced PG synthesis that started
already at younger age this suggests onset of OA in the cartilage. Histological and func-
tional studies with mice at a younger age might identify the location of the first patho-
logical change. Independent of the disease etiology, our present data clearly showed more
severe cartilage erosion and ligament ossification in IL-6-/- male mice. 
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Abstract
Interleukin-6 (IL-6) is highly produced during arthritis but its exact function is still
unknown. In this study we examined if IL-6, apart from its role in immunity, was
involved in the local inflammatory response in experimental arthritis. IL-6 deficient (IL-
6-/-) and wild-type mice were first compared in the antigen-induced arthritis model. IL-
6 deficiency resulted in a mild , transient inflammation whereas wild-type mice devel-
oped a chronic, destructive synovitis. Wild-type mice immunized with one-tenth of the
normal antigen dose still developed chronic arthritis despite low antibody levels, exclud-
ing reduced humoral immunity in IL-6-/- mice as a crucial phenomenon. In addition,
passive immune-complex-induced arthritis did not differ between wild-type and IL-6-/-
mice. Another option is reduced levels of Th1 cells in IL-6-/- mice. However, transfer of
antigen-specific wildtype lymph node cells to IL-6-/- mice enhanced acute joint inflam-
mation and increased cartilage damage but still could not sustain chronic inflammation,
suggesting involvement of nonimmune elements of IL-6 activity in chronicity. In line
with this , nonimmunologically mediated zymosan-induced arthritis developed similar-
ly in the first week, but only wild-type mice developed chronic synovitis. These results
indicate an important role for IL-6 in propagation of joint inflammation, potentially
independent of its role in immunity. 
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by a chronic
inflammation of the joints. This inflammation finally leads to tissue destruction that dis-
ables the patient. Although the exact cause of RA is not yet known pro-and anti-inflam-
matory cytokines seem to play an important role in the pathology of the disease.1
Interleukin-6 (IL-6) is a member of the IL-6 family to which leukemia inhibitory factor,
oncostatin M, ciliary neurotrophic factor, and IL-11 also belong.2,3 Both IL-6 and the
agonistic soluble IL-6 receptor are found in large quantities in synovial fluid and serum
of RA patients.4 The main producers of IL-6 in the inflamed joint are articular chon-
drocytes and synovial fibroblasts.5,6 Studies on the relation of disease activity and IL-6
concentration have yielded conflicting results.7-9 Anti-IL-6 monoclonal antibodies
showed transitory clinical improvement in RA patients.10 Surprisingly, this effect was
accompanied by an increase in IL-6 serum levels, which makes it unclear what caused the
improvement. 
Both pro-and anti-inflammatory properties have been ascribed to IL-6, complicating
the establishment of its role in RA. IL-6 plays an important role in the maturation of B
cells into antibody-secreting plasma cells,11 differentiation of osteoclasts12 and
macrophages,13 generation of an acute-phase response in the liver,14-16 and has a co-
stimulatory role in T cell activation.17,18 On the other hand, IL-6 can induce expression
of IL-1 receptor antagonist, soluble tumor necrosis factor (TNF) receptor, and tissue
inhibitor of metalloproteinases,19,20 which could down-regulate inflammation and
reduce connective tissue damage in the inflamed joint. IL-6 also can reduce TNF pro-
duction.21 
The dual face of IL-6 as a pro-and anti-inflammatory protein is also reflected by stud-
ies in IL-6 gene knockout (IL-6-/-) mice. The local inflammatory response against tur-
pentine was impaired in IL-6-/- mice whereas systemic inflammatory reactions on
lipopolysaccharide were not.22 The inflammatory response against Candida albicans was
also impaired in IL-6-/- mice.23 Xing et al24 in contrast found increased inflammatory
reactions in endotoxic lung or during endotoxemia in IL-6-/- mice and proposed an anti-
inflammatory role of IL-6 during acute infection. IL-6-/- mice also had a higher incidence
of arthritis after infection with Borrelia burgdorferi25 demonstrating an anti-inflammato-
ry role of IL-6. In a previous study we looked into the role of IL-6 in zymosan-induced
arthritis (ZIA),26 a nonimmunologically mediated irritant-induced joint inflamma-
tion.27 During the first week of ZIA the inflammation developed synchronically in IL-6-
/- and wild-type mice. Intriguingly, cartilage damage was increased in the IL-6-/- mice,
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pointing at a cartilage protective role for IL-6. A recent study by Ohshima et al28 showed
the importance of IL-6 for development of antigen-induced arthritis (AIA), an immuno-
logically mediated model with features of RA such as synovial hyperplasia, influx of
inflammatory cells, and cartilage damage.29 Their study focused at the outcome of arthri-
tis at day 14 and differences in the antigen-specific immunity. It remains unclear what
caused amelioration of the disease in IL-6-/- mice: the developed, but impaired, antigen-
specific immune response or the absence of IL-6 during the inflammation. In the present
study we wanted to examine if IL-6, independent of its role in immunity was involved in
the inflammatory response in different experimental arthritis models. In these models
wild-type and IL-6-/- mice were compared. We confirmed that initial inflammation in
IL-6-/- mice did not develop into a chronic inflammatory infiltrate during AIA.
Differences in cellular but not humoral immunity had major influence on the onset of
AIA. However, transfer of wild-type lymph node cells enhanced the mild inflammatory
response in IL-6-/- mice but still did not lead to a chronic infiltrate. In the nonimmuno-
logically mediated ZIA we also found that the acute inflammation of the first week did
not develop into a chronic synovial infiltrate in IL-6-/- mice. These results suggest that in
both immunologically and nonimmunologically mediated experimental arthritis, there
is an important role for IL-6 in propagation of the inflammatory infiltrate. 
Materials and Methods 
IL-6-/- and Wild-Type Mice 
Homozygous IL-6-/- and wild-type (C57Bl/6x129/Sv) F2 mice30 and IL-6-/- mice back-
crossed into C57Bl/6 for eight generations (N8) were obtained from Dr. M. Kopf (Basel,
Switzerland) and bred in our SPF animal facilities. IL-6 deficiency was routinely checked
by polymerase chain reaction (PCR) of genomic DNA. A standard diet and acidified tap
water were provided ad libitum. At the age of 11 to 13 weeks the animals were used in the
experiments. Experiments were performed according to national and institutional regu-
lations for animal use. 
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AIA
Mice were immunized with 100 µg of methylated bovine serum albumin (mBSA; Sigma,
St. Louis, MO) in Freund’s complete adjuvant (Difco, Detroit, MI) divided over the front
paws and both flanks. They also received an intraperitoneal injection of 2x109 heat-killed
Bordetella pertussis bacteria (National Institute of Public Health, Bilthoven, The
Netherlands) in 1 ml of saline. Seven days later, mice were boostered with 100 µg of
mBSA in Freund’s complete adjuvant divided over two places in the neck region. Three
weeks after the booster 60 µg of mBSA in saline (6 µl total volume) was injected in the
knee joint cavity of the right hind leg to induce arthritis. 
Immune-Complex-Induced Arthritis 
An immune-complex-induced arthritis was elicited in naive mice as described by van
Lent et al.31 Mice were injected intravenously with 0.2 ml of a polyclonal rabbit anti-
lysozyme serum of which the complement had been heat-inactivated. Arthritis was
induced 16 hours later by injecting 6 µl of poly-L-lysine-coupled lysozyme (3 µg; Sigma)
in the joint. 
ZIA
ZIA was elicited by intra-articular injection of 180 µg of zymosan A (Saccharomyces cere-
visiae) as described before.26 
Assessment of Joint Swelling 
Mice were injected subcutaneously in the neck with 20 µCi of 99mTechnetium pertech-
netate (99mTc) in 0.2 ml of physiological saline. After 15 minutes, mice were sedated by
intraperitoneal injection of 4.5% chloral hydrate (0.1 ml/10 mg of body weight; Merck,
Darmstadt, Germany). Accumulation of the isotope because of increased blood flow and
edema in the knee was determined in duplicate by external γ counting using a NaI crys-
tal. The ratio of 99mTc uptake in the inflamed over the contralateral knee joint was deter-
mined and a ratio higher than 1.1 indicated joint swelling. 
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Histological Evaluation of Knee Joints 
Knee joints were dissected, fixed in formalin, decalcified, dehydrated, and embedded in
paraffin. Standard frontal sections of 7 µm were prepared. For assessing cartilage dam-
age, sections were stained with safranin-O and counterstained with fast green. Serial sec-
tions were scored in a blind-folded manner by two independent observers. Cartilage
depletion was scored from 0 (normal safranin-O staining, no depletion) up to 3 (com-
plete loss of safranin-O staining, complete depletion). Also cellular infiltrate and exudate
were scored in a scale from 0 up to 3.  
Semiquantitative Reverse Transcriptase (RT)-PCR on Synovial mRNA 
Synovial mRNA was isolated and quantitated as described by van Meurs et al.32 Patellae
were isolated from knee joints and two pieces of tissue adjacent to the patella were
punched out with a 3-mm biopsy punch (Stiefel Laboratorium GMbH, Offenbach am
Main, Germany). The tissue was immediately frozen in liquid nitrogen. Tissue samples
were homogenized in a freeze mill, thawed in 1 ml of TRIzol reagent, and further
processed according to the manufacturers protocol. All reagents for RNA isolation and
RT-PCR were from Life Technologies (Breda, The Netherlands). Isolated RNA was treat-
ed with DNase before being reverse-transcribed into cDNA with Moloney murine
leukemia virus reverse transcriptase. After increasing numbers of PCR cycles samples
were taken and run on an agarose gel. The cycle number at which the PCR product was
first detected on the gel was taken as a measure for the amount of specific mRNA origi-
nally present in the isolated synovial RNA. PCR for glyceraldehyde-3-phosphate dehy-
drogenase was performed to verify that equal amounts of cDNA were used. Primers,
annealing temperature, and MgCl2 concentration for murine VCAM-1,33 ICAM-1, E-
and P-selectin,34 MCP-1, Mip-1α and Mip-2 (Blom et al, submitted), TNF-α, IL-1β, and
glyceraldehyde-3-phosphate dehydrogenase35 were as described.
Assessment of mBSA-Specific Antibody Titers 
mBSA-specific antibody titers in sera were determined by enzyme-linked immunosorbent
assay. Ninety-six-well flatbottom plates (Costar, Corning, NY) were coated overnight with
mBSA (0.1 mg/ml; Sigma), blocked the next day with gelatin (1% in phosphate-buffered
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saline) and incubated with serial dilutions of the sera. Horseradish peroxidase-labeled sec-
ondary antibodies were from Southern Biotechnologies Associates (goat anti-mouse IgG1
or anti-mouse IgG2b; Birmingham, AL) or from Nordic (rat anti-mouse IgG or anti-
mouse IgG2a; Tilburg, The Netherlands). Color development after adding substrate (5-
aminosalicylzuur, 0.8 mg/ml, 0.8 µl 30% H2O2/ml in 50 mmol/L of sodium-phosphate, pH
6.0) was monitored in an enzyme-linked immunosorbent assay reader at 450 nm. Dilution
curves were plotted and the dilution at optical density 50% was determined. A standard
serum of mBSA immunized C57Bl/6 mice was included for intra-assay variation. 
Lymphocyte Stimulation Test 
Antigen-specific T cell immunity was determined by the proliferative response of T cells to
mBSA. Axillary and inguinal lymph nodes were isolated under sterile conditions and dis-
rupted. The suspension was enriched for T cells by nylon wool adherence for 30 minutes.
Nonadherent cells were washed from the column and adjusted to 2x106 cells/ml in medi-
um (RPMI/penicillin 100 U/ml and streptomycin 100 µg/ml/1 mmol/L pyruvate/5% fetal
calf serum; Life technologies). Cells were plated in a 96-well round-bottom plate (Costar)
and antigen-presenting cells were added at 2x107/ml. As antigen-presenting cells irradiat-
ed spleen cells from naive mice were used after disruption and lysis of erythrocytes (in 17
mmol/L Tris/144 mmol/L ammonium chloride, pH 7.2). Cells were incubated in three-or
sixfold with medium, medium with twofold serial dilutions of mBSA starting at 25 µg/ml
(data shown for 25 µg/ml) or with concanavalin A (Flow laboratories, Irvine UK) at 1
µg/ml as an aspecific stimulus. The plates were incubated for 3 days at 37°C and 5% CO2.
For the last 16 hours the cells were labeled with 0.25 µCi 3H-thymidine. After harvesting,
incorporation of 3H-thymidine was measured in a β-plate reader and the increase in counts
per minute (cpm) caused by stimulation with mBSA was determined. 
Multiplex PCR for T Cell Subsets 
T cells were isolated and stimulated as described above. After 1 day RNA was isolated as
described above. For RT-PCR analysis of T cell subsets the mouse Th1/Th2 CytoXpress
kit was used according to the manufacturers protocol (BioSource, Camarillo, Ca).
Products were run on a 2% agarose gel and analyzed with the multianalyst system
(BioRad, Richmond, CA). 
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Cell Transfer Experiments 
For cell transfer experiments single-cell preparations of lymph nodes (axillary and
inguinal) were made from immunized wild-type or IL-6-/- mice. To prevent a possible
graft-versus-host reaction C57Bl/6 mice were used as donors and C57Bl/6 IL-6-/- (N8)
mice as recipients. Arthritis development did not differ between these mice and the
C57Bl/6x129/Sv IL-6-/- mice (data not shown). Lymph node cells (4x107)in 200 µl of
RPMI medium were injected in the tail vein of immunized IL-6-/- mice before induction
of arthritis in the knee joint. As controls IL-6-/- mice were injected intravenously with
lymph node cells from ovalbumin (Sigma) immunized wild-type mice. 
IL-6 Measurement 
For measuring local IL-6 production in the joint the patella was isolated with surround-
ing soft tissue (tendon and synovium). The patella was incubated in 200 µl of serumfree
RPMI 1640 for 1 hour. The concentration of IL-6 in these patellar wash-outs and sera
was determined by a B9 bioassay as described before.26 
Statistical Analysis 
Statistical comparison between groups was performed with Student’s t-test. Values of P
< 0.05 were considered significant. 
Results
Joint Inflammation Subsided after Day 1 in IL-6-/- Mice 
After immunization a mono-articular arthritis was induced by injecting 60 µg of mBSA
in the knee joint cavity of wild-type and IL-6-/- mice. Joints of both strains became high-
ly swollen at day 1 after injection (Figure 1) but thereafter swelling disappeared rapidly
in IL-6-/- mice, whereas it subsided more gradually and remained significantly higher in
wild-type mice. Histological evaluation of the arthritic knee joints showed onset of
inflammation in IL-6-/- mice but the inflammatory infiltrate disappeared rapidly within
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the first week (Table 1). In both strains the first cells entering the joint were predomi-
nantly polymorphonuclear cells. At day 2 a synovial infiltrate became apparent although
smaller in knee joint cavities of IL-6-/- mice (Figure 2, A and C). By day 7 joints from
wild-type mice were highly inflamed whereas the cellular infiltrate and the cartilage pro-
teoglycan depletion had almost disappeared in the IL-6-/- mice (Figure 2, B and D; Table
1). In wild-type mice the inflammation persisted for weeks. Flare-up of the inflammation
in wild-type mice by low doses of mBSA, that normally do not induce arthritis, further
illustrates reactivity of the chronic synovitis (joint swelling 24 hours after injection on
day 21 of AIA, intra-articular saline 1.15 ± 0.09 or intra-articular 2 µg mBSA  1.58 ± 0.24,
n = 7, one of three experiments).
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Figure 1 Joint swelling at day 1 and
2 after mBSA injection. Immunized
and naive mice were injected with 60
µg of mBSA. Joint swelling was mea-
sured as the ratio of 99mTc uptake
in the arthritic knee (right) over the
nonarthritic knee (left). , IL-6-/-;
, wild type (n = 7; *, P < 0.05; **,
P < 0.005, Student’s t-test). 
Table 1 Development of Joint Inflammation and Cartilage Damage during AIA 
Cellular infiltrate, exudate, and cartilage damage as observed in safranin-O-stained sections. Cartilage
damage was assessed as loss of red staining observed in patella, femur, or medial tibia. Histology was
scored by two independent observers and ranged from 0 (no infiltrate/exudate or no depletion) to 3
(maximal infiltrate/exudate or maximal depletion). Statistical differences between IL-6-/- and wild-
type mice are indicated (nd, not determined; *, P < 0.05, †, P < 0.005; Student’s t-test). WT, wild type.
DAY1 AIA   DAY2 AIA                     DAY4 AIA    DAY7 AIA
IL-6 /
(n 6)
WT
(n 10)
IL-6 /
(n 9)
WT
(n 10)
IL-6 /
(n 8)
WT
(n 13)
IL-6 /
(n 8)
WT
(n 10)
Infiltrate        0.5 0.3            0.7 0.3              0.8 0.4            1.6 0.4 †  0.4 0.3             2.3 0.8 †   0.3 0.2             2.8 0.6 †
Exudate            1.5 0.4            2.1 0.5*            0.7 0.4            1.9 1.0*            0.1 0.2             0.6 0.5*             0.1 0.1             1.5 0.9 †
Patella               0.2 0.2            0.4 0.4              1.7 0.6            2.5 0.5*            1.7 0.6             2.6 0.7*             0.5 0.7             3.0 0.0 †
Femur               0.2 0.3            0.7 0.7              1.6 0.9            2.3 0.7              1.6 0.6             2.7 0.7 †   0.8 0.8             3.0 0.0 †
Medial
tibia
nd                        nd                    1.1 0.6            2.6 0.5 †  1.9 0.7             2.8 0.4 †   1.3 0.9             2.6 0.7 †
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Expression of Adhesion Molecules and Chemokines during Onset of AIA 
IL-6 together with its soluble receptor has been shown to stimulate gene expression
mediating cellular influx36,37 and this could be impaired in joints of IL-6-/- mice during
onset of AIA. We therefore compared synovial gene expression in the arthritic joint with
basal expression in the contralateral uninjected joint by RT-PCR.32 Both IL-6-/- and
wild-type mice showed increased mRNA expression for the investigated adhesion mole-
cules (ICAM-1, VCAM-1, E-selectin, and P-selectin), chemokines (MCP-1, Mip-1α, and
Mip-2) and cytokines (TNF-α and IL-1β) in the arthritic joint at 24 (Figure 3A) and 48
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Figure 2. Inflammation and cartilage damage in wild-type (A and B) and IL-6-/- (C and D) mice on
day 2 (A and C) and 7 (B and D) of the AIA. Sections were stained with safranin-O and cartilage dam-
age was observed as loss of red staining. E: Position of patella (P), femur (F), synovium (S), growth
plate (GP), and cartilage (C) is shown. Original magnification, x200.
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hours (Figure 3B) after injection. IL-6 mRNA expression was also highly increased in
wild-type mice but undetectable in IL-6-/- mice. For this set of genes IL-6-/- mice
responded similarly to wild-type mice at the mRNA level. This suggests that joints of IL-
6-/- mice could support a normal influx of inflammatory cells during onset of AIA. 
Complement Activation in IL-6-/- Mice 
A reduced activation of complement in IL-6-/- mice could contribute to the short-lasting
inflammation. To test this possibility we induced an immune-complex-induced-arthri-
tis in both strains by administrating antigen and antibodies to naive mice. Previously this
model was shown to depend on complement activation.31 During immune-complex
arthritis joint swelling on day 2 did not differ between both strains (IL-6-/-,1.37 ± 0.16;
wildtype, 1.34 ± 0.12; one of two experiments, n = 6). Also the inflammatory infiltrate at
day 7 did not differ between IL-6-/- and wild-type mice (IL-6-/-, 1.5 ± 1.0; wild-type, 1.2
± 0.6; one of two experiments, n = 6). These results indicate that IL-6-/- mice can support
a normal complement-mediated joint inflammation.
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Figure 3 mRNA expression in synovia from wild-type and IL-6-/- mice on day1(A) and 2 (B) of the
AIA. The number of PCR cycles needed to first detect the specific band on an agarose gel was com-
pared between synovia from arthritic and contralateral nonarthritic knee joints. Increased mRNA
expression for the investigated gene in arthritic synovia results in a reduced number of PCR cycles to
first detect the specific band. Four mice per group were used and equal amounts of cDNA were used
as assessed by PCR for glyceraldehyde-3-phosphate dehydrogenase (all appeared at cycle 14). Basal
expression in the nonarthritic synovia did not differ between wild-type and IL-6-/- mice. No signal for
IL-6 was detected at the end point of the PCR with cDNA from IL-6-/- mice. , IL-6-/-; , wild type.
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Differences in Antigen-Specific Antibody Subclasses before Induction of AIA 
On the day of arthritis induction comparable mBSA-specific IgG1 and slightly lower IgM
levels were found in IL-6-/- mice. In contrast, levels of the complement binding IgG2a
and IgG2b subclasses were greatly reduced in the IL-6-/- mice (Figure 4A). 
Next, we used an immunization protocol to lower the IgG2a levels in wild-type mice
to elucidate their role during onset of inflammation. Wild-type mice were immunized
and boostered with 10, 30, or the normal 100 µg of mBSA. Wild-type mice immunized
with 10 µg of mBSA developed IgG2a titers comparable to normally immunized IL-6-/-
mice (Figure 4B), but they still showed significantly higher joint swelling on day 2
(Figure 4C). Although there was a dosage effect on joint swelling at day 2, development
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Figure 4 A: mBSA-specific antibody subclasses before onset of AIA. Titers as depicted are the dilution
of sera needed to give half the maximal optical density at 450 nm as described in Materials and
Methods. , IL-6-/-; , wild type (n = 7). B: mBSA-specific IgG2a titers in mice immunized and
boostered with 100 µg of mBSA (IL-6-/-) or with 10 or 100 µg of mBSA (wild type). Each symbol rep-
resents one mouse (P = 0.22, IL-6-/- (100 µg) versus wild type, (10 µg) Student’s t-test). Total IgG
titers also did not differ (IL-6-/-: 1/720 ± 194, wild type: 1/734 ± 180). C: Joint swelling in wild-type
mice immunized with 10, 30, or 100 µg of mBSA (n = 8). Joint swelling was measured as the ratio of
99mTc uptake in the arthritic knee (right) over the nonarthritic knee (left). , IL-6-/-; , wild type
(A and C: *, P < 0.05; **, P < 0.005, Student’s t-test). One of three experiments is shown.
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of arthritis at day 7 was not reduced after immunization with less antigen (infiltrate at
day 7 was 2.7 ± 0.4, 2.6 ± 0.6, and 2.8 ± 0.3, respectively, for wild-type mice in the 10-,
30-, and 100-µg groups). These results suggest that lower antibody titers were not
primarily responsible for a mild inflammatory response as observed in IL-6-/- mice. 
T Cell Immunity in IL-6-/- Mice 
Because even the wild-type mice immunized with the lowest amount of mBSA (10 µg)
did develop a normal arthritis despite reduced antibody levels we chose this group to
evaluate T cell immunity. T cells were isolated from lymph nodes of wild-type (10 µg
mBSA)-or IL-6-/- (100 µg mBSA)-immunized mice and stimulated with mBSA in the
presence of irradiated spleens from naive mice as antigen-presenting cells. IL-6-/- T cells
responded to the antigen in the same way as wild-type T cells (Figure 5A). The ratio of
mBSA-specific proliferation of IL-6-/- over wild-type T cells (0.90 ± 0.14 from four dif-
ferent experiments) showed that IL-6-/- T cells responded normally to the antigen in
vitro. Multiplex RT-PCR analysis showed higher IL-4 and IL-5 expression after ConA
stimulation of IL-6-/- T cells (+20.0% and + 11.4%, respectively; Figure 5B) suggesting a
minor shift toward the Th2 type in IL-6-/- mice after immunization.
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Figure 5  A: mBSA-specific increase in cpm (cpm mBSA minus cpm medium). Lymph nodes from
seven mice per group were pooled and enriched for T cells as described in Materials and Methods.
Lymph node cells (2x106) together with 2x107irradiated antigen-presenting cells were incubated for
72 hours with mBSA at 25 µg/ml. Cells were plated in sixfold. Cultures were labeled with 3H for the
last 16 hours. Antigen-presenting cells were used from naive mice of the same strain. IL-6-/- and wild-
type mice did not differ in the response to concanavalin A at 1 µg/ml (IL-6-/-, 28,002 ± 7,291 cpm;
wild type, 25,436 ± 1,216 cpm) One of four experiments is shown. B: Th1/Th2 multiplex RT-PCR of
IL-6-/- (100 µg mBSA) or wild-type (10 µg mBSA) T cells stimulated for 24 hours with conA (1
µg/ml). C = positive control.
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Transfer of Wild-Type Lymphocytes Restored Joint Swelling on Day 2 
in IL-6-/-Mice
To adapt for possible differences in cellular immunity we transferred lymph node cells
from immunized wild-type mice (10 µg mBSA) to immunized IL-6-/- mice (100 µg
mBSA) at onset of arthritis. Again immunizations yielding comparable IgG2a titers were
used.
Transfer of mBSA-specific wild-type lymph node cells completely restored joint
swelling in IL-6-/- mice on day 2 of AIA (Figure 6A). Transfer of ovalbumin-specific
Table 2. Joint Inflammation and Cartilage Damage at Day 7 of AIA after Transfer of Wild-Type
Lymph Node Cells 
Cellular infiltrate, exudate, and cartilage damage at day 7 after cell transfer and induction of AIA was
scored as described in Table 1. WT/OVA, transfer of lymph node cells from ovalbumin immunized
wildtype mice. WT, wild-type mice immunized with 10 µg of mBSA. Statistical differences relative to
IL-6-/- mice plus WT/mBSA lymph node cells are indicated (*, P < 0.05; †, P < 0.005; Student’s t-test).
WT/mBSA, transfer of lymph node cells from mBSA-immunized wildtype mice. 
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Figure 6 Joint swelling on day 2 of AIA in IL-6-/- mice after transfer of 4x107lymph node cells derived
from mBSA (wild-type/mBSA) or ovalbumin (wild-type/OVA) immunized wild-type mice (A) or of
mBSA (IL-6-/-/ mBSA) immunized IL-6-/- mice (B). NT = normal AIA in wild-type mice immunized
with 10 µg of mBSA. Joint swelling was measured as the ratio of 99mTc uptake in the arthritic knee
(right) over the nonarthritic knee (left) (n = 6; *, 
P < 0.05, Student’s t-test, n.s. = not significant). , IL-6-/- , , wild type. One of three experiments is
shown.
Acceptor     IL-6 / (n 6) IL-6 / (n 11) WT( n 11)
Donor             WT/OVA              WT/mBSA             No transfer
Infiltrate           0.2 0.1                   0.8 0.7              2.7 0.5 †
Exudate            0.0 0.0*                 0.6 0.6              1.5 0.6 †
Patella               0.3 0.6*                 1.4 1.1              3.0 0.0 †
Femur               0.8 0.9 †  2.0 0.7              3.0 0.0 †
Medial
tibia
 0.8 0.8*                 2.1 1.0              2.9 0.3*
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wildtype or mBSA-specific IL-6-/- lymph node cells in contrast did not restore joint
swelling in IL-6-/- mice (Figure 6, A and B). The reverse experiment with transfer of
mBSA-specific IL-6-/- lymph node cells to wild-type mice did not influence joint swelling
in wild-type mice (Figure 6B). 
Although transfer of wild-type cells restored joint swelling on day 2 and led to an
increase in cartilage damage it did, however, not sustain joint inflammation at day 7 in
IL-6-/- mice (Table 2). At 14 days after transfer of wild- type cells and induction of arthri-
tis, joint inflammation was absent in IL-6-/- mice (data not shown).
ZIA Does Not Become Chronic in IL-6-/- Mice 
The results of the cell transfer pointed at an important role for IL-6 in developing a
chronic infiltrate. This was confirmed in the nonimmunologically mediated ZIA model.
During the first week of ZIA, inflammation did not differ between both strains. By week
3, however, inflammation persisted in wild-type mice whereas it had disappeared in IL-
6-/- mice (Table 3). Although the time scale was different in ZIA and AIA, we found in
both models that IL-6 was important in either maintaining or turning the acute inflam-
mation into a chronic synovitis.
Discussion
IL-6 is a protein that is highly expressed in joints and serum of arthritic patients, but its
exact role during arthritis is not yet known. The generation of IL-6 knockout mice30
made it possible to assess the role of IL-6 in murine arthritis models. In most of these
models the role of IL-6 in immune development and the possible role in joint inflam-
mation itself will be intermingled. In our study on AIA we found influence of IL-6 on
Table 3 Synovial Infiltrate on Day 7 and 21 of Zymosan-Induced Arthritis 
Cellular infiltrate as observed in safranin-O-stained sections. Histology was scored as described in
Table 1 (n = 7 per group). One of three experiments is shown. (*, P < 0.005, Student’s t-test; ns = not
significant).
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Infiltrate                              IL-6 / Wild-type
Day 7 ZIA                               1.4 0.6                          1.9 1.0ns
Day 21 ZIA                             0.3 0.3                          2.2 0.7*
bw-de hooge\50  30-08-2004  15:44  Pagina 61
both humoral and cellular immunity. During onset of arthritis the T cell plays a major
role, because transfer of wild-type lymph node cells restored early joint swelling in IL-6-/-
mice. The cell transfer, however, also showed that there are two phases in the AIA model
in which IL-6 plays an important role. First, IL-6 is necessary for developing a good
immune response before induction of arthritis. Second, IL-6 is important for developing
and maintaining the inflammatory infiltrate.
In a study by Ohshima et al,28 on the immunologically mediated AIA, IL-6-/- mice
hardly showed joint inflammation on day 14 of AIA. During the first days of the AIA we
observed that IL-6-/- mice do develop an inflammatory infiltrate and show cartilage dam-
age. Joint inflammation, however, decreased rapidly and by day 7 almost no inflamma-
tory cells were seen. Another striking observation was the sharp decrease in joint swelling
in IL-6-/- mice after day 1. These findings pointed at an important role for IL-6 during
the first days of the AIA in development of an inflammatory infiltrate. 
The decrease in joint swelling after day 1 could be caused by reduced expression of
genes facilitating cellular influx. IL-6 has been reported to stimulate cellular influx.36,37
However, when we compared mRNA expression for chemokines, adhesion molecules,
and pro-inflammatory cytokines we found small or no differences for the investigated set
of genes between wild-type and IL-6-/- mice on day 1 and 2 of the AIA. This indicates that
synovia of IL-6-/- mice show a normal pro-inflammatory reaction and it seems that the
reduced joint swelling and cellular influx cannot be explained by reduced pro-in-flam-
matory gene expression. This is in line with equal synovial mRNA expression for TNF-α
and IL-1β in IL-6-/- and wild-type mice on day 4 of the AIA.28 
One of the first cells that enter a site of inflammation is the neutrophil. Romani et al23
had found that IL-6-/- mice could not mount a peripheral blood neutrophilia in response
to infection with C. albicans. In our model the number of neutrophils in blood smears
did not differ between immunized wild-type and IL-6-/- mice on day 0 and 7 of the
arthritis (data not shown). Neutrophils were also the predominant type of cells in the
infiltrate during onset of arthritis in both IL-6-/- and wild-type mice, although the total
infiltrate in IL-6-/- mice was reduced. Polymorphonuclear cells and macrophages derived
from IL-6-/- mice did not exhibit differences in in vitro chemotaxis as compared to wild-
type cells.37 This finding, the results from our RT-PCR analysis, and equal cell influx dur-
ing the immune-complex-induced arthritis and the first week of ZIA26 strongly support
that neutrophils could enter the arthritic joint in IL-6-/- mice. 
Because the developed mBSA-specific immunity is important for inducing arthritis in
the mBSA-injected knee joint we compared the immune status of wild-type and IL-6-/-
mice. IL-6 plays a role in B cell maturation into antibody-secreting plasma cells.11 Lower
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mBSA-or collagen-specific total IgG titers have been reported for IL-6-/- mice. 28,38,39
When we looked into IgG subclasses we found strongly reduced IgG2a and IgG2b titers
in IL-6-/- mice, whereas IgG1 titers were not affected. The effect of IL-6 deficiency on
antibody subclasses seems to depend in part on the antigen or the type of adjuvant used
for immunization.40 This seems also true for experimental arthritis because during Lyme
arthritis, in which no previous immunization takes place, IL-6-/- mice developed wild-
type levels of IgG1 and IgG2a.25 The reduction in IgG2a and IgG2b subclasses we found
in the IL-6-/- mice during AIA seemed not to have a great influence on the primary
inflammation. Wildtype mice immunized to generate low IgG2a titers still showed joint
swelling at day 2 and developed normal joint inflammation.
Besides antibody levels the activation of complement or complement levels itself
could also differ between IL-6-/- and wild-type mice. Kopf et al,41 had found equal basal
levels for complement C3, but IL-6-/- mice failed to increase C3 after immunization.
When we compared IL-6-/- and wild-type mice in the passive immune-complex-induced
arthritis we did not find differences in joint swelling. Immune-complex arthritis is a pas-
sive immunization model that depends on complement activation in response to
immune complexes.31 Our results showed that complement activation was not impaired
in IL-6-/- mice. The above findings showed that the humoral immunity was probably not
the main determining factor during onset of AIA. IL-6 also has a role in cellular immu-
nity and a different T cell response against mBSA could occur in IL-6-/- mice during
AIA. 
Antigen-specific cellular immunity in IL-6-/- mice was compared with that in wild-
type mice immunized with one-tenth of the normal amount of mBSA. These wild-type
mice still developed AIA although their humoral immunity was reduced to that found
in IL-6-/- mice. T cells from wild-type and IL-6-/- mice proliferated to the same extent in
response to mBSA. Higher mRNA expression of IL-4 and IL-5 after conA stimulation of
IL-6-/- T cells, however, suggested a small shift toward the Th2 type in IL-6-/- mice. In
vitro results of Ohshima et al,28 also suggested a shift toward the Th2 type in IL-6-/- mice. 
The difference in T cell subtypes could influence arthritis development in IL-6-/- mice.
To investigate the importance of the T cell type in more detail, we transferred lymph
node cells from wild-type to IL-6-/- mice. Previous experiments with C57Bl6 mice had
shown that the T cell fraction in lymph-node cell preparations could transfer AIA.42 For
these experiments wild-type mice immunized with 10 µg instead of 100 µg of mBSA were
used as donors because they had mBSA-specific IgG2a titers comparable to IL-6-/- mice
and still showed higher joint swelling and developed a chronic arthritis. Transfer of
lymph node cells from mBSA-immunized but not from ovalbumin-immunized wild-
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type mice restored joint swelling on day 2 in IL-6-/- mice to wild-type levels. mBSA-
specific antibody titers, as assessed by IgG2a, did not increase between day 1 and 2 after
transfer and induction of arthritis (data not shown). This suggests an important involve-
ment of the antigen-specific cellular response in joint swelling during onset of arthritis.
Transfer of lymph node cells from immunized IL-6-/- mice to immunized IL-6-/- mice
did not restore joint swelling. This shows that the restored joint swelling after transfer of
mBSA-specific wild-type cells is not caused by increased T cell numbers but instead sug-
gests influence of the T cell subtype on joint swelling. 
Despite equal joint swelling, IL-6-/- mice receiving mBSA-immunized wild-type
lymph node cells did not develop arthritis as severe as that found in wild-type mice. In
synovial washouts on day 1 or 2 after cell transfer no locally produced IL-6 was measured
in a B9 bioassay. In joints of wild-type mice, IL-6 is expressed at high levels during AIA.43
The inability to develop a chronic infiltrate by IL-6-/- mice even after transfer of wild-
type lymph node cells could be caused by a reduced local immune development. In
human rheumatoid synovium, the development of germinal centers has been
described.44 Interestingly, IL-6-/- mice develop smaller germinal centers compared to
wild-type mice41 and this could also be the case in inflamed synovia. 
Transfer of the wild-type lymph node cells 3 days before injection of mBSA showed
that they could survive in IL-6-/- mice and remained capable of restoring joint swelling
(day 2: 1.68 ± 0.30). Their survival in the inflamed joint, however, could be impaired, as
an anti-apoptotic function of IL-6 has been described.45,46 IL-6 has been shown to
enhance in vitro the survival of T cells by inducing the anti-apoptotic protein Bcl-2.47 A
very recent report showed increased apoptosis of mucosal T cells after inhibition of IL-6
signaling in Crohn’s disease.48 This further supports an anti-apoptotic role of IL-6 in
chronic inflammatory diseases. Increased apoptosis in the joints of IL-6-/- mice could
inhibit formation of a normal infiltrate and influence local immune development despite
the presence of wild-type T cells. An anti-apoptotic role of IL-6 would also influence sur-
vival of other synovial cells such as macrophages and fibroblasts. We currently have start-
ed experiments on this issue. A recent report showing development of collagen-induced
arthritis in mice lacking functional T and B cells49 further stresses the importance of
nonimmunological mechanisms in experimental arthritis. 
During the nonimmunologically mediated ZIA, inflammation developed normally in
IL-6-/- mice during the first week but declined thereafter. Preliminary results showed up-
regulation of suppressors of cytokine signaling (SOCS) expression in the inflamed syn-
ovia during ZIA. For SOCS3 there was a small increase in expression in both strains. The
increase of SOCS1 mRNA expression, however, was much higher for IL-6-/- mice than
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for wild-type mice at day 14 of the ZIA. This suggests a causal relationship with an early
remission of arthritis in IL-6-/- mice. 
SOCS1 belongs to the SOCS family of proteins,50,51 an important group of inhibitors
of cytokine signaling by the JAK-STAT pathway. Differences in expression of SOCS pro-
teins could affect the inflamed synovium in several ways. First, SOCS proteins inhibit sig-
naling by different pro-inflammatory cytokines such as IL-2,52 interferon-γ,50 and mem-
bers of the IL-6 family.50,53 Second, there is evidence that SOCS proteins could influence
other pathways besides the JAK-STAT pathway. SOCS1 for example has been shown to
inhibit the proliferative signaling of the Kit receptor in hematopoietic and fibroblast
cells.54 Third, SOCS proteins might inhibit signaling by binding to activated signaling
proteins and targeting them for degradation by the proteasome.55,56
Although SOCS proteins function in a negative feedback loop it has also been sug-
gested that they can be expressed independent of cytokine signaling.51,57,58 Future
research will have to address the regulation of cytokine signaling in inflamed synovia and
the role of SOCS proteins in chronicity of arthritis. 
In conclusion, we have found in the immunologically mediated AIA and also in the
nonimmunologically mediated ZIA that IL-6 plays an important role in progression of
initial joint inflammation into a chronic infiltrate. In RA patients, autoimmunity already
exists but our finding suggests that anti-IL-6 therapy could still influence maintenance of
synovial infiltrates.
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Abstract
Objective. STAT proteins play an important role in cytokine signaling. Some investiga-
tors have reported preferential activation of STAT-1, and others have reported preferen-
tial activation of STAT-3, in response to endogenous interleukin-6 (IL-6), in patients
with rheumatoid arthritis. The present study was undertaken to investigate synovial
STAT-1 and STAT-3 activation in an experimental animal model of arthritis. 
Methods. Zymosan was injected intraarticularly into naive wild-type (WT), IL-6
-/-
,
and STAT-1-/- mice to induce arthritis. Western blots of synovial lysates were probed
with phosphospecific antibodies to detect STAT-1/STAT-3 activation. Inflammation was
assessed histologically. Synovial gene expression of the STAT-induced feedback
inhibitors suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 in WT and STAT-1
-
/-
mice was investigated by reverse transcriptase- polymerase chain reaction. 
Results. STAT-3 was activated in inflamed synovium of WT mice throughout the
course of disease, whereas activated STAT-1 was observed only during the chronic phase.
In IL-6-/-mice, STAT activation was limited to STAT-3 on day 1. Although macrophage
influx was not inhibited, disease went into remission after day 7 in IL-6-/- mice. STAT-1
deficiency resulted in exacerbation of chronic joint inflammation and granuloma forma-
tion. In STAT-1-/-mice, STAT-3 activation in the inflamed joints was unaltered as com-
pared with WT mice. However, synovial SOCS-1, but not SOCS-3, gene expression was
markedly reduced in STAT-1-/- mice. 
Conclusion. The results in the IL-6-/- mice suggest that STAT-3 is involved in the
chronicity of ZIA. Exacerbation of arthritis in STAT-1-/- mice suggests an opposing effect
of STAT-1, i.e., suppression of joint inflammation. The expression of SOCS-1 could be
the underlying mechanism by which STAT-1 controls joint inflammation.
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Introduction
The JAK/STAT pathway plays an important role in cytokine and growth factor-induced
signal transduction. Signaling through this pathway is mediated by phosphorylation of
STAT proteins (1). Upon activation the STATs dimerize, translocate to the nucleus, and
initiate transcription of STAT-responsive genes. Seven different STATs (STATs 1-4, 5a,
5b, and 6) that can form both STAT homo-and STAT heterodimers have been described
to date. During recent years it has become clear that STATs play key roles in
developmental processes, growth control, immune system development, and resistance
to infection (2). Dysregulated STAT function contributes to human disease, as has been
studied most extensively in cancer development (3). 
Rheumatoid arthritis (RA) is characterized by chronic inflammation of the joint.
Although its exact cause is still unknown, pro-and antiinflammatory cytokines seem to
play an important role in RA pathology (4). Studies on activation of STATs in RA syn-
ovial fluid (SF) cells have yielded conflicting results. Activated STAT-3 has been found in
SF cells from RA patients (5). Furthermore, SF from RA patients has been shown to
induce STAT-3 activation in monocytes (6); this activity could be blocked by neutraliza-
tion of IL-6. Yokota et al, in contrast, observed activation of STAT-1, and not STAT-3,
in RA SF cells (7); this activation could also be prevented by incubation with anti-IL-6
antibodies. The reason for these differences regarding STAT-1 and STAT-3 activation is
not yet clear. 
IL-6 is a multifunctional cytokine that is found in large quantities in the SF and serum
of patients with RA (8). Amelioration of collagen-induced arthritis (9,10) as well as anti-
gen-induced arthritis (AIA) (11,12) in IL-6-/- mice has been reported, which indicated an
important proinflammatory role for IL-6. In these models, IL-6 deficiency led to reduced
antigen-specific immunity prior to actual joint inflammation. We recently reported that
transfer of wild-type (WT) lymph node cells could enhance the acute inflammation and
also the cartilage damage in IL-6-/- mice with AIA. Chronic synovitis, however, still did
not develop in IL-6-/- mice (12). This suggests an important role for IL-6 in chronicity of
arthritis, which is possibly independent of its role in immunity. Studies of IL-6 blocking
in RA patients have demonstrated a significant therapeutic effect on clinical and labora-
tory parameters (13). To date, the effect of anti-IL-6 treatment on STAT activation has
not been investigated. 
Different biologic effects of STAT-1 and STAT-3 have been described, and it remains
to be determined which subtype contributes to the proinflammatory effect of IL-6 in RA.
In the present study we compared synovial STAT-1 and STAT-3 activation during the
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course of experimental arthritis in WT and IL-6-/-mice. To avoid differences caused by
immunizations, we compared these mice during the acute and chronic phases of non-
immunologically mediated zymosan-induced arthritis (ZIA) (14). To further investigate
STAT-1 involvement, we induced ZIA in STAT-1
-/- 
mice and studied arthritis develop-
ment in these animals. 
Materials and methods 
Animals
Breeding pairs of homozygous IL-6-/- mice, WT (C57BL/6 x129Sv)F2 mice (15), and IL-
6-/- mice backcrossed onto C57BL/6 mice for 8 generations were obtained from Dr. M.
Kopf (Basel, Switzerland). C57BL/6 mice were obtained from Charles River Deutschland
(Sulzfeld, Germany). All mice were housed in filtertop cages in our specific pathogen-
free animal facilities. A standard diet and acidified tap water were provided ad libitum.
The animals were studied at the age of 8-10 weeks. STAT-1-/- mice were originally devel-
oped by Dr. D. Levy (New York, NY) (16). Breeding pairs of STAT-1-/- mice and their
WT controls were kept at the Institute for Agrobiotechnology. Experiments with STAT-
1-/- mice were performed in isolators at the animal facilities of the University of
Nijmegen. Sterile food and water were provided ad libitum. Experiments were conduct-
ed according to national and institutional regulations for animal use. 
Zymosan-induced arthritis
A 30-mg/ml suspension of zymosan A (Saccharomyces cerevisiae) was made in
endotoxinfree saline. The suspension was autoclaved and arthritis was induced by
intraarticular injection of 180 µg of zymosan A into the knee joint cavity. The contralat-
eral knee joint served as a within-animal control. Physiologic saline was used for control
injections. 
Histologic study of knee joints
Knee joints were dissected, fixed in formalin, decalcified, dehydrated, and embedded in
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paraffin. Standard 7-µm frontal sections were prepared and stained with hematoxylin
and eosin or Safranin O. Serial sections were scored for inflammation on a scale of 0-3
by 2 independent observers, in a blinded manner. For differences in inflammation score,
P values less than < 0.05 (by rank sum test) were considered significant. 
Isolation of inflamed synovium for protein determinations 
Synovial tissue was isolated in a standardized manner as described previously (17).
Surrounding muscle, patellar ligament, and patella were removed before isolation of the
synovial tissue. Care was taken not to damage large blood vessels. The tissue was imme-
diately frozen in liquid nitrogen. Tissue samples were homogenized in a freeze mill and
lysed on ice for 15 minutes in lysis buffer containing 0.5% Nonidet P40, 10 mM Tris HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4 (pH 10.0), and 1x protease
inhibitor cocktail (PharMingen, Woerden, The Netherlands). Insoluble material was
removed by centrifugation. Protein concentrations were determined with the BCA
Protein Assay Kit (Pierce, Rockford, IL). 
Western blotting 
For Western blotting, 30 µg of synovial cell lysate was run on a sodium dodecyl sulfate-
7.5% polyacrylamide gel. Cell lysates from HeLa cells (Cell Signaling Technology,
Beverly, MA) with or without interferon-α (IFNα) treatment served as positive and neg-
ative controls for STAT-1/STAT-3 activation. Proteins were electrophoretically trans-
ferred onto polyvinylidene difluoride membranes (Hybond P; Amersham Pharmacia
Biotech, Buckinghamshire, UK). Membranes were blocked with Tris buffered saline-
Tween/1% bovine serum albumin (BSA; Sigma, St. Louis, MO)/1% nonfat dry milk
(Campina, Eindhoven, The Netherlands). After incubation with first and secondary anti-
bodies, the membranes were developed with an enhanced chemiluminescence detection
system (ECL+Plus; Amersham Pharmacia Biotech). For reprobing, the membranes were
stripped in 0.2M glycine (pH 2.5)/0.05% Tween 20 at 80°C for 20 minutes. 
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Antibodies 
Rabbit anti-mouse antibodies specific for STAT-1, STAT-3, phosphorylated STAT-1
(Tyr701), and phosphorylated STAT-3 (Tyr705) were obtained from Cell Signaling
Technology. Goat anti-mouse actin (Santa Cruz Biotechnology, Santa Cruz, CA) was
used as a control for protein loading. Horseradish peroxidase-labeled secondary anti-
bodies (goat anti-rabbit IgG and donkey anti-goat IgG) were from Santa Cruz
Biotechnology. 
NIMP-R14 and F4/80 staining 
Knee joint sections were stained for the presence of the NIMP-R14 epitope (18), which
is mainly present on neutrophils, and for the F4/80 cell surface glycoprotein, which is
expressed on macrophages. Sections were deparaffinized and, after antigen retrieval and
preincubation for 15 minutes with 20% normal rabbit serum, were incubated for 1 hour
with anti-NIMP-R14 antibodies (a kind gift from Dr. M. Strath, London, UK), anti F4/80
(Instruchemie, Hilversum, The Netherlands), or normal rat Ig. After incubation for 30
minutes with peroxidase-labeled rabbit anti-rat secondary antibody in 5% normal
mouse serum/ phosphate buffered saline, the sections were incubated for 10 minutes
with diaminobenzidine (1 mg/ml in 50 mM Tris HCl [pH 7.6], 0.001% H2O2). Sections
were counterstained with hematoxylin for 30 seconds. 
Synovial RNA isolation 
Synovial tissue was isolated in a standardized manner and immediately frozen in liquid
nitrogen. The tissue was homogenized in a freeze mill, thawed in 1 ml of TRIzol reagent,
and further processed according to the protocol recommended by the manufacturer
(Life Technologies Breda, The Netherlands). Isolated RNA was treated with DNase I
before being reverse transcribed into complementary DNA (cDNA) with Moloney
murine leukemia virus reverse transcriptase. 
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Semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for
SOCS-1 and SOCS-3
Primers were designed with Primer3 software (19) and manufactured at Eurogentec
(Seraing, Belgium). The following primers were used: for SOCS-1, forward 5’-CTTAAC-
CCGGTACTCCGTGA-3’, reverse 5’-GAGGTCTCCAGCCAGAAGTG-3’; for SOCS-3,
forward 5’-ATTCACCCAGGTGGCTACAG-3’, reverse 5’-AACACCGGACCAGTTCC
AGG-3’. Primers were annealed at 55°C. The reaction mixture contained 2 µl of cDNA,
1 x PCR buffer, 20 pmoles of each primer, 0.2 mM of each dNTP, 1mM MgCl2, and 2
units Taq DNA polymerase. All PCR reagents were from Life Technologies. 
Samples were taken after increasing numbers of PCR cycles as described previously
(17) and run on a 1.6% agarose gel. PCR products were stained with ethidium bromide
and visualized under ultraviolet light. The cycle number at which the PCR product was
first detected on the gel was taken as a measure for the amount of specific messenger
RNA (mRNA) originally present in the isolated synovial RNA. PCR for GAPDH was per-
formed to verify that equal amounts of cDNA were used. PCR for IL-6 confirmed IL-6
deficiency in IL-6-/- mice. 
RESULTS 
Zymosan-induced arthritis and STAT activation in WT mice 
Injection of zymosan into the knee joints of naive WT mice elicited a local inflammation
that could be divided into 2 phases. Acute joint swelling and an influx of polymor-
phonuclear granulocytes (PMNs) characterized the first 7 days (Figure 1A). Synovial
hyperplasia and infiltration of mononuclear cells dominated the second phase, between
week 2 and week 4 (Figure 1B). Protein lysates of synovia from inflamed and con-
tralateral uninjected knee joints were made. We first studied synovial STAT-3 activation
with antibodies specific for Tyr705-phosphorylated STAT-3. In WT mice, STAT-3
became activated during both the acute and the chronic phase of ZIA (Figure 2). We
observed STAT-3 activation until the end of the experiments (at week 4 of arthritis). No
synovial STAT-3 activation was observed on day 1 or day 6 after injection of saline
(results not shown), excluding the possibility of a side effect of the injection. Activation
of STAT-1 was investigated with antibodies specific for Tyr701-phosphorylated STAT-1.
No STAT-1, activated or not, could be detected in inflamed synovia of WT mice during
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Figure 1 Joint inflammation induced by intraarticular injection of zymosan into wild-type mice. A,
Day 7 of zymosan-induced arthritis (ZIA). Inflammation is evident. B, Day 21 of ZIA. The inflamma-
tion has progressed to chronic synovitis. Similar results were obtained in 3 experiments with 7 mice
per group. P = patella; F = femur; S = inflamed synovium. (Hematoxylin and eosin stained; original
magnification x 155.)
Figure 2 Continuous STAT-3 activa-
tion during zymosan-induced arthri-
tis (ZIA) in wild-type (WT) mice.
Activated STAT-3 was detected in the
inflamed arthritic synovium (A) of
WT mice during both the acute phase
(days 1-7) and the chronic phase
(after day 7) of ZIA. Although STAT-
3 was expressed, no STAT-3 activa-
tion was detected in synovium from
uninjected contralateral knee joints
(C) of the same mice. Similar results
were obtained in at least 2 indepen-
dent experiments with 3-4 mice per
time point. STAT-3p = phosphorylat-
ed STAT-3.
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the time of ZIA onset. Minor STAT-1 activation started in some mice on day 7.
Thereafter, the total amount of STAT-1 protein in the synovium increased and STAT-1
activation became clearly detectable (days 14 and 21 of ZIA) (Figure 3).
Zymosan-induced arthritis and STAT activation in IL-6-/- mice.
Injection of zymosan induced an acute inflammation in IL-6-/-mice (Figures 4A and C).
In contrast to ZIA in WT mice, joint inflammation in  IL-6-/- mice did not became
chronic after the first week and was completely resolved by day 21 (Figure 4B). 
In the original description of the ZIA model, 2 inflammatory phases could be distin-
guished: an acute phase characterized by PMN influx and a chronic phase with mononu-
clear cells as the main infiltrating cell type. This latter phase was characterized by synovial
hypertrophy and pannus formation, features of chronic arthritis. The transition took
place between day 7 and day 14. At no time were lymphoid aggregates or plasma cells
observed during ZIA (14). Immunostaining with NIMPR14 confirmed the presence of
PMNs during the acute inflammation and their decline in the chronic phase of ZIA in
WT mice (Figures 5A and E). In IL-6-/- mice, PMNs were also the dominant cell type in
the acute phase but, in contrast to WT mice, they were completely absent when the
inflammation went into remission (Figures 5C and G). Macrophages (F4/80-positive
cells) were absent during the acute phase in WT mice (Figure 5B), started to enter dur-
ing the transition phase, and were clearly present during the chronic phase (Figure 5F).
In IL-6
-/- 
mice, in contrast, macrophages were present in both the acute and the remis-
sion phases (Figures 5D and H). 
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Figure 3 STAT-1 activation in the inflamed synovium of WT mice. Activated STAT-1 was observed in
the arthritic synovium of WT mice during the chronic phase of ZIA (days 14 and 21). No activation was
observed during the acute phase of ZIA (day 2). No or very limited STAT-1 activation was observed on
day 7. At no time was STAT-1 activation observed in contralateral knee joints (C; day 21 shown as an
example); similarly, it was not induced by injection of physiologic saline. Similar results were obtained
in at least 2 independent experiments with 3-4 mice per time point. See Figure 2 for definitions.
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Figure 4 Impaired inflammation in interleukin-6-/- (IL-6-/-) mice. A, Acute inflammation in an IL-6-/-
mouse on day 7. B, Absence of chronic synovitis in an IL-6-/- mouse on day 21. C and D, Detail of
inflamed synovium on day 7 of ZIA in an IL-6-/- and a WT mouse, respectively. Similar results were
obtained in 3 experiments with 7 mice per group. P = patella; F = femur; S = inflamed synovium (see
Figure 2 for other definitions). (Hematoxylin and eosin stained; original magnification x 155 in A and B;
x 400 in C and D.)
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Synovial cell lysates from arthritic IL-6-/- mice showed activation of STAT-3 on the first
day of ZIA (Figure 6A). After day 1, STAT-3 activation was no longer detectable in syn-
ovia of IL-6-/- mice (Figure 6B), even though the joint remained inflamed during the first
week. STAT-1 activation was completely absent in synovia of IL-6-/- mice (Figure 6C).
This lack of STAT activation does not seem to reflect absence of inflammatory cells since
both PMN and macrophage influx occurred in the IL-6-/- mice as demonstrated by
immunohistochemistry analysis. 
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Figure 5 Immunodetection
of polymorphonuclear cells
(PMNs) and macrophages in
inflamed synovia of WT and
interleukin-6-/- (IL-6-/-)
mice. PMNs were detected
with NIMP-R14 staining and
macrophages with F4/80
staining, as described in
Materials and Methods. A
and B, Staining with NIMP-
R14 and F4/80, respectively,
in WT mice on day 2 of ZIA.
C and D, Staining with
NIMP-R14 and F4/80,
respectively, in IL-6-/- mice
on day 2 of ZIA. E and F,
Staining with NIMP-R14
and F4/80, respectively, in
WT mice on day 14 of ZIA.
G and H, Staining with
NIMP-R14 and F4/80,
respectively, in IL-6-/- mice
on day 14 of ZIA. Normal
rat Ig did not produce stain-
ing on sections from either
strain (results not shown).
See Figure 2 for other defini-
tions. (Original magnifica-
tion x 200.)
bw-de hooge\50  30-08-2004  15:44  Pagina 79
Exacerbation of ZIA in STAT-1-/- mice 
Activation of STAT-1 was detectable only during the chronic phase of ZIA. To investi-
gate whether activated STAT-1 plays a role in the chronicity of arthritis, we injected
zymosan into the knee joints of STAT-1-/- mice. Histologic analysis (Figures 7A and B)
showed that inflammation in these mice was significantly increased, to a degree that
caused joint immobilization (mean ± SD inflammation score 2.9 ± 0.4 in STAT-1-/- mice
versus 1.75 ± 0.3 in WT mice; n = 8 per group) (p < 0.001 by rank sum test). Such joint
immobilization was not observed in WT mice with ZIA. The inflamed synovium of
STAT-1-/- mice was highly infiltrated with PMNs that partly were concentrated in gran-
uloma-like structures (Figure 7C). Although more severe than in WT mice, the inflam-
mation remained restricted to the injected joints, and no other signs of disease were
observed in the STAT-1-/- mice. Injection of saline did not induce joint inflammation in
STAT-1-/- mice (Figure 7D). Proteoglycan depletion in the articular cartilage  was
observed in both WT and STAT-1-/- mice (Figures 7E and F). The increased inflamma-
tion, however, did not lead to enhanced cartilage or bone erosion in the STAT-1-/- mice.
This suggests that STAT-1 predominantly plays a role in regulating the inflammation
during arthritis. Western blot analyses of synovial lysates showed that STAT-3 becomes
activated during ZIA in STAT-1-/- mice (Figure 8). 
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Figure 6 Impaired STAT-3 and STAT-1 activa-
tion in interleukin-6 -/- (IL-6-/-) mice. A, As
in WT mice, STAT-3 became activated in the
synovium of IL-6-/- mice on day 1 after
intraarticular injection of zymosan. B, No
STAT-3 activation was observed in the synovi-
um of IL-6-/- mice on day 2, 7, or 14 after
intraarticular injection. C, No STAT-1 activa-
tion was observed in the synovium of IL-6-/-
mice after zymosan injection. In the studies of
STAT-3 activation on days 2, 7, and 14 and of
STAT-1 activation on days 2, 7, 14, and 21, a
positive signal was observed for the positive
control that was present on the same blot
(results not shown). Similar results were
obtained in at least 2 independent experiments
with 3-4 mice per time point. See Figure 2 for
other definitions.
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SOCS-1 and SOCS-3 expression in inflamed synovia 
The SOCS family proteins are important regulators of STAT activation; these proteins
are inhibitors that are themselves induced by activated STATs. By semiquantitative RT-
PCR it was shown that SOCS-1 gene expression was enhanced in inflamed joints on day
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Figure 7 Exacerbated inflammation in STAT-1-/- mice. A, Exacerbation of joint inflammation in a STAT-
1-/- mouse on day 14 of ZIA. The enhanced inflammation led to joint fixation in these mice; this was
observed in 3 different experiments with 6-8 mice per group (hematoxylin and eosin stained). B,
Conventional ZIA in a WT mouse (hematoxylin and eosin stained). C, Granuloma-like structures in the
inflamed synovium of a STAT-1-/-mouse. NIMP-R14 staining showed these structures to be rich in poly-
morphonuclear cells (diaminobenzidine stained [dark dots] and hematoxylin counterstained). D, Lack of
inflammation in the joint of a STAT-1-/- mouse injected with physiologic saline (hematoxylin and eosin
stained). E and F, Proteoglycan (PG) loss but no cartilage erosion in both STAT-1-/- (E) and WT (F) mice
on day 14 of ZIA. In both strains, PG loss is shown in the upper cartilage layers by reduced staining with
Safranin O. Arrowheads in E indicate the tidemark that separates the PG-depleted upper cartilage layer
(gray) from the nondepleted deeper layers (dark). P = patella; F = femur; S = synovium (see Figure 2 for
other definitions). (Original magnification x 50 in A, B, and D; x 200 in C; x 400 in E and F.)
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14 of ZIA in WT mice (Table 1). This coincided with the activation of STAT-1 in this
inflamed synovial tissue. SOCS-3 gene expression, in contrast, was enhanced on both day
7 and day 14 of ZIA, and this coincided with the activation of STAT-3. 
The exacerbation of arthritis in STAT-1-/- mice could be caused by a derailment of
SOCS regulation. We therefore compared synovial SOCS-1 and -3 gene expression
between WT and STAT-1
-/- 
mice. Reduced SOCS-1 expression was found in inflamed
synovia of STAT-1-/- mice during ZIA (Table 2). SOCS-3 expression, in contrast, was not
reduced in STAT-1-/- mice. 
Taken together, the present results demonstrate local activation of both STAT-1 and
STAT-3 during chronic ZIA. Furthermore, they suggest an important role of STAT-1 in
controlling the inflammation. The reduced SOCS-1 expression in STAT-1-/- mice makes
SOCS-1 a candidate gene that could contribute to the control of arthritis. 
Table 1 Expression of SOCS-1 and SOCS-3 mRNA and of phosphorylated STAT-1 and STAT-3 in the
synovium of wild-type mice with zymosan-induced arthritis (ZIA) 
*Expression of mRNA for suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 was determined
by semiquantitative reverse transcriptase- polymerase chain reaction (RT-PCR) as described in
Materials and Methods. For each sample, the cycle number at which GAPDH, SOCS-1, and SOCS-3
were first detected was determined. The cycle numbers for SOCS-1 and SOCS-3 have been corrected
for GAPDH expression by presenting the number of cycles after the first detection of GAPDH. A lower
cycle number indicates that the product is expressed at higher levels. At each time point, synovial tis-
sue from 6 mice was examined and PCR was performed twice. Values are the mean or the mean ± SD
for 1 of 2 independent experiments with similar results (where only the mean is shown, the SD was 0). 
†- = no activation in inflamed synovium; -/+ = no or minimal activation in inflamed synovium; ++ =
marked activation in inflamed synovium.
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Figure 8 STAT-3 activation in the inflamed
joints of STAT-1-/- mice. Activated STAT-3 was
detected in the inflamed synovium of STAT-1-
/- mice on days 7 and 14 of ZIA. No STAT-3
activation was detected in the contralateral knee
joint. Inflamed synovia from 4 STAT-1-/- mice
were examined, with similar results. See Figure
2 for definitions.
RT-PCR*               Westernblot †
Cycle,
SOCS-1
Cycle,
SOCS-3
Phosphorylated
STAT-1
Phosphorylated
STAT-3
No arthritis        12 2        11 1                   –                                 –
ZIA day 7                 12            7 1                 –/
ZIA day 14                6                 6            
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Discussion 
In the present study, temporal differences in STAT activation were found. STAT-1
expression and activation were restricted to the chronic phase of ZIA (days 14-21). In IL-
6-/- mice, continuous STAT-3 activation was not observed even though these animals
exhibited the expected acute inflammation. Our results provide evidence that without
STAT-1 activation, mice develop a chronic granulomatous synovitis. 
Zymosan-induced arthritis is characterized by an acute (days 1-7) influx of PMNs
(observed with NIMP-R14 immunostaining) followed by a gradual increase (days 7-21)
of mononuclear cell infiltration into the synovium (observed with F4/80 immunostain-
ing). In  IL-6-/-mice, the acute joint inflammation did not develop into a chronic phase.
Previous in vitro studies have demonstrated a direct role of IL-6 in the recruitment of
PMNs and monocytes. Endothelial cells lack the IL-6 receptor (gp80), and only in com-
bination with the soluble IL-6 receptor α subunit (sIL-6Rα) can IL-6 induce the PMN-
binding proteins E-selectin and intercellular adhesion molecule 1 and the monocyte
binding protein vascular cell adhesion molecule 1 (20). This role of IL-6 in PMN influx
was not confirmed in this study or in a previous study showing that IL-6 deficiency did
not affect the acute phase of antigen-induced joint inflammation or the gene expression
of adhesion molecules E-selectin and P-selectin (12). In studies of zymosan-induced
peritonitis, however, the acute inflammation was reduced in IL-6-/- mice (21). 
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Table 2 Expression of SOCS-1 and SOCS-3 mRNA in the synovium of wild-type WT and STAT1-/-
mice with ZIA* 
*Expression of mRNA for SOCS-1 and SOCS-3 was determined by semiquantitative RT-PCR as
described in Materials and Methods. For each sample, the cycle number at which GAPDH, SOCS-1,
and SOCS-3 were first detected was determined. The cycle numbers for SOCS-1 and SOCS-3 have
been corrected for GAPDH expression by presenting the number of cycles after the first detection of
GAPDH. A lower cycle number indicates that the product is expressed at higher levels. The experi-
ments were performed once on day 7 and twice on day 14. At each time point, synovial tissue from 6
mice was examined and PCR was performed twice. Values are the mean or the mean ± SD (where only
the mean is shown, the SD was 0). PBS = phosphate buffered saline (see Table 1 for other definitions).
Cycle, SOCS-1                             Cycle, SOCS-3
Wild-type
mice
STAT1 /
mice
Wild-type
mice
STAT1 /
mice
PBS day 7              14 1               14 1               13 1              12 1.5
ZIA day 7                5 1.5              8 1                 5 1.5             4 1
PBS day 14            13 0.5            13 1.5            11 1              11 1.5
ZIA day 14              5 2                     8                  6.5 0.5                 5
bw-de hooge\50  30-08-2004  15:45  Pagina 83
This discrepancy in the IL-6 dependency of inflammation could be related to the site
of inflammation. It was previously shown, in experiments using zymosan to induce
inflammation, that acute peritonitis is dependent on the integrins lymphocyte function-
associated antigen 1 and Mac-1, whereas these integrins are not important in joint
inflammation (22). Likewise, zymosan can elicit joint inflammation via complement
activation (23), but complement is minimally involved in zymosan-induced peritonitis
(24). It is therefore possible that, in contrast to the situation in peritonitis, IL-6, though
present during the onset of ZIA, does not play a decisive role during this phase of the dis-
ease and is overruled by the action of other cytokines. 
In this study we identified a major role of IL-6 in the transition from the acute to the
chronic phase of arthritis. The transition from PMN to mononuclear cell infiltration can
be explained by enhanced clearance of PMNs and the induction of the mononuclear cell
chemokine monocyte chemotactic protein 1 by the endothelium after stimulation with
the IL-6/sIL-6R α complex (25,26). However, after the first week of joint inflammation,
PMNs were still present in WT mice but absent in IL-6-/- mice, and this suggests a pro-
tective effect of IL-6 on PMN survival. There is compelling evidence that STAT-3 is
involved in the survival of PMNs (27,28), possibly by prevention of apoptosis. The role
of IL-6 in the clearance of PMNs could, however, be far more complex, with IFNγ con-
tributing to the IL-6/sIL-6R-mediated clearance of PMNs from the site of inflammation
(29). IFNγ largely signals through STAT-1 activation, and STAT-1 could therefore be
involved in PMN resolution. This is consistent with the finding of exaggerated and pro-
longed PMN infiltration in the STAT-1-/- mice in the present study. 
We showed that during ZIA, synovial SOCS-1 and -3 mRNA expression coincided
with the activation of STAT-1 and STAT-3, respectively (Table 1). In recent studies using
genetically modified mice and gene therapy approaches, it has been demonstrated that
STAT-1/3 activation and SOCS expression are important regulators of experimental
arthritis. Mice with a point mutation in the SH2-binding site of gp130 (Y759), the dock-
ing site of SOCS-3, develop autoimmune-mediated joint inflammation, probably due to
prolonged STAT-3 activation in their T cells (30). Furthermore, periarticular adenoviral
overexpression of SOCS-3 is effective in attenuating collagen-induced arthritis in mice
(31). SOCS proteins, however, might redirect signaling pathways in a concentration-
dependent manner (32-34). In the absence of SOCS-3, prolonged STAT-3 and STAT-1
activation has been observed in vitro and in vivo after stimulation with IL-6. The pro-
longed STAT-1 activation most likely contributed to the IFNγ-like gene expression in
response to IL-6 (33,34). 
We found that SOCS-1 expression was diminished in the STAT-1-/- mice. In studies
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of mice lacking the SOCS-1 gene, it has been shown that SOCS-1 is an important nega-
tive regulator of acute arthritis in the methylated BSA/IL-1 arthritis model (35). In
experiments using SOCS-1-/- macrophages, Kinjyo et al demonstrated that SOCS-1
could negatively regulate lipopolysaccharide-induced cytokine production by inhibiting
Toll-like receptor 4 signaling (36). This inhibition was mediated through interference
with IL-1R- associated kinase-mediated NF-κB activation and demonstrates that SOCS
proteins can also directly inhibit other signaling pathways besides JAK-STAT. The exper-
iments performed in the STAT-1-/- mice clearly showed that SOCS-1 gene expression
was decreased, and this might have caused unrestricted proinflammatory cytokine sig-
naling and exacerbation of arthritis. 
Microarray analysis of synovial biopsy specimens from 21 patients showed that the RA
population could be divided into 2 groups with different levels of STAT-1 expression,
and with higher levels of STAT-1 indicative of an immunologically mediated inflamma-
tory process (37). That study, however, did not include an investigation of either STAT-
1 activation or the relationship between STAT-1 expression and disease parameters.
Whether STAT-1 plays a pro-or an antiinflammatory role in human RA requires further
examination. This division on the basis of STAT-1 expression and the reported differ-
ences in STAT activation (5,7) could be reflective of different phases of RA, as was sug-
gested by the temporal expression and activation of STAT-1 in the ZIA model. 
Besides the JAK/STAT pathway, IL-6 can also activate mitogen-activated protein
kinase and phosphatidylinositol 3-kinase pathways. These pathways could also be
involved in RA (38). Future studies should address their induction by IL-6 and the inter-
play between these different pathways in arthritis. 
Our study adds further data on the involvement of STAT proteins in the progression
of arthritis and elucidates a possible role of STAT-1 in the downregulation of arthritis
and of STAT-3 in the perpetuation of joint inflammation. STAT-1 involvement is not
limited to the arthritis induced by the irritant zymosan, since preliminary experiments
showed that STAT-1 deficiency also exacerbates immune complex-induced arthritis.
Opposing effects of activated STAT-1 and STAT-3 have been described for different dis-
eases (39,40), and our study demonstrates that this could be true for RA as well (41). The
present results also show that STAT-1 and STAT-3 are differentially regulated during the
acute and chronic phases of arthritis. The findings reported herein suggest that selective
manipulation of STAT activation or SOCS expression may have therapeutic efficacy in
RA. This warrants further investigation. 
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Abstract
Oncostatin M (OSM) has been described as a bone-remodeling factor either stimulating
osteoblast activity or osteoclast formation in vitro. To elucidate the in vivo effect of OSM
on bone remodeling, we injected an adenoviral vector encoding murine OSM in knee
joints of mice. OSM strongly induced interleukin (IL)-6 gene expression, a known medi-
ator of osteoclast development. We investigated the OSM effect in wild-type and IL-6-
deficient mice and found a similar degree of OSM-induced joint inflammation. Within
the first week of inflammation, the periosteum along the femur and tibia increased in cell
number and stained positive for the osteoblast marker alkaline phosphatase. At these
sites bone apposition occurred in both strains as demonstrated by Goldner and Von
Kossa staining. In vitro OSM enhanced the effect of bone morphogenetic protein-2 on
osteoblast differentiation. Immunohistochemistry demonstrated expression of receptor
activator of nuclear factor-κB ligand (RANKL) and its receptor , receptor activator of
nuclear factor-κB (RANK), in the periosteum but osteoclasts were not detected at sites
of bone apposition. Induced mRNA expression for the receptor activator of nuclear fac-
tor-κB ligand inhibitor osteoprotegerin probably controlled osteoclast development dur-
ing OSM overexpression. Our results show that OSM favors bone apposition at
periosteal sites instead of resorption in vivo. This effect was not dependent on or inhib-
ited by IL-6.
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Introduction
Oncostatin M (OSM) is a 28-kd glycoprotein that belongs to the interleukin (IL)-6 fam-
ily.1 It was originally discovered by its ability to inhibit the growth of the melanoma cell
line A375.2 Subsequently, more effects were discovered and OSM was found to be a mul-
tifunctional cytokine like the other IL-6 family members. OSM can for example stimu-
late an acute-phase response in liver cells3 and enhance expression of tissue inhibitor of
metalloproteinase-14 and adhesion molecules such as ICAM-1.5 Macrophages and acti-
vated T cells have been shown to produce OSM.2,6 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that is accompanied by
destruction of joints. Elevated levels of OSM can be detected in the synovial fluid of RA
patients and synovial macrophages are the source of this OSM.7,8 Unlike its family mem-
ber IL-6, OSM was not detected in the serum of RA patients.7 This suggests a local rather
than a systemic role for OSM in RA. Circumstantial evidence for a local role is the posi-
tive correlation found between concentrations of OSM and cartilage degradation mark-
ers in synovial fluid.9 Injection of recombinant human OSM in the joints of goats
induced inflammation,10 further supporting a local and pro-inflammatory role for OSM
in joint pathology. Recently, intraperitoneal administration of blocking antibodies to
OSM ameliorated experimental arthritis in mice,11 demonstrating a pro-inflammatory
role for OSM in murine arthritis. A systemic effect of blocking OSM can, however, not
be excluded under these experimental conditions. 
The receptor complex for OSM consists of the glycoprotein gp130 that is used by all
of the IL-6 family members, and a second receptor. This second receptor in the complex
is either the leukemia inhibitory factor receptor-β or the OSM receptor-β.12 The isolation
of the murine OSM receptor-β showed that the use of these receptor complexes differed
between species.13 Human OSM utilizes both receptor complexes on human cells but
only the gp130/leukemia inhibitory factor receptor-β complex on murine cells. Murine
OSM in contrast only binds to the gp130/OSM receptor-β complex on murine cells. At
present it is not known if this differential use of receptor complexes is also true for other
combinations of species. The conflicting pro-inflammatory5 and anti-inflammatory14
effects of human OSM in mice, however, stress the need to use species-specific OSM in
experimental disease models. 
Injection of an adenoviral vector expressing murine OSM (AdmuOSM) in murine
knee joints led to inflammation and synovial cell proliferation.15 OSM has been shown
to be a potent inducer of IL-6 gene expression. IL-6 plays a pivotal role in development
and chronicity of experimental arthritis.16-18 In the present study we have injected this
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same vector in the knee joints of wild-type and IL-6-deficient mice to elucidate a role for
IL-6 in the AdmuOSM-induced pathology. 
Bone erosion can take place in patients with RA19 and IL-6 family members are also
implicated to play a role in this process. IL-6 together with the soluble IL-6 receptor has
been shown to induce the formation of osteoclast-like cells.20 IL-6 also has been shown to
enhance the resorbing activity of tartrate-resistant acid phosphatase (TRAP)-positive mult-
inucleated cells.21 The role of OSM during pathological bone remodeling is at present
unclear. OSM can influence differentiation and proliferation of osteoblasts22 relating it to
bone development. On the other hand can OSM also induce the formation of osteoclast-
like cells20,23 relating it to bone erosion. Interestingly, we discovered apposition of new
bone tissue after injection of the AdmuOSM vector. This new bone apposition took place
under inflamed conditions and was not dependent on nor inhibited by IL-6. 
Materials and Methods 
Animals
For this study C57BL/6 mice were obtained from Charles River (Sulzfeld, Germany). IL-
6-deficient mice24 backcrossed for eight generations into C57BL/6 mice were obtained
from Dr. M. Kopf (Basel, Switzerland) and breeding colonies were kept at the Central
Animal Facilities of the Catholic University of Nijmegen. Male animals were used
between 11 and 13 weeks of age. All mice were housed in filter-top cages under specific
pathogen-free conditions and a standard diet and water were provided ad libitum. The
mice were housed in isolators after adenoviral injection. Experiments were performed
according to national and institutional regulations for animal use. 
Adenoviral Vectors and Intra-Articular Injection 
The construction of the replication-deficient E1-deleted AdmuOSM was described
before.25 As a control vector Addl70-3 (No. 5), a vector without insert, was used. For in
vivo experiments the virus was diluted in physiological saline and 2.106-plaque-forming
units (pfu) in a total volume of 6 µl were injected in the knee joint cavity. 
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Histological Evaluation of Knee Joints 
Knee joints were dissected, fixed in formalin, decalcified, dehydrated, and embedded in
paraffin. Standard frontal sections of 7 µm were prepared and stained with safranin-O
and counterstained with fast green. Synovial inflammation was scored on five semiserial
sections of the joint. Scoring on a scale from 0 up to 3 was performed in a blindfolded
manner by two independent observers. 
Isolation of Synovial RNA and Semiquantitative Reverse 
Transcriptase-Polymerase Chain Reaction (RT-PCR) 
Synovial mRNA was isolated and quantitated as described by van Meurs and col-
leagues.26 Patellae with surrounding synovium were isolated from knee joints and two
pieces of tissue adjacent to the patella were punched out with a 3-mm biopsy punch
(Stiefel Laboratorium GMbH, Offenbach am Main, Germany). The tissue was immedi-
ately frozen in liquid nitrogen. Tissue samples were homogenized in a freeze mill, thawed
in 1 ml of Trizol reagent, and further processed according to the manufacturer’s proto-
col. All reagents for RNA isolation and RT-PCR were from Life Technologies (Breda, The
Netherlands). Isolated RNA was treated with DNase I before being reverse-transcribed
into cDNA with MMLV reverse transcriptase. After increasing numbers of PCR cycles,
samples were taken and run on an agarose gel. The cycle number at which the PCR prod-
uct was first detected on the gel was taken as a measure for the amount of specific mRNA
originally present in the isolated synovial RNA. PCR for glyceraldehyde-3-phosphate
dehydrogenase was performed to verify that equal amounts of cDNA were used. Primers
for osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand
(RANKL)27 were used as described before. For IL-6 the following primers were used: IL-
6 forward 5’TCT-GCA-AGA-GAC-TTC-CAT-CCA   and reverse  5’GCA-AGT-GCA-
TCA-TCG-TTG-TTC (55°C, 1 mmol/L MgCl2). 
Alkaline Phosphatase (ALP) Staining 
Cryostat sections of knee joints (7 µm) were stained for ALP activity with the naphthol
AS-BI (Sigma, St. Louis, MO) method.28 
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Von Kossa and Goldner’s Trichrome Staining 
Whole formalin-fixed knee joints were embedded in plastic and 7-µm thick sections were
cut. Sections were stained with von Kossa staining29 to identify calcified bone and with a
Goldner’s trichrome staining30 to demonstrate the presence and maturation of newly
formed bone. 
Image Analysis of Newly Formed Bone 
The surface area of the newly formed bone in wild-type and IL-6-deficient mice was mea-
sured using the Qwin image analysis system (Leica Imaging Systems Ltd., Cambridge, UK).
Images of safranin-O-stained sections were captured using a JVC 3-CCD color video cam-
era (Victor Company of Japan Ltd., Tokyo, Japan) and displayed on a computer monitor.
Per joint four measurements of bone apposition on the femur were performed in a stan-
dardized manner. Both the length of the original cortical bone (marked by a precipitation
line in the staining) and the area of the newly formed bone were measured. The amount of
newly formed bone is expressed as µm2 new bone/10 µm cortical bone. 
TRAP Staining 
Whole formalin-fixed knee joints were decalcified in 10% ethylenediaminetetraacetic acid
(Titriplex III; Merck, Darmstadt, Germany)/1 mmol/L Tris-HCl (pH 7.4) for 2 weeks at
4°C. Decalcified knee joints were processed for paraffin embedding and 7-µm thick tissue
sections were prepared. These sections were stained for TRAP with the leukocyte acid
phosphatase kit (Sigma, St. Louis, MO) according to the manufacturer’s protocol. 
Immunohistochemistry of RANKL and RANK 
Tissue sections (7 µm) of paraffin-embedded whole knee joints were treated for 15 min-
utes with 3% H2O2/methanol at room temperature. After antigen retrieval (2 hours in 10
mmol/L of citrate, pH 6.0, at room temperature) sections were incubated with the pri-
mary antibody or normal serum for 1 hour. Antibodies used were rabbit anti-RANK
(H300) at 2 µg/ml, goat anti-RANKL (N19) at 1 µg/ml, goat IgG at 1 µg/ml (all from
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Santa Cruz Biotechnology Inc., Santa Cruz, CA) and rabbit IgG at 2 µg/ml (DAKO,
Glostrup, Denmark). After rinsing, sections were blocked for 20 minutes at room tem-
perature with 4% normal mouse serum for RANKL and normal goat serum for RANK.
Thereafter, sections for RANKL were incubated for 30 minutes with biotinylated mouse
anti-goat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) and detected by
biotin-streptavidin/peroxidase staining (Elite kit; Vector Laboratories, Burlingame, CA).
Sections for RANK were incubated for 30 minutes with horseradish peroxidase-conju-
gated goat anti-rabbit IgG (DAKO). Development of the peroxidase staining was done
with 3’,3’diaminobenzidine. Sections were counterstained with hematoxylin. 
ALP Assay on C2C12 Cells 
C2C12 cells were obtained from the American Tissue Culture Collection (Rockville,
MD). The cells were grown in Dulbecco’s modified Eagle’s medium/10% newborn calf
serum/100 U/ml penicillin/100 µg/ml streptomycin at 37°C in a humidified atmosphere
at 7.5% CO2. The cells were seeded at 6.7 x 103 cells per well in a 96-well round-bottom
plate. The next day the cells were washed with phosphate-buffered saline (PBS).
Subsequently, the cells were stimulated for 3 days in medium containing 5% newborn
calf serum and different combinations of the following recombinant proteins: recombi-
nant murine OSM, recombinant human bone morphogenetic protein-2 (BMP-2),
recombinant human IL-6, and recombinant soluble IL-6 receptor (R&D Systems,
Minneapolis, MN). IL-6 and soluble IL-6 receptors were used in a 1:1 ratio. After 3 days
the cells were washed with cold Hank’s buffer and fixed for 10 minutes with 4% forma-
lin on ice. Thereafter the cells were washed with cold PBS and incubated with substrate
(1 mol/L diethanolamine, 1 mmol/L MgCl2, and 5.26 mg/ml p-nitrophenylphosphate).
The plate was placed at 37°C in the dark. The reaction was stopped after 5 minutes with
0.5 mol/L of NaOH and the OD 405 nm was measured on a Ceres UV 900C spec-
trophotometer (Bio-Tek Instruments Inc., Winooski, VT). The effect of recombinant
proteins on the number of cells was measured by Neutral Red staining31 and measured
at 550 nm. 
Statistical Analysis 
Statistical comparison between groups was performed with Student’s t-test. Values of P
< 0.05 were considered significant. 
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Results
Adenoviral Overexpression of OSM Induces Joint Inflammation in Wild-
Type and IL-6-Deficient Mice 
Intra-articular injection of 2.106-pfu AdmuOSM, but not of the control vector Addl70-3,
in the joint of wild-type mice induced an inflammation that was characterized by influx of
mononuclear and polymorphonuclear cells and synovial hyperplasia. Synovitis lasted at
least until week 4 after injection, the last time point studied. No signs of inflammation were
macroscopically observed in the ankle or foot of the leg receiving AdmuOSM in the knee
joint, indicating that OSM induced a localized joint inflammation. 
OSM is a strong inducer of IL-6 gene expression and semiquantitative RT-PCR of
injected knee joints showed that AdmuOSM induced IL-6 expression (Figure 1). To elu-
cidate the role of IL-6 in the AdmuOSM-induced inflammation, we injected this vector
in knee joints of IL-6-deficient mice. Histological scoring of joint inflammation showed
no difference between both strains indicating that the inflammatory effect of OSM did
not depend directly on IL-6 (Figure 2). 
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Figure 1 IL-6 gene expression in AdmuOSM-injected knee
joints. Semiquantitative RT-PCR showed enhanced IL-6 gene
expression (data shown for 30 cycles) in the AdmuOSM-
injected knee joint. IL-6 gene expression was not detected
after Addl70-3 injection (not even after 40 PCR cycles). RNA
was isolated from synovia of three mice on day 3 after injec-
tion of the adenoviral vectors. PCR for glyceraldehyde-3-
phosphate dehydrogenase was performed to assess the
amount of cDNA used (data shown for 18 cycles). PCR sam-
ples were taken during the PCR and analyzed on a 1.6%
agarose gel as described in Materials and Methods. IL-6
mRNA expression in AdmuOSM-injected knee joints was
first detected after 27 PCR cycles.
Figure 2 Histological scoring for the joint inflammation at
days 7 and 14 after AdmuOSM injection. , Wild-type mice;
, IL-6-deficient mice. Per time point six mice per group
were evaluated. Both strains did not differ in the inflamma-
tion (P > 0.05, Student’s t-test).
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Bone Formation in AdmuOSM-Injected Knee Joints 
OSM can influence both cell types that are involved in bone remodeling, the osteoblast
and the osteoclast. Its family member IL-6, in contrast, is generally described as an ero-
sive cytokine through the induction of osteoclast development.20 It was therefore of
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Figure 3 A: Activated periosteum of the femur 7 days after injection of AdmuOSM. Stained by Safranin-O. An arrow
indicates the surface of the femoral cortical bone. B: Positive staining of the activated periost for ALP activity (red) is
indicated with an arrow. Bone and inflammation is stained in green with methyl green. C: New bone formed on the
femur of a wild-type mouse 14 days after injection of AdmuOSM (large arrow). A small arrow indicates the former
surface of the bone. D: Goldner staining of the newly formed bone. The latest formed and still unmineralized bone is
stained in orange and is indicated with an arrow. The mineralized bone is stained in green. E: Von Kossa staining of
a section adjacent to the section of D. The mineralized bone is stained in brown. The newly formed and unmineral-
ized bone is not stained by the Von Kossa staining (white layer indicated by an arrow). B, Bone marrow; C, cortical
bone of the femur; F, femur; P, periosteum, S, inflamed synovium. Original magnifications: x400 (A, C-E); x180 (B).
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interest to compare the effect of OSM and the OSM-induced inflammation on the artic-
ular bone in both wild-type and IL-6-deficient mice. 
Already at day 3 of the inflammation, we observed the formation of several layers of
periosteal cells along the femur and tibia of the AdmuOSM-injected knee joint (Figure
3A). Positive staining of these layers for ALP activity showed the osteoblast-like nature
of these cells (Figure 3B). During the second week of inflammation apposition of new
bone occurred next to this thickened periosteal cell layer as shown for day 14 after ade-
noviral injection (Figure 3C). A Goldner staining demonstrated the most recently
formed and still not completely mineralized new bone closest to the periosteal cell layer
in orange (Figure 3D). This layer could not be stained by the Von Kossa technique
(Figure 3E) further demonstrating that mineralization of this bone is still not complet-
ed. The mineralization of new bone that was already completed was demonstrated by
both stainings. This clearly shows that new bone is formed in AdmuOSM-injected knee
joints and that the process of bone formation is still continuing at day 14 after injection.
Injection of the control vector Addl70-3 did not lead to new bone formation. Periosteal
bone apposition and joint inflammation were also observed with AdmuOSM when the
contralateral knee joint was not injected (Dr. C. D. Richards, McMaster University,
Hamilton, Ontario, Canada, unpublished observation). 
The formation of layers of osteoblast-like cells and the deposition of new bone
occurred in both wild-type and IL-6-deficient mice. The IL-6-deficient mice did not dif-
fer from wild-type mice in the amount of newly formed bone (Figure 4). Adenoviral
expression of murine IL-6 did not induce apposition of new bone in the knee joint (data
not shown). This strengthens our results in the IL-6-deficient mice showing that the
observed OSM effect on the articular bone is not mediated by IL-6.  
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Figure 4 Quantification of newly formed bone in wild-
type and IL-6-deficient mice. The surface area of newly
formed bone was measured as described in Materials and
Methods and was expressed as µm2 new bone/10 µm cor-
tical bone. No significant difference was found between
wild-type (n = 10) and IL-6-deficient mice (n = 8) (P =
0.469, Student’s t-test). Injection of the control vector
Addl70-3 did not lead to bone apposition. Data shown
are for day 14 after adenoviral injection. , Wild-type
mice; , IL-6-deficient mice. 
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OSM Enhances BMP-2-Induced ALP Activity in Vitro 
A possible direct effect of OSM on development of the ALP-positive cell layer was fur-
ther investigated in vitro. For these experiments we used pluripotent murine C2C12 cells
that can differentiate toward the osteoblast lineage32 and measured ALP activity after 3
days of culture. Recombinant murine OSM alone was, in contrast to a bone-forming fac-
tor such as BMP-2, not able to induce ALP activity in these cells. Addition of OSM to a
constant BMP-2 concentration, however, had a strong enhancing effect on the BMP-2-
induced ALP activity (Figure 5A). The mean induction of three experiments was 2.1 ±
0.2 for 100 ng/ml BMP-2, 3.7 ± 1.0 for 100 ng/ml BMP-2 + 0.36 ng/ml OSM (P < 0.05),
and 5.8 ± 1.1 for 100 ng/ml BMP-2 + 5 ng/ml OSM (P < 0.005) (Student’s t-test, n = 6).
The other concentrations of OSM tested in combination with BMP-2 also differ signifi-
cantly from incubations with BMP-2 alone. Equal neutral red staining for C2C12 cells
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Figure 5 OSM enhances the BMP-2-induced ALP activity in C2C12 cells. A: C2C12 cells were incubated for 3 days
with variable concentrations of recombinant murine OSM in the presence or absence of 100 ng/ml of recombinant
human BMP-2. ALP activity was measured as described in Materials and Methods. The OD 405-nm value for cells
without OSM or BMP-2 added to the medium was set at 1 and used for calculating the effect of BMP-2, OSM, and
the combination of both proteins. OSM alone did not induce ALP activity in these cells even at concentrations up to
500 ng/ml (data not shown). BMP-2 alone gave a twofold induction of ALP activity. This BMP-2-induced ALP activ-
ity was greatly enhanced by OSM. This same effect of OSM was also found when 300 ng/ml of BMP-2 was used
(data not shown). B: C2C12 cells were incubated for 3 days with variable concentrations of recombinant IL-6 and
the soluble IL-6 receptor in the presence or absence of 100 ng/ml of recombinant human BMP-2. In contrast to
OSM the IL-6/sIL-6R combination did not enhance the BMP-2-induced ALP activity. IL-6/sIL-6R alone did also not
induce ALP activity in the C2C12 cells. The experiments of Figure 5, A and B, were performed in duplicate for at
least three times with similar results. One representative experiment is shown. The SD in ALP activity was less than
5% between duplicate measurements. 
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treated with BMP-2 or BMP-2 and OSM excluded an effect on cell proliferation (data not
shown). The enhanced ALP activity does not seem to depend directly or indirectly on IL-
6 because it was not observed after incubation with the combination of BMP-2, IL-6, and
the soluble IL-6 receptor (Figure 5B). These results suggest that the in vivo observed
effect of OSM is dependent on cooperation of OSM with other bone-forming factors
such as, for example, BMP-2. 
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Figure 6 Immunohistochemistry for RANK and RANKL expression in AdmuOSM-injected knee joints. RANK (A)
and RANKL (B) are detected in the periosteum and the inflamed synovium 7 days after injection of AdmuOSM.
Continued expression of RANK (C) and RANKL (E) 14 days after AdmuOSM injection. Control sera for the RANK
(D) or RANKL (F) antisera did not show staining of the periosteum or the inflamed synovium. Data shown are for
day 14 after AdmuOSM injection. Arrows indicate the surface of the cortical bone of the femur before injection of
AdmuOSM. N, Newly formed bone; P, periosteum; and S, inflamed synovium. Original magnifications, x400. 
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Expression of RANKL, RANK, and OPG in the Inflamed Joint
The new deposited bone had an irregular border facing the joint cavity in wild-type mice
as well as in the IL-6-deficient mice. Because in vitro results have implicated that OSM
could induce osteoclast formation,23 it was possible that OSM not only induced bone
formation but also bone resorption in the inflamed joint. A key molecule involved in
osteoclastogenesis is RANKL. Because IL-6-type cytokines have been shown to enhance
RANKL mRNA levels,33 we studied expression of RANKL and its receptor RANK in the
AdmuOSM-induced inflammation. Both RANKL and RANK were detected
immunohistochemically in the inflamed synovium and the periosteal cell layers (day 7;
Figure 6, A and B) and expression continued after apposition of the new bone (day 14;
Figure 6, C and E). No RANK or RANKL could be demonstrated in Addl70-3-injected
knee joints (data not shown). A similar expression pattern for RANKL and RANK was
detected in joint sections from AdmuOSMinjected wild-type and IL-6-deficient mice. 
The RANK/RANKL system and the development of osteoclasts can be controlled by
the RANKL antagonist OPG. Semiquantitative RT-PCR on synovial mRNA showed that
besides expression for RANKL, OPG expression also was up-regulated in the
AdmuOSM-induced inflammation (Figure 7). Induction of OPG occurred in both wild-
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Figure 7 Enhanced synovial mRNA expression for
RANKL and OPG at days 7 and 14 of the AdmuOSM-
induced inflammation. Gene expressions for RANKL and
OPG were compared between synovia from AdmuOSM-
injected and contralateral Addl70-3-injected knee joints
as described in Materials and Methods. Six mice per
group were used and equal amounts of cDNA were used
as assessed by PCR for glyceraldehyde-3-phosphate dehy-
drogenase. RT-PCR reactions were performed at least
twice. , RANKL; , OPG. 
Figure 8 Trap staining of a wild-type knee joint 14 days
after injection of AdmuOSM. TRAP-positive cells were
observed in the bone marrow but not in the inflamma-
tion or on the new bone. A joint from a mouse with col-
lagen-induced arthritis served as a positive control for the
staining (data not shown). A small arrow indicates the
former surface of the bone. The large arrows indicate
TRAP-positive cells in the bone marrow. B, Bone mar-
row, C, cortical bone of the femur; N, newly formed
bone; P, periosteum; S, inflamed synovium. Original
magnification, x200.
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type and IL-6-deficient mice. Gene induction for OPG could provide a counterbalance
against the observed RANKL expression. TRAP staining of AdmuOSM-injected knee
joints did not identify osteoclasts in the inflamed synovium or at sites of new bone for-
mation (Figure 8). TRAP-positive multinucleated cells were also not detected on the
layer of osteoblast-like cells earlier during inflammation on day 7 (data not shown).
These results indicate that the OSM-induced inflammation does not create an environ-
ment favoring osteoclast development. Our results show that OSM can induce bone for-
mation in vivo, an effect found to be independent of IL-6. 
Discussion
OSM is a member of the IL-6 family of cytokines. Experiments with recombinant OSM
have led to conflicting results as both pro-and anti-inflammatory properties have been
published.5,14 Most reports, however, describe OSM to be pro-inflammatory. These con-
flicting results could be related to the different models used. Human and murine IL-6 use
the same receptor complex on murine cells. Human and murine OSM, in contrast, make
use of different receptor complexes on murine cells.13 This finding could be another
complicating factor and murine OSM should therefore be used to establish its role in
experimental inflammatory models in mice. 
OSM can be detected in the synovial fluid but not in the serum of RA patients.7 This
suggests a local role for OSM in the inflammation and joint damage during RA. Recently,
it was shown that murine OSM stimulated anchorage-independent growth of murine
synovial fibroblasts in vitro and that AdmuOSM induced joint inflammation in the knee
joints of mice.15 This was not observed with a control vector. Our in vivo results confirm
these data and support a local pro-inflammatory role for OSM during RA. 
Adenoviral vectors have been used to express proteins of interest in the knee joint.34
Advantages of these vectors are that they can infect both dividing and nondividing cells and
can express a protein for days in the knee joint. Adenoviral vectors, however, can by them-
selves also cause inflammation. In our hands no inflammation is induced in naive knee
joints injected with 1.107-pfu empty control virus or virus-expressing luciferase or β-galac-
tosidase marker genes. In the present study we have used five times less virus and we did
not observe inflammation in the contralateral knee joint injected with control virus.
The fact that no sensitive test is available specific for murine OSM makes is difficult
to address the production by the AdmuOSM vector. We have tried to set up a bio-assay
by incubating the murine B9 cell line with wash-outs of AdmuOSM injected IL-6 defi-
102 CHAPTER 5
bw-de hooge\50  30-08-2004  15:45  Pagina 102
cient knee joints. This IL-6 dependent cell line can also respond to OSM, although at
higher concentration.37 The detection limit for recombinant murine OSM was 2 ng/ml.
This is relatively high compared to the several 100 pg/ml that we generally observe with
1.107 PFU of vectors expressing other transgenes. The AdmuOSM wash-outs did not
show a production above the detection limit. The production of OSM is therefore less
than 2 ng/ml but a precise measurement awaits the development of a more sensitive spe-
cific assay.
In our study we have found a high induction of gene expression for IL-6 after injec-
tion of AdmuOSM in naive wt mice. IL-6 plays a very important role during experimen-
tal arthritis.16-18 IL-6 gene expression was, however, not necessary for development of
the AdmuOSM induced inflammation. This was demonstrated by a similar degree of
inflammation when we injected the AdmuOSM vector in the joints of wt and IL-6 defi-
cient mice. Injection of an adenoviral vector expressing murine IL-6 did not lead to
inflammation even in a tenfold higher concentration.15 This observation was confirmed
by results in our laboratory  (unpublished data). Together these data suggest that locally
produced OSM plays by itself a pro-inflammatory role during joint inflammation.
Secondly, it suggests that members of the IL-6 family play different roles during joint
inflammation and that they cannot simply be substituted for by other family members.  
Under nonpathological circumstances there is a continuous synthesis of new bone by
osteoblasts and breakdown of bone by osteoclasts. This balance can be disrupted as is
shown by the occurrence of bone erosion during RA. Osteoclasts have been identified as
the main bone resorbing cells in RA.38 The members of the IL-6 family can influence dif-
ferentiation and activation of both osteoblasts and osteoclasts and hence influence bone
homeostasis.22 Unraveling the precise involvement of these cytokines in bone remodel-
ing and homeostasis could not only be important for RA but also for other osteolytic dis-
eases such as Paget’s disease and giant cell tumors. IL-6 is generally described to stimu-
late bone resorption. OSM can influence both osteoblasts and osteoclasts and its role is
less clear. The results observed after injecting the AdmuOSM vector in the knee joints of
naive mice showed apposition of new bone in the periosteum of the inflamed joint. This
phenomenon was observed in all knee joints injected with AdmuOSM in four different
experiments. We studied the role that both osteoblasts and osteoclasts could play in this
phenomenon.
Expression of OSM by the AdmuOSM vector not only caused inflammation but also
activated the periosteal cells along the femur and tibia. These cells were positive for ALP
activity, a marker for osteoblasts and osteoblast-like cells. In all wild-type and IL-6-defi-
cient mice tested bone apposition occurred at these sites with a thickened layer of
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periosteal cells. The formation of this ALP-positive cell layer pointed at an important
influence of OSM on osteoblastic cells in vivo. Most experiments on the relation between
OSM and osteoblast function have been performed in vitro with human OSM.
Recombinant human OSM has been found to activate murine osteoblasts and to inhibit
basal bone resorption in vitro.39 Also, human OSM did prevent apoptosis in both murine
and human osteoblastic cell lines.40 As described above the use of human or murine
OSM on murine cells might lead to different results. To obtain additional information
on the role of OSM in osteoblast differentiation and activation we have performed in
vitro experiments with recombinant murine OSM on the murine C2C12 cell line. These
cells can differentiate toward the osteoblast lineage and express osteoblastic markers such
as ALP, osteocalcin, and Cbfa1.32 They also showed mRNA expression of the specific
OSM receptor-β (data not shown). 
When ALP activity was measured in the C2C12 cells, we found that murine OSM by
itself did not differentiate these cells toward the osteoblast lineage. Similarly, it was found
that human OSM did not differentiate murine embryonic fibroblasts toward the
osteoblast lineage.41 The ALP activity of C2C12 cells in response to BMP-2, however, was
clearly enhanced by addition of OSM and not by IL-6. This suggests that the in vivo-
observed ALP activity might be an effect of OSM co-operating with a bone-forming fac-
tor. We previously reported that an intraarticular injection of recombinant BMP-2 pro-
tein induced chondrogenesis in the murine knee joint.42 Uusitalo and colleagues43 found
that adenoviral transfection of the periosteum with BMP-2 also caused cartilage callus
tissue formation and that endochondral ossification replaced most of this callus cartilage
by bone. Previous studies using crude extracts of BMPs showed direct periosteal bone
induction that was not preceded by chondrogenesis.44 Further research is needed to
determine whether OSM has stimulatory or (re)directing effects on BMP-2 or other
bone-forming factors in vivo. 
The observed bone formation could also be a direct effect of OSM on mature
osteoblast-like cells in vivo. OSM can activate the signal transducer and activator of tran-
scription (STAT)-3 in osteoblasts.45 Activation of STAT-3 by OSM can induce expres-
sion of c-Fos as shown in the hepatoma cell line HepG2.46 Fos proteins form together
with the Jun proteins, the activator protein-1 (AP-1) transcription complex. Recently, it
was shown that overexpression of the fos proteins FRA-147 or ∆FosB48 led to a progres-
sive increase in overall bone mass in an as yet unknown way. Further research on the sig-
nal transduction and gene expression of osteoblasts under influence of OSM is therefore
needed to determine whether the observed new bone formation is regulated by AP-1.
Another factor that could play a role in the AdmuOSM-induced bone formation is
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Cbfa1, the first osteoblast-specific transcription factor. It controls the rate of bone for-
mation by differentiated osteoblasts.49 A relation between Cbfa1 and OSM, however, has
not yet been investigated. 
Bone formation is besides locally also systemically controlled.50 An effect of OSM on
the endocrine system during the AdmuOSM-induced inflammation seems, however,
unlikely because no activation of osteoblasts or bone formation was observed in the con-
tralateral knee joints injected with Addl70-3. 
Consistent with our findings using the adenoviral vector, excessive bone growth was
observed in the femur of a transgenic mouse expressing bovine OSM.51 However, no
overt inflammation was detected surrounding this new bone (Dr. C. Clegg, personal
communication). This suggests that the effect of OSM on bone formation does not
depend directly on the observed pro-inflammatory properties of OSM. 
The other cell type involved in bone remodeling and homeostasis, the osteoclast, can
also be influenced by OSM. Recombinant murine OSM increased in vitro the formation
of osteoclasts in co-cultures of murine bone marrow and calvaria cells.23 TRAP-positive
cells were, however, not detected in the inflamed synovium of AdmuOSM-injected knee
joints. Only very rarely were they detected on the newly formed bone. Langdon and col-
leagues15 showed with this same virus that in some joints the inflammation protruded
through the bone marrow. We also observed this occasionally in our experiments, but
not at sites of bone apposition. The existence of channels between the bone marrow and
the synovium has been described.52 It is possible that cell trafficking between the
inflamed synovium and the bone marrow occurs through these channels. This could be
accompanied by widening of these channels, although a mechanism behind this is still
unknown. TRAP staining of AdmuOSM-injected knee joints did not detect osteoclasts in
these channels. This makes it unlikely that in our experimental conditions osteoclasts are
involved in widening of the channels. Aggressive fibroblasts could be involved in this
process. Synovial fibroblasts with a transformed phenotype are present in synovial pan-
nus tissue and their presence has been related to joint damage.53-55 This would be in line
with the observed positive effect of murine OSM on the anchorage-independent growth
of mouse synovial fibroblasts.15 
OSM has been shown to induce expression of RANKL in stromal/osteoblastic cells.33
This RANKL can interact with the receptor RANK on the precursors of osteoclasts. 
The RANK/RANKL system and the interaction between osteoblasts and osteoclast 
precursor cells are crucial for the development of osteoclasts.56 Semiquantitative RT-
PCR analysis showed increased expression of RANKL in the inflamed synovium.
Immunohistochemistry showed expression of RANKL and RANK proteins in the syn-
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ovium and in the activated osteoblast-like cell layers. At present, we do not have an assay
to demonstrate presence of the soluble RANKL inhibitor OPG on histological sections
but increased mRNA expression for OPG was found in the synovium. The ratio between
RANKL and OPG expression has been implicated as a determining factor in bone resorp-
tion during RA.57 In our experiments expression of RANKL and RANK did not induce
osteoclast development in vivo. It could be that the balance between RANKL and OPG
favors bone formation during the AdmuOSM-induced inflammation but this needs fur-
ther experimental research. Another option is expression of an inhibitor or repression of
an osteoclast activator that as yet has not been related to OSM.
We have observed formation of new bone from the periosteum in both the antigen-and
the zymosan-induced arthritis in mice.58,59 Because of the irregular shape of the newly
formed periosteal bone it will not always have been recognized as bone apposition. The
results of the Goldner’s trichrome staining and the absence of TRAP-positive cells in the
periosteum clearly demonstrates that in our model with the AdmuOSM vector bone appo-
sition and not erosion takes place. OSM could also play a role in bone apposition in exper-
imental arthritis models but further research on this is needed. Expression of the pro-
inflammatory cytokines IL-1 or IL-17 did induce inflammation and bone erosion but no
bone apposition in naive knee joints (manuscript in preparation). This indicates that
inflammation is not always accompanied by bone apposition. The cytokine environment
could influence the effect of a given cytokine on bone remodeling. The effects of OSM on
the periosteum, but not its pro-inflammatory properties, could be negatively influenced by
other cytokines in RA. During RA, bone erosion instead of apposition occurs. In other hu-
man arthropathies the cytokine environment could have a different effect and bone appo-
sition and erosion can even occur at different parts of the joint. Periosteal bone apposition
for example takes place in diseases such as Reiter disease,60 juvenile chronic arthritis,61 ero-
sive os-teoarthritis,62 and hypertrophic osteoarthropathy.63 OSM could have a role in these
diseases, as suggested by our results with the OSM adenoviral vector. Future therapies for
these diseases, as well as RA, might therefore be targeted at this cytokine. 
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Abstract
Objective. To investigate the involvement of proinflammatory and destructive mediators
in oncostatin M (OSM)-induced joint pathology, using gene-deficient mice. 
Methods. An adenoviral vector expressing murine OSM was injected into the joints of
naive wild-type mice and mice deficient for interleukin-1 (IL-1), IL-6, tumor necrosis
factor α (TNFα), or inducible nitric oxide synthase (iNOS). Reverse transcription-poly-
merase chain reaction was used to study gene expression. Inflammation and cartilage
proteoglycan (PG) depletion were assessed by histology. OSM and IL-1 levels in synovial
fluid from patients with juvenile idiopathic arthritis (JIA) were measured by enzyme-
linked immunosorbent assay. 
Results. Adenoviral expression of murine OSM led to joint inflammation, bone appo-
sition, chondrophyte formation, articular cartilage PG depletion, and VDIPEN neoepi-
tope expression in wild-type mice. A unique and consistent observation was the focal PG
depletion and disorganization of the growth plate cartilage during the first week of
inflammation. Synovial IL-1β, IL-6, TNFα, and iNOS gene expression was strongly
induced. Of these factors, only deficiency in IL-1 markedly reduced inflammation and
PG depletion and completely prevented growth plate damage. In addition, this is the first
study in which OSM was detected in JIA synovial fluid. Most samples were also IL-1β
positive. 
Conclusion. IL-1, but not IL-6, TNFα, or iNOS, plays an important role in joint dis-
ease induced by intraarticular gene transfer of OSM in mice. The effect of OSM on
murine connective tissue and the presence of OSM in human synovial fluid make
involvement of OSM in human arthropathies very likely.
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Introduction
Oncostatin M (OSM) is a multifunctional cytokine that belongs to the interleukin-6 (IL-6)
family (1). Elevated levels of OSM can be detected in the synovial fluid, but not in the
serum, of patients with rheumatoid arthritis (RA) (2). Immunohistochemical analysis of
RA synovial tissue showed that synovial macrophages are the source of OSM in the
inflamed joint (3). A pathologic role for OSM in RA is suspected, because OSM by itself
can induce joint inflammation in animals. Injecting recombinant human OSM into the
joints of goats induced the influx of polymorphonuclear cells (PMNs), followed by cells of
the macrophage/monocyte lineage (4). Joint inflammation was also induced by adenoviral
expression of murine OSM in mice (5,6). The enhanced expression of adhesion molecules
such as E-selectin and P-selectin (7,8), CXC chemokines (8), and the CC chemokine
monocyte chemotactic protein 1 (9) by OSM could contribute to the influx of inflamma-
tory cells. Furthermore, synovial fibroblasts displayed a transformed phenotype under the
influence of OSM (5), suggesting involvement of OSM in pannus formation.
Besides chronic joint inflammation, RA is also characterized by destruction of articu-
lar cartilage and bone. Cartilage consists of a framework of collagen fibers in which pro-
teoglycans (PGs) are entrapped. These PGs can retain water, which enables the cartilage
to resist compressive forces. Proinflammatory cytokines such as IL-1 (10,11) are involved
in cartilage degradation. Results from experiments in recent years suggest a similarly
important role for OSM in the cartilage degradation of RA. OSM was shown to induce
collagen release from bovine cartilage in vitro (12). It also stimulated PG release and sup-
pressed PG synthesis in porcine articular cartilage explants (13). Injecting OSM into the
joints of goats (4) decreased the cartilage PG content. In humans, OSM concentrations
in synovial fluid correlate positively with levels of cartilage degradation markers (14).
OSM was also the first cytokine that, in combination with IL-1α, was demonstrated to
induce collagen release from human cartilage (3). 
The development of joint inflammation and cartilage damage in experimental arthritis
can be greatly influenced by the expression of proinflammatory cytokines and other medi-
ators. We previously demonstrated that blocking of IL-1 could prevent inhibition of PG
synthesis in experimental arthritis (15,16). The formation of nitric oxide (NO) was shown
to be involved in IL-1-induced inhibition of PG synthesis in vitro (17), and PG loss was
reduced in experimental arthritis in mice deficient for the inducible NO synthase (iNOS)
gene (18). Studies entailing blocking of tumor necrosis factor α (TNFα) showed involve-
ment of TNFα in the early phase of joint inflammation (19,20), while studies of experi-
mental arthritis in IL-6-deficient mice showed involvement of IL-6 in the chronicity of
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arthritis (21). In the present study, we investigated the involvement of these proinflamma-
tory mediators in OSM-induced joint disease. We injected an adenoviral vector expressing
murine OSM into the joints of mice deficient for IL-1, IL-6, TNFα, or iNOS and studied
the effects of these gene deletions on OSM-induced joint pathology. 
Ubiquitous transgenic overexpression of bovine OSM has been found to be lethal for
newborn mice. One mouse survived and developed growth plate disorganization, with
enhanced growth of the hind legs (22). Growth plate damage (23,24) as well as localized
growth abnormalities (25) are characteristic features of juvenile idiopathic arthritis (JIA).
Therefore, we studied the effects of murine OSM gene transfer not only on development
of inflammation and articular cartilage damage, but also on the growth plate.
Furthermore, we studied expression of OSM in the synovial fluid of patients with JIA. 
Patients and methods
Animals
For this study, male mice deficient for the following genes were used: IL-1α and IL-1β
(26), IL-6 (27), TNFα (28), and iNOS (29). C57BL/6 and C57BL/6 x 129Sv mice were
used as wild-type controls. Breeding colonies were kept at the Central Animal Facilities
of the University of Nijmegen. Animals used in the experiments were between 11 and 13
weeks of age. All mice were housed in filter-top cages under specific pathogen-free con-
ditions. A standard diet and water were provided ad libitum. After injection of the
adenoviral vector, the mice were housed in isolators. Experiments were performed
according to national and institutional regulations for animal use. 
Adenoviral vectors and intraarticular injection
The construction of adenoviral vectors expressing murine OSM (AdMuOSM) or murine
IL-17 (AdmIL-17) has been described previously (30,31). AdDL70-3, a vector without
insert, was used as a control vector. For in vivo experiments, the virus was diluted in
physiologic saline, and 2 x 106 plaque-forming units (PFU) in a total volume of 6 µl were
injected into the knee joint cavity. Construction of NIH3T3 cells overexpressing human
IL-1β will be described elsewhere (Joosten L: unpublished observations). A total of 2.5 x
104 cells were injected into the knee joint. 
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Histologic evaluation of knee joints
Knee joints were dissected, fixed in formalin, decalcified, dehydrated, and embedded in
paraffin. Standard 7-µm frontal sections were prepared. Sections were stained with
Safranin O and counterstained with fast green for assessing cartilage damage. His-
topathologic findings were scored on 5 semi-serial sections of the joint. Scoring was per-
formed in a blinded manner by 2 independent observers. Cartilage depletion was scored
from 0 (normal Safranin O staining; no depletion) to 3 (complete loss of Safranin O
staining; complete depletion). Joint inflammation was also scored on a 0-3-point scale. 
NIMP-R14 staining
The influx of PMNs was assessed by staining knee joint sections for the presence of the
NIMP-R14 epitope (32), which is present mainly on neutrophils. Sections were deparaf-
finized, treated with 0.1% trypsin in 0.1% CaCl2, pH 7.8 and preincubated for 15 min-
utes with 20% normal rabbit serum before incubation for 1 hour with anti- NIMP-R14
antibodies (a kind gift from Dr. M. Strath, London, UK). After incubation with a perox-
idase-labeled rabbit anti-rat secondary antibody in 5% normal mouse serum/phosphate
buffered saline (PBS) for 30 minutes, the sections were incubated with diaminobenzidine
(1 mg/ml in 50 mM Tris HCl, pH 7.6, 0.001% H2O2) for 10 minutes. Sections were
counterstained with hematoxylin for 30 seconds. Normal rat immunoglobulin was used
as a negative control. 
Image analysis of newly formed bone
The area of newly formed bone was measured using the QWin image analysis system
(Leica, Cambridge, UK). Images of Safranin O-stained sections were captured using a
JVC 3-CCD color video camera and displayed on a computer monitor. For each joint, 4
measurements of the length of the original cortical bone (marked by a precipitation line
in the staining) and the area of newly formed bone on the femur were performed in a
standardized manner. The amount of newly formed bone is expressed as µm2 of new
bone/10 µm of cortical bone.
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Isolation of synovial RNA and semiquantitative reverse 
transcription-polymerase chain reaction (RT-PCR)
Synovial messenger RNA (mRNA) was isolated and quantitated as described previously
(33). The patellae (with surrounding synovium) were isolated from the knee joints, and
2 pieces of tissue adjacent to the patella were punched out with a 3-mm biopsy punch
(Stiefel, Wächters Bach, Germany). The tissue was immediately frozen in liquid nitrogen.
Tissue samples were homogenized in a freeze mill, thawed in 1 ml of TRIzol reagent, and
further processed according to the manufacturer’s protocol. All reagents for RNA isola-
tion and RT-PCR were obtained from Life Technologies (Breda, The Netherlands).
Isolated RNA was treated with DNase I before being reverse transcribed into comple-
mentary DNA (cDNA) with Moloney murine leukemia virus reverse transcriptase. 
After increasing numbers of PCR cycles, samples were obtained and run on an agarose
gel. The cycle number at which the PCR product was first detected on the gel was obtained
as a measure for the amount of specific mRNA originally present in the isolated synovial
RNA. PCR for GAPDH was performed to verify that equal amounts of cDNA were used.
Primers for IL-1β, TNFα, GAPDH (34), and IL-6 (6) were used as described previously.
The iNOS primers used (at 55°C, 1mM MgCl2) were as follows: forward CCC-TAA-GAG-
TCA-CCA-AAA-TGG, reverse CTA-CAG-TTC-CGA-GCG-TCA-AA. The OSM primers
used (at 55°C, 1 mM MgCl2) were as follows: forward CTT-GGA-GCC-CTA-TAT-CCG-
CC, re-verse GTG-TGG-AGC-CAT-CGT-CCC-ATT-C. Primers were designed using
Oligo 4.0 and Primer software (Molecular Biology Insights, Cascade, CO). 
Ex vivo PG synthesis
PG synthesis was assessed by 35S-sulfate incorporation in patellar cartilage. Patellae from
knee joints injected with adenoviral vectors and from the uninjected contralateral knee
joints were dissected, with a minimum amount of surrounding synovium, under sterile
conditions. The ex vivo synthesis assays were performed with RPMI supplemented with
100 units/ml penicillin, 100 µg/ml streptomycin, 1 mmole/liter pyruvate, and 5% fetal
calf serum (Life Technologies). The patellae were placed separately in 200 µl of medium
containing 4 µCi 35S-sulfate and incubated for 3 hours at 37°C in a humidified atmos-
phere of 5% CO2. After labeling, the patellae were washed with physiologic saline and
fixed overnight in 4% formalin. Fixed patellae were decalcified in 5% formic acid for 4
hours, dissected, and dissolved in 0.25 ml Lumasolve (Omnilabo, Breda, The
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Netherlands). After addition of 1 ml of Lipoluma (Omnilabo), the 35S-sulfate content of
each patella was measured by liquid scintillation counting in a TriLux 1450 MicroBeta
(Perkin-Elmer Wallac, Turku, Finland). Data for joints injected with adenoviral vectors
are presented as a percentage of the normal chondrocyte PG synthesis in the contralat-
eral, uninjected knee joint. 
VDIPEN neoepitope staining
Irreversible PG damage was assessed by immunohistochemistry for the VDIPEN neo-
epitope. Joint sections were deparaffinized, rehydrated, and digested for 1 hour at 37°C
in 0.25 units/ml of chondroitinase ABC in 0.1M Tris HCl, pH 8.0 (Sigma, Zwijndrecht,
The Netherlands) to remove chondroitin sulfate from the PGs. Sections were treated
with 1% H2O2 in methanol for 20 minutes, followed by treatment with 0.1% Triton X-
100 in PBS for 5 minutes. After incubation with 1.5% normal goat serum for 20 minutes,
sections were incubated overnight at 4°C with affinity-purified rabbit anti-VDIPEN IgG
(a kind gift from Dr. I. Singer, Rahway, NJ) or with normal rabbit IgG. The next day, the
sections were incubated with biotinylated goat anti-rabbit IgG followed by labeling with
avidin-peroxidase (Elite kit; Vector, Burlingame, CA). Peroxidase development was per-
formed using nickel enhancement to increase sensitivity. Sections were counterstained
with 2% orange G for 5 minutes. 
Synovial fluid from patients with JIA
Synovial fluid was collected from children with JIA who attended the University Medical
Center Nijmegen or the St. Maartens Clinic for intraarticular glucocorticosteroid injec-
tion. The samples were collected in accordance with local ethics legislation and were
made available anonymously to the authors after informed consent was received from
the parents. Diagnosis according to the revised International League of Associations for
Rheumatology criteria (35) is described in Table 1. The synovial fluid was centrifuged for
10 minutes at 3,000 revolutions per minute, aliquoted, and stored at -70°C.
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Cytokine measurement in synovial fluid
The amount of OSM and IL-1β in synovial fluid was determined by enzyme-linked
immunosorbent assay (ELISA), using the Quantikine human OSM immunoassay or the
Quantikine human IL-1β immunoassay (R&D Systems, Minneapolis, MN), according to
the manufacturer’s protocol. 
Statistical analysis
The rank sum test was used for statistical comparison between groups. P values less than
0.05 were considered significant. 
Results
Joint pathology after OSM gene transfer
In wild-type mice, intraarticular injection of AdMuOSM induced joint inflammation
(Figures 1A and B) that was characterized by the influx of PMNs (Figure 1C) and
mononuclear cells as well as by synovial hyperplasia. The AdMuOSM-induced inflam-
mation led to cartilage PG loss in the patella and femur, as demonstrated by loss of red
staining in the Safranin O-stained knee joint sections (Figures 1A and B). Both inflam-
mation and cartilage PG loss lasted for at least 4 weeks. The periosteum became activat-
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Table 1 OSM and IL-1β in synovial fluid of patients with JIA* 
* All samples were obtained from knee joints, except sample 10, which was obtained from an ankle
joint. In patients 2, 4, and 6, the arthritic leg was longer than the unaffected leg. Bony overgrowth of
the knee occurred in patients 1, 6, and 10. Oncostatin M (OSM) and interleukin-1β (IL-1β) were
determined by enzyme-linked immunosorbent assay, performed twice, in duplicate. Values are the
mean ± SD. JIA = juvenile idiopathic arthritis; ND = not detectable; RF = rheumatoid factor; NM =
not measured.
Patient                                                      Age, years/sex                      JIA subtype                                  OSM, pg/ml                             IL-1 , pg/ml
1                                                                                 6/F  Oligoarthritis                                  18.4 4.1                                    5.2 0.8
2                                                                            10.9/M  Oligoarthritis                                        ND                                              ND
3    10.2/F  RF – polyarthritis                 12.7 0.5                                    5.1 1.0
4            7.6/F                      Oligoarthritis                                  17.5 1.4                                        ND
5(left knee)     9.1/F                      Oligoarthritis                                  10.1 0.5                                    5.4 0.8
5(right knee)     9.1/F  Oligoarthritis                                  13.7 0.4                                         ND
6      2.6/F  Oligoarthritis                                        ND                                              NM
7    15.4/F  RF – polyarthritis                         ND                                        11.3 2.7
8       13/F  RF – polyarthritis                                                        9.6 1.6                                    2.2 0.5
9      5.7/F  Systemic                                           23.1 0.2                                    4.2 1.1
10      6.2/F  Oligoarthritis                                  27.4 0.9                                  56.7 5.2
11    11.3/F  Oligoarthritis                                    4.1 0.5                                        ND
12      4.4/F  Oligoarthritis                                 16.3 2.5                                  11.7 2.7
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Figure 1 Joint pathology induced by the adenoviral murine oncostatin M vector (AdMuOSM) in
wild-type mice. Inflammation and cartilage proteoglycan (PG) depletion on A, day 7 and B, day 14
after injection of AdMuOSM into the knee joint of wild-type mice. PG depletion is shown by reduced
red staining of the upper cartilage layer of the patella and femur. In B, arrows indicate periosteal bone
apposition. C, NIMPR-14 staining of polymorphonuclear cells in the inflamed synovium on day 7
after AdMuOSM injection. D, Normal joint histology on day 14 after injection of the control vector
AdDL70-3. Similar histology was observed on day 7 after injection (results not shown). E,
Chondrophyte formation (arrow) at the femoral head on day 14 after AdMuOSM injection. F, No
chondrophyte formation is observed at the femoral head on day 14 after AdDL70-3 injection. F =
femur; P = patella; S = inflamed synovium. (Safranin O stained [except in D]; original magnification
x 50 in A, B, and D; x 200 in C, E, and F.) 
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ed (Figure 1A), and apposition of new bone occurred at this site (Figure 1B). No addi-
tional apposition or remodeling of the new bone occurred after day 14. Chondrophytes,
abnormal cartilaginous masses that can develop on the articular surface of bone, were
formed on the patella and femur (Figure 1E) and increased in size until at least week 4.
In contrast, injection of 2 x 106 PFU of the control vector AdDL70-3 did not induce joint
inflammation, PG loss, bone apposition, or chondrophyte formation (Figures 1D and F). 
Growth plate damage after OSM gene transfer
A unique feature of OSM gene transfer that has not been previously reported is that the
AdMuOSM vector also caused damage to the growth plate cartilage. In all wild-type mice
studied, we observed PG depletion and loss of matrix integrity in the growth plates
(Figure 2A) adjacent to the periosteum. The PG content in the growth plates recovered
after the first week of inflammation, but the matrix integrity and the normal arrange-
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Figure 2 Growth plate damage induced by the adenoviral murine oncostatin M vector (AdMuOSM) in
wild-type mice. A, Proteoglycan depletion and disorganization of the growth plate on day 7 after injec-
tion of AdMuOSM. B, Normal growth plate on day 7 after injection of AdDL70-3. Note also the
absence of inflammation after AdDL70-3 injection. C, Normal growth plate after injection of 2.5 x 104
NIH3T3 cells expressing human interleukin-1β. D, Normal growth plate after injection of the aden-
oviral murine interleukin-17 vector, S = inflamed synovium. (Safranin O stained; original magnifica-
tion x 200.)
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ment of chondrocytes were not restored. This growth plate damage was not observed
after injection of the control vector AdDL70-3 (Figure 2B). It also was not observed after
local gene transfer of IL-1 or IL-17 (Figures 2C and D), although both induced joint
inflammation and articular cartilage PG depletion (Joosten LAB, Koenders MI: unpub-
lished observations). These observations exclude the possibility that the damage
occurred as a general consequence of local proinflammatory cytokine overexpression.
Cytokine dependence of OSM-induced joint pathology
RT-PCR revealed synovial expression of OSM gene in the knee joint injected with
AdMuOSM, but not in that injected with AdDL70-3 (Figure 3A). On day 3, the first
OSM PCR product was detected 2 cycles after detection of the first GAPDH PCR prod-
uct. On day 7, it was detected a mean (± SD) of 5 ± 1 cycles after detection of the first
GAPDH PCR product, indicating a decrease in OSM gene expression. OSM can induce
expression of IL-6 (36) and can enhance the effects of other proinflammatory cytokines
such as IL-1 and TNFα (3). Semiquantitative RT-PCR analysis showed upregulated
expression of mRNA for IL-1β, IL-6, and TNFα associated with the AdMuOSM-induced
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Figure 3 Oncostatin M (OSM) and cytokine
gene expression during adenoviral murine
OSM (AdMuOSM)-induced inflammation. A,
OSM gene expression in synovium 3 days
after injection of AdMu-OSM, as detected by
semiquantitative reverse transcription- poly-
merase chain reaction (RT-PCR). Results rep-
resent the linear part of the PCR reaction (26
PCR cycles for OSM and 22 cycles for
GAPDH). B, Enhanced gene expression for
interleukin-1β (IL-1β), IL-6, tumor necrosis
factor α (TNFα), and inducible nitric oxide
synthase (iNOS) on day 3 after injection of
the adenoviral vector. Gene expression was
compared between synovia from AdMuOSM-
injected and contralateral AdDL70-3-injected
knee joints in 4 mice, as described in Patients
and Methods. The control vector in the
contralateral knee joint served as a within-
animal control. Gene expression was exam-
ined in 2 groups of 2 pooled synovia. Equal
amounts of complementary DNA were used,
as assessed by PCR for GAPDH. Semiquan-
titative RT-PCR was performed at least twice.
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inflammation (Figure 3B). Because these cytokines can have great influence on joint
inflammation, chondrocyte metabolism, and cartilage damage, we determined their role
in the AdMuOSM-induced joint disease by injecting 2 x 106 PFU AdMuOSM into the
knee joints of mice deficient for IL-1, IL-6, or TNFα. Mice deficient for the iNOS gene
also received the injection. This factor (iNOS) plays a role in the suppression of cartilage
PG synthesis and was also up-regulated at the mRNA level (Figure 3B).
IL-1 was observed to play an important role during the first week of AdMuOSM-induced
joint pathology. Histologic scoring showed a reduced synovial infiltrate on day 7 after
injection of AdMuOSM in IL-1α/β-deficient mice (Table 2). The influence of IL-1 on
joint inflammation decreased after day 7, and by day 14, inflammation in wild-type and
IL-1α/β-deficient mice did not differ (Table 2). Deficiency for TNFα, IL-6, and iNOS did
not affect AdMuOSM-induced joint inflammation. Inflammation in the TNFα-deficient
mice tended to be reduced on day 7 after injection, but this difference versus wild-type
mice did not reach statistical significance (P = 0.05). 
Cartilage PG depletion was also significantly reduced in the IL-1α/β-deficient mice
during the first week of inflammation (Table 2). Ex vivo PG synthesis was increased after
injection of AdMuOSM into wildtype mice (Table 2). This suggests that the observed PG
depletion in wild-type mice is caused by enhanced PG breakdown. The fact that the ex
Table 2 AdMuOSM-induced joint pathology in wild-type and cytokine-deficient mice* 
* Data shown are for 1 representative experiment with 5-9 mice per group. Except where indicated
otherwise, values are the mean ± SD. IL-1α/β = interleukin-1α/β; TNFα = tumor necrosis factor α;
iNOS = inducible nitric oxide synthase. 
† Scored on a 0-3-point scale. Data for proteoglycan (PG) depletion are for patellar cartilage; similar
results (not shown) were obtained for femoral cartilage. 
‡ Ex vivo patellar PG synthesis was compared with synthesis in the patella of the uninjected contralat-
eral knee joint. Values >100% indicate increased PG synthesis in the patella from the adenoviral
murine oncostatin M (AdMuOSM)-injected knee joint. Injection of AdDL70-3 induced only a slight
increase of PG synthesis (mean ± SD 111 ± 14.9%). Six to 8 patellae per group were used, and PG syn-
thesis was measured twice. 
§ Percentage of mice.
¶ P < 0.05 versus wild-type mice, by rank sum test.
# P < 0.005 versus wild-type mice, by rank sum test.
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Mice
Inflammation† PG depletion†
Relative PG
synthesis, %,
day 4‡
Chondrophyte
incidence,
day14§
Bone apposition,
m2 of new bone/
10 m of cortical bone,
day 14¶
Growth plate
damage incidence,
day 7§Day7                   Day14              Day7                    Day14
Wild-type          1.7 0.6            0.9 0.4         1.8 0.6            1.9 0.6         142 34.8              88                                 338 47                                 100
IL-1 / / 1.0 0.2¶          0.7 0.4         0.5 0.3#          2.0 0.7         167 10.3            100                                 317 41                                     0
TNF / 1.0 0.5            1.0 0.6         1.4 0.5            1.5 0.4               NM                  100                                 374 74¶                               100
IL-6 / 1.5 0.5            1.0 0.6         2.3 0.5            2.4 0.4               NM                  100                                 312 76                                 100
iNOS / 1.8 0.7            1.1 0.4         1.6 1.1            2.2 1.2               NM                    80                                 355 62                                 100
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vivo PG synthesis increased further in IL-1 α/β-deficient mice suggests that endogenous
IL-1 can at least partly counteract OSM-induced stimulation of PG synthesis. Deficiency
for TNFα, IL-6, and iNOS did not affect the AdMuOSM-induced PG loss on days 7 and
14 after injection of the vector.
By day 14, PG loss in the IL-1α/β-deficient mice had developed to the same extent as that
in the wild-type mice (Table 2), with marked expression of the matrix metalloproteinase
(MMP)-generated VDIPEN neoepitope (Figures 4A and C). In contrast, the AdDL70-3
control vector did not lead to generation of the VDIPEN neoepitope (Figure 4B).
Cytokine dependence of OSM-induced growth plate damage
The endogenous role of IL-1 was even more prominent in the AdMuOSM-induced
growth plate damage. No loss of PGs or disruption of the matrix integrity was found in
the growth plates of AdMuOSM-treated IL-1α/β -deficient mice (Table 2). In contrast to
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Figure 4 VDIPEN neoepitope staining in cartilage after injection of AdMuOSM. A, Positive VDIPEN
staining in the cartilage of a wild-type mouse 14 days after AdMuOSM injection. Staining is detected
in the matrix surrounding the chondrocytes at the surface and in the deeper cartilage layers. B,
Negative VDIPEN staining in a wild-type mouse 14 days after injection with AdDL70-3. C, Positive
VDIPEN staining in an interleukin-1α/β - deficient mouse 14 days after injection of AdMuOSM. D,
Negative staining in a wild-type mouse 14 days after injection of AdMuOSM, when preimmune serum
was used. (Original magnification x 760.)
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the IL-1α/β -deficient mice, growth plate damage did develop in all mice deficient for
TNFα, IL-6, or iNOS (Table 2). Similar to the situation in wild-type mice, the PG con-
tent of the affected growth plate was restored on day 14 of inflammation in mice defi-
cient for TNFα, IL-6, and iNOS. 
OSM in synovial fluid of patients with JIA
The OSM-induced joint disease in the mice resembled the arthritic changes that are
observed in human arthropathies such as RA and JIA. For this reason, we were interest-
ed in determining whether OSM could be detected in JIA synovial fluid, as was already
demonstrated for RA synovial fluid (2,3). Indeed, we could measure OSM in 77% of the
JIA synovial fluid samples that were examined by ELISA (Table 1). Furthermore, 70% of
the OSM-positive samples were also positive for IL-1β (Table 1). 
Discussion
OSM is produced in the inflamed joints of patients with RA (3), and results of several in
vitro experiments suggest that OSM could play an important role in cartilage damage in
RA. OSM induced collagen release from bovine cartilage explants (12) and, in combina-
tion with IL-1, from human cartilage explants (3). Furthermore, OSM stimulated PG
release and suppressed PG synthesis in porcine articular cartilage (13). In the present
study, we used an adenoviral vector expressing murine OSM to investigate in vivo the
influence of proinflammatory mediators, which are important for RA, on OSM-induced
joint pathology. 
The AdMuOSM vector induced inflammation, cartilage PG depletion, periosteal bone
apposition, and chondrophyte formation in the joints of naive mice. Semiquantitative
RT-PCR analysis showed increased expression of mRNA for IL-6, TNFα, IL-1β, and
iNOS in the AdMuOSM-injected knee joint. A relationship with OSM-induced patholo-
gy was investigated in mice deficient for these proinflammatory factors. 
OSM is a strong inducer of IL-6 gene expression. We had previously observed that
AdMuOSM-induced inflammation was not inhibited by IL-6 deficiency (6). The present
results demonstrate that cartilage PG depletion is also not affected in these mice. In con-
trast to the important role of IL-6 in experimental arthritis (21,37), the present results do
not indicate such a role for IL-6 in AdMuOSM-induced joint disease. A positive correla-
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tion between TNFα and OSM concentrations has been demonstrated in synovial fluid
obtained from patients with RA (14). However, whether there is a direct relationship
between these cytokines was, until now, not clear. Results of the present study show that
cartilage PG depletion induced by AdMuOSM was not affected by TNFα deficiency.
Although inflammation in TNFα-deficient mice tended to be reduced on day 7, by day
14 inflammation in these mice did not differ from that in wild-type mice. This is consis-
tent with reports showing that TNFα is important during disease onset, but that TNFα
deficiency or inhibition did not prevent development of severe arthritis in experimental
models (38,39). Taken together, our results do not suggest an important role for TNFα
in OSM-induced joint pathology. 
Nitric oxide is produced in the inflamed joints of patients with RA (40) and can con-
tribute to IL-1- induced inhibition of PG synthesis (16,41). We previously demonstrat-
ed that cartilage PG depletion, but not joint inflammation, is significantly reduced in
iNOS deficient mice with zymosan-induced arthritis (18). In the present experiments,
PG depletion did not differ between iNOS-deficient and wild-type mice, indicating that
NO formation is not essential for AdMuOSM-induced cartilage damage. 
Joint inflammation and cartilage PG depletion in IL-1α/β-deficient mice were signif-
icantly reduced on day 7. This shows an important role for IL-1 in AdMuOSM-induced
joint pathology. IL-1 has been shown to be a key factor in the development of experi-
mental arthritis (10,42). Both inhibition of PG synthesis and stimulation of PG break-
down can induce PG depletion in arthritis, and IL-1 can be involved in both processes
(11,43). In our experiments, ex vivo PG synthesis in patellae from AdMuOSM-injected
joints was not inhibited, but rather was increased. This excess in PG synthesis, however,
could not prevent articular cartilage PG loss. Breakdown of PGs would, therefore, be the
main cause of the observed PG loss in wild-type mice. In the IL-1α/β-deficient mice, ex
vivo PG synthesis was even further increased, and this could (at least in part) contribute
to the reduced PG loss in these mice. The increased PG synthesis in the IL-1α/β-deficient
mice furthermore indicates that in wild-type mice, IL-1 will partly inhibit the elevation
of PG synthesis. We previously observed that blocking of IL-1 in experimental arthritis
completely prevented inhibition of PG synthesis but did not influence inflammation-
induced PG breakdown (15). 
Bell et al (4) reported that coinjecting human OSM with recombinant human IL-1
receptor antagonist (IL-1Ra) into the joints of goats could not attenuate OSM-induced
cartilage PG depletion. In a previous study, we observed that prolonged high concentra-
tions of IL-1Ra were necessary to prevent IL-1-induced inhibition of PG synthesis in
antigen-induced arthritis. These concentrations could be achieved with mini- osmotic
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pumps but not by bolus injection of IL-1Ra (15). The negative results described by Bell
et al could therefore be attributable to poor pharmacokinetics of IL-1Ra in the joint. In
the present study, we used IL-1α/β-deficient mice to circumvent these problems and
observed clear involvement of IL-1 in the OSM-induced PG loss that occurred during the
first week of inflammation. 
We have previously shown that repeated injections of IL-1 induce inflammation and
cartilage damage in the murine knee joint (11). In that study, the polymorphonuclear
cell was the predominant cell type in the inflammatory infiltrate. A role for PMNs in car-
tilage damage has been shown in vitro (44) and in vivo (45). Recently, OSM was shown
to selectively recruit PMNs in an in vitro flow chamber assay (46). Using NIMP-R14
staining, we could detect PMNs in the inflamed synovium of both wild-type and IL-
1α/β-deficient mice (results not shown), suggesting that IL-1 is not necessary for OSM-
induced PMN influx. This, however, does not exclude a relationship between IL-1 and
PMNs in the observed PG depletion. Activation of PMNs might differ between wild-type
and IL-1α/β-deficient mice; this requires further investigation. 
During AdMuOSM-induced inflammation, irreversible damage to the PG network
occurred, as demonstrated by the presence of the MMP-induced VDIPEN neoepitope.
Expression of VDIPEN was shown to correlate with severe cartilage damage in murine
arthritis (47). The VDIPEN neoepitope was also detected in cartilage from IL-1α/β-
deficient mice, indicating that irreversible PG damage can occur independent of IL-1.
Future research is needed to identify the enzyme that is responsible for this irreversible
damage and its relationship to OSM. 
Periosteal bone apposition and chondrophyte formation were induced in both wild-
type and gene-deficient mice. Periosteal bone apposition can occur in the short tubular
bones of the phalanges, metacarpals, and metatarsals, and also in the long bones during
JIA (48,49). To our knowledge, little is known about the significance of periosteal bone
apposition in JIA. Bone apposition was not induced by overexpression of IL-1 or IL-17
(data not shown), which excludes the possibility that bone apposition was a general con-
sequence of inflammation. We previously had observed that OSM could enhance in vitro
the bone morphogenetic protein 2-induced differentiation of C2C12 cells toward the
osteoblastic lineage (6). This suggests that OSM could play a positive regulatory role dur-
ing bone formation by enhancing the activity of bone-forming factors. Chondrophyte
and osteophyte formation is common in osteoarthritis (OA). Osteophytes can also devel-
op in RA and JIA with secondary OA, but this happens less frequently. 
In general, adenovirally mediated gene transfer to the joint results in a transient trans-
gene expression (50,51) lasting from 1 to 2 weeks. We observed that most of the changes
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in the murine knee joint had already developed during the first week, when OSM gene
expression was demonstrated. The involvement of IL-1 provides circumstantial evidence
for a relationship between transgene expression and the observed joint pathology. This
was evident on day 7 but not on day 14. After day 7, OSM-induced inflammation sub-
sided, and the growth plate PG content returned to normal levels. During the first week,
periosteal activation, leading to bone apposition on day 14, also took place. Thereafter,
the process of new bone formation did not proceed. Surprisingly, articular cartilage PG
depletion continued after day 7. This is probably not directly related to OSM activity but
could be a result of irreversible cartilage damage, delayed repair mechanisms, or mor-
phologic changes (e.g., chondrophyte formation), which could influence cartilage
integrity. 
A unique finding associated with injection of AdMuOSM is that the growth plate
became damaged. This was not observed with vectors expressing either IL-1 or IL-17,
although both induced articular cartilage damage. Such growth plate damage has not
been previously observed in experimental arthritis in mice of the same age. This process
was demonstrated to be dependent on endogenous IL-1. In growth plates, there is a bal-
ance between cartilage matrix degradation, proliferation, matrix formation, and hyper-
trophy. Expression of IL-1 mRNA has been detected in the growth plate of developing
bones in mice (52). In vitro results of studies using growth plate chondrocytes from the
rat suggested that IL-1 induces resting growth cells to acquire a phenotype of growth
zone cells in an autocrine manner (53). Furthermore, IL-1 could play a role in the bone
and cartilage resorption processes that occur in the growth plate during the formation of
new bone. OSM could either enhance or modify the autocrine effects of IL-1 on growth
plate chondrocytes, thereby leading to growth plate PG loss, disorganization, and finally
growth abnormalities. 
Growth plate changes in patients with JIA have been reported. Magnetic resonance
imaging studies have shown epiphyseal cartilage loss in the knees of patients with JIA
(23), and in unilateral juvenile arthritis the femoral epiphysis of the arthritic side was
observed to be enlarged (24). Although IL-6 is found in elevated concentrations in serum
and synovial fluid in JIA (54), the presence of OSM has, as far as we know, not been
investigated in these patients. Using ELISA techniques, we detected OSM in synovial
fluid of most of the examined children, and we could also detect IL-1β in most of our
OSM-positive samples. Our experiments in the cytokine-deficient mice indicated that
OSM, in the presence of IL-1, could cause serious risks to the integrity of growth plate
cartilage. It is possible that the combination of these cytokines is similarly involved in
growth plate damage in JIA. 
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Both increased growth and growth retardation occur frequently in JIA (25,55). Most of
our synovial fluid samples were obtained from patients with oligoarthritis who had
involvement of the knee joint. A study by Simon et al (56) showed a relationship between
age at disease onset, involvement of the knee, and localized growth abnormalities in
oligoarthritis (formerly called monoarticular and pauciarticular RA). In patients in whom
JIA began before age 9 years, the involved side was the longer one. Disease onset after this
age led to rapid premature closure of the growth plate and shortening of the involved side.
Among the positive samples in our study, the highest concentrations of OSM were found
in those obtained from the younger children, which could implicate a role for OSM in
increased growth of the involved side. This is further supported by the finding that a
mouse transgenic for bovine OSM had enlarged hind limbs (22). We recently began
collaborations in order to increase the number of synovial fluid samples available for
study from patients with the different forms of JIA. We hope that this will also enable us
to further characterize OSM expression during the time course of the disease. 
In conclusion, our results demonstrate an important role for endogenous IL-1 in
AdMuOSM-induced joint pathology, but no involvement of TNFα, IL-6, or iNOS. The
induction of growth plate damage in mice adds a newly recognized pathologic conse-
quence of OSM expression that would be particularly relevant in JIA. The AdMuOSM
vector provides a useful tool to further investigate this process in more detail. Our results
in the cytokine-deficient mice and the detection of OSM in synovial fluid of patients with
JIA suggest that the proinflammatory and cartilage-damaging effects of OSM are relevant
in human arthropathies such as RA and JIA. 
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Abstract
To achieve a disease-regulated transgene expression for physiologically responsive gene
therapy of arthritis, a hybrid promoter was constructed. The human IL-1b enhancer
region ( -3690 to -2720) upstream of the human IL-6 promoter region (-163 to +12) was
essential in mounting a robust response in HIG-82 synovial fibroblasts and in RAW
264,7 macrophages. A replication-deficient adenovirus was engineered with luciferase
(Luc) controlled by the IL-1/IL-6 promoter (Ad5.IL-1/IL-6-Luc). LPS caused a 23- and
4.6-fold induction of Luc. activity in RAW cells transfected with Ad5.IL-1/IL-6-Luc or
the conventional Ad5.CMV-Luc construct, respectively. Next, adenoviruses (106 ffu)
were injected into the knees of C57Bl/6 mice. An intra-articular injection of zymosan, 3
days after Ad5.IL-1/IL-6-Luc, increased Luc. activity by 39-fold but had no effect in the
Ad5.CMV-Luc joints. The constitutive CMV promoter was rapidly silenced and could
not be reactivated in vivo. In contrast, the IL-1/IL-6 promoter could be reactivated by
Streptococcal cell wall (SCW)-induced arthritis up to 21 days after infection. Next the IL-
1/IL-6 promoter was compared to the C3-Tat/HIV-LTR two-component system in wild-
type, IL-6-/- and IL-1-/- gene knockout mice. Both systems responded well to LPS-,
zymosan- and SCW-induced arthritis. However, the basal activity of the IL-1/IL-6 pro-
moter was lower and IL-6 independent. This study showed that the IL-1/IL-6 promoter
is feasible to achieve disease-regulated transgene expression for treatment of arthritis.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease with unknown etiology. The clinical
course of RA is characterized by a variable disease activity of spontaneous remissions and
exacerbations (Flare-ups) of the chronic inflammatory joint process. In females patients,
remissions are often associated with pregnancy and exacerbations occur postpartum.1,2
These flare-ups of the joint of the rheumatoid joint disease have often the characteristics of
an acute type of inflammation superimposed on the smouldering joint inflammation
already present.
In experimental animals, flare-up reactions of joint inflammation have been studied
predominantly in immunologically mediated arthritis models. Flare-ups can be induced
by a rechallenge of non-arthritogenic dosages of antigen, growth factors, for example,
colony-stimulating factors, and cytokines like IL-1.3-5 Resident macrophage-like syn-
ovial lining cells play an important role in the antigen-induced flare-up reaction,6 and
both TNFα and IL-1 were markedly produced at the time of flare-ups. We demonstrat-
ed that selective blocking of IL-1 during the antigen-induced flare-up clearly reduced
joint swelling and cartilage proteoglycan loss.7
The feasibility of local or systemic gene therapy for RA has been demonstrated in
numerous animal experiments.8 Two phase I clinical trials are undertaken with the
objective to block IL-1 by local IL-1Ra overexpression in future therapies.9,10 Constant
high levels of antiinflammatory proteins could be undesirable; they might increase the
risk of infection as now observed with anti- TNF and anti-IL-1 treatment of patients with
RA.11-14 Furthermore, the homeostatic balance might adapt to the constant high con-
centrations of transgene protein so as to reduce its therapeutic efficacy (tachyphylaxis).
Ideally, treatment of RA must parallel the intermittent course of the disease to meet the
variable physiological demands and prevent undesirable exposure of the system. A num-
ber of vectors with drug-regulatable promoters for achieving regulatable transgene
expression have been described.15 A drawback is the necessity of constant disease moni-
toring to achieve optimal efficacy in RA, which is further complicated by the unpre-
dictable, relapsing clinical course. The major challenge is a disease-regulated expression
of a recombinant protein to meet the variable demands during RA: high during a relapse
and low during remission of the disease. Currently the cytomegalovirus (CMV) is the
most frequently used promoter to express the transgene, but this constitutive promoter
when used in adenoviral vectors is rapidly silenced giving short-lasting expression in
vivo. Varley et al16 have developed a two-component expression system that responds to
inflammatory stimuli in vivo. In their system, the complement factor 3 regulates pro-
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duction of the HIV transactivator of transcription (Tat) protein, which regulates the HIV
long terminal repeat (LTR) promoter for transgene expression. The feasibility of this
two-component system as an inflammation-inducible promoter for autoregulated
expression of IL-10 and IL-1Ra was recently demonstrated in two different experimental
arthritis models.17,18 However, this promoter may not be suitable for RA as the Tat is a
foreign immunogenic protein and may have undesirable effects by transactivating host
genes, and Tat immunogenicity has been implicated in CNS disorder AIDS dementia due
to its toxicity. For this we constructed a hybrid promoter of the enhancer region of the
human IL-1 promoter with the human IL-6 promoter, which does not possess the gene-
silencing CpG regions that are present in most viral promoters (eg CMV promoters).
From many animal studies, others and we demonstrated that both IL-1 and IL-6 belong
to the early responsive genes, which are upregulated at the primary onset and secondary
flare-ups of experimental arthritis.7,19 In this study, we demonstrated that the IL-1/IL-6
promoter fulfills the criteria of a disease-inducible promoter - low basal activity and high
during the acute inflammatory response - showing that this promoter might be feasible
for autoregulated protein drug treatment of RA.
Results
IL-1 enhancer is critical for the inducible character of the IL-1/IL-6 hybrid promoter 
The murine RAW 264,7 macrophage cell line and the rabbit synovial fibroblast cells (HIG-
82) were transiently transfected with the pGL3 luciferase reporter vector (Figure 1). Cells
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Figure 1 The IL-1 enhance sequence enhances the IL-6 promoter activity. HIG-82 cells (a) or RAW
264,7 cells (b) were transiently transfected with the pGL3 luciferase reporter vector without a promo-
ter or the IL-6 promoter ( -162 to +12) alone or in combination of the IL-1 enhancer sequence ( -360
to  -2720). Cells were either not stimulated  or stimulated with LPS (20 µg/ml)+PMA (10
ng/ml)+dbcAMP (100 nM) . After 18 h, the luciferase activity in the cell lysate was measured and
expressed as relative light units and corrected for the amount of protein extracted (RLU/µg).
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were stimulated with lipopolysaccharide (LPS, 20 µg/ml)+phorbol 12-myristate 13-acetate
(PMA, 10 ng/ml) + 8-bromo-cAMP (dbcAMP, 100 nM) for broad-range gene activation
by NF-κB, PKC and PKA activated protein kinases (AP1), respectively. The human IL-6
promoter region ( -163 to +12) alone did not respond to this cocktail; however, when the
human IL-1 beta enhancer region ( -3690 to  -2720) was placed upstream, a pronounced
induction of 5.3-fold in HIG82 cells and 18-fold in RAW cells was observed.
In vitro characterization of the IL-1/IL-6 promoter using a first-generation 
adenoviral Luc reporter vector
RAW macrophages were infected with Ad5.IL-1/IL-6-Luc or the control virus
Ad5.CMV-Luc with an MOI of 10 and in the presence of an Fc-CAR fusion protein to
enhance infection efficiency (Figure 2). Transfected cells were challenged with LPS (0.2-
2 µg/ml) and this stimulated Luc expression 3.7-5.5-fold (range of four separate experi-
ments) using the CMV promoter and 20-51.4-fold using the IL-1/IL-6 hybrid promoter
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Figure 2 LPS-induced activation of the IL-1/IL-6 promoter in an adenoviral reporter vector. RAW
264,7 (105 cells) were transfected with Ad5.CMV-Luc or Ad5.IL-1/IL-6-Luc at an MOI of 10 (a, b) or
1 (c, d). After 4 h of infection, the medium was replaced and cells were stimulated with LPS. At 1 day
after LPS (2 µg/ml) stimulation, the luciferase content of the cells (a) and the nitrite concentration in
the culture supernatant (b) were measured. In a second experiment, RAW cells were once stimulated
with LPS (0.2 g/ml) 6 h after Ad5.IL-1/IL-6.Luc infection (LPS>med) or after 56 h (Med>LPS) or
twice at both 6 and 56 h (LPS>LPS). Luciferase activity (c, RLU) and nitrite concentration 
(d, OD540 nm) were measured 72 h after infection.
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(Figure 2a). LPS-induced nitrite production by Ad5.CMV-Luc and Ad5.IL-1/IL-6-Luc-
transfected cells was enhanced 3.2-4.7-fold, independent of the virus used (Figure 2b),
indicating that the cellular LPS triggering was not different between both adenoviral vec-
tors. In another experiment we investigated whether the IL-1/IL-6 promoter could be
reactivated by a second LPS challenge. RAW cells were transfected with Ad5.IL-1/IL-6-
Luc and challenged with LPS. Pulse-chase experiments showed that the Luc. activity in
the cells transfected with Ad5.IL-1/IL-6-Luc returned to almost background levels 48 h
after the LPS stimulation. A second LPS rechallenge at this time point could still enhance
the Luc. activity to the same extent as the first LPS challenge, indicating that the IL-1/IL-
6 promoter remains responsive also after the first activation period. The cytokine respon-
siveness of the IL-1/IL-6 hybrid promoter was tested on an immortalized murine chon-
drocyte cell line. These cells were infected at an MOI of 50 and stimulated with different
murine recombinant proteins or LPS. A significant upregulation of luciferase activity was
found after stimulation of the cells with IL-1a, TNFα, IL-6, IL-17 and IL-18, and a combi-
nation of the cytokines; TNF, IL-1 and IL-18 showed additive effect on the IL-1/IL-6 pro-
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Figure 3 Cytokine response profile of the IL-1/IL-6 (a) and the CMV promoter (b) in a murine
chondrocyte cell line. The murine immortalized chondrocyte cell line (H4) were transfected and 4 h
later the culture medium was changed and cells were stimulated with murine recombinant IL-1α, IL-
18 (both at 10 ng/ml), IL-6, IL-17, TNFα (all three at 100 ng/ml), or the combination of TNF, IL-1
and IL-18 (All), or LPS (5 mg/ml). After 18 h, the luciferase activity in the cell lysates (a, b) and the
nitrite concentration in the conditioned culture supernatant (d) were measured. Levelling the basal
Luc. activity showed that both promoters had the same cytokine induction index (c). None, no stimu-
lation; RLU, relative light units. *Statistically significant using the Student’s t-test with P-values
<0.0001 as compared to the nonstimulated group.
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moter (Figure 3a). The cytokine response of the IL-1/IL-6 promoter was different from the
endogenous iNOS gene, as both IL-6 and IL-18 failed to induce nitric oxide (NO) produc-
tion in these cells under the same condition (Figure 3d). The CMV promoter also showed
a high background activity in these cells as compared to the IL-1/IL-6 promoter.
Nonetheless, the CMV promoter showed the same cytokine responsiveness as the IL-1/IL-
6 promoter, although the effect of IL-18 did not reach significance (Figure 3b and c).
In vivo characterization of the IL-1/IL-6 promoter using
A first-generation adenoviral Luc reporter vector Ad5.IL-1/IL-6-Luc (106 ffu) was inject-
ed into both murine knee joint cavities of wild-type, IL-6-/- and IL-1a/b-/- double knock-
out mice. After 3 days, zymosan (180 µg) was injected into the right knee joint cavities
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Figure 4 In vivo response of the IL-1/IL-6 pro-
moter in gene knockout mice. Wild-type, IL-6-
/- and  IL-1a/b-/- double knockout mice were
injected intra-articularly with 106 ffu Ad5.IL-
1/IL-6-Luc virus into both knee joints. After 3
days, the right knees received 180 mg of zymo-
san material by an intra-articular injection
(black bars). At 1 day thereafter, patellae with
adjacent synovial tissue were isolated from both
left and right knee joints, partially digested, and
the luciferase activity was measured in the lysa-
te. A significant induction (white numbers in
the black bars) of luciferase expression
(P<0.001) was observed in all mouse strains.
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Figure 5 In vivo comparison of the CMV with the IL-1/IL-6 promoter responsiveness to an arthritic
stimulus. Mice were injected intraarticularly with 106 ffu of Ad5.CMV-Luc (a) or Ad5.IL-1/IL-6-Luc
(b) virus into both knee joints. After 1 day, the Luc. activity was measured in the synovial tissue. At
days 8, 14 and 21 after infection, the right knee joints (black bars) received 25 µg SCW material as an
arthritogenic trigger. After 24 h, the Luc. activity was measured in the synovial tissue obtained from
both naive and SCW-injected knees. Luciferase activity reached statistically significant differences
compared to the naive knee joints with P-values <0.05 (*) and <0.001 (**) using the Student’s t-test.
The fold inductions of Luc. activities are depicted in white numbers. Note that the CMV promoter
caused a high initial luciferase expression.
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only. After 24 h, Luc. activity was 12.5  increased in wild-type, 15  in IL-6-/- and 18  in
IL-1αβ-/- mice as compared to their contralateral noninflamed knee joint (Figure 4). The
CMV promoter is rapidly silenced in the murine knee joint and could not be activated
by an intraarticular injection of the arthritogenic Streptococcal cell wall (SCW) material
(Figure 5a). In contrast to the CMV promoter, the IL-1/IL-6 promoter is not constitu-
tively active (day 1 after infection) but could be activated even up to 21 days after infec-
tion by an intra-articular injection of SCW material (Figure 5b). Hirt extraction and
quantification of PCR products for viral DNA showed that the loss of adenoviral DNA
was approximately 60% between days 1 and 15 after injection and not significantly dif-
ferent for both the CMV and IL-1/IL-6 constructs (Figure 6). The loss of viral DNA may
be responsible for the short expression kinetics of Luc using the CMV promoter con-
struct. As the viral DNA levels are reduced in both groups, an enhanced immune
response (cytotoxic T cells) against the Ad5.CMV-Luc-infected cells is highly unlikely
and cannot explain the differences found in responsiveness with the Ad5.IL-1/IL-6-Luc-
injected knee joints.
Comparative study of IL-1/IL-6 hybrid system with 
the C3-Tat/Hiv two-component system
Varley et al16 developed a disease-inducible two-component expression system, which is
efficacious in animal models of arthritis.17,18 We compared the expression characteris-
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Figure 6 Loss of viral DNA in vivo. Mice (n=5 per group) were injected intra-articularly with 106 ffu
of Ad5.CMV-Luc or Ad5.IL-1/IL-6-Luc virus into both knee joints. At days 1 and 15, synovial tissue
was taken from the infected joints and viral DNA was extracted by Hirt extraction. The luciferase con-
tent in the extract (Hirt extraction without SDS) was measured (a) and in the same sample the viral
DNA was amplified by PCR and quantified as described in Materials and methods (b). Note the same
reduction (%) in the viral DNA content of both groups.
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tics of this two-component system with the IL-1/IL-6 hybrid promoter construct. The
C3-Tat/Hiv two-component system in RAW cells showed the same high background
activity and LPS induction comparable to the conventional CMV promoter (Figure 7).
The IL-1/IL-6 promoter had a 10-fold lower background activity and the LPS-induced
increment of Luc. activity (23-fold) exceeded that of the two other expression systems
(4.5-fold). Next, the in vivo performance of the C3-Tat/Hiv two-component system was
compared to the IL-1/IL-6 hybrid promoter system. For this, the same amounts (106 ffu)
of adenoviral luciferase reported vectors were injected into the knee joint of wild-type,
IL-6-/- and IL-1α/β-/- gene knockout mice. After 3 days, zymosan (180 µg) was injected
intra-articularly and 24 h later the Luc. activity was measured. The zymosan-induced
luciferase activity was similar between the Ad5.IL-1/IL-6-Luc- and Ad5.C3-Tat/Hiv-Luc-
injected knee joints (Figures 4 and 8). However, a significant reduction of zymosan-
induced luciferase activity (45%, P<0.0001) was found in the IL-6-deficient mice with
the Ad5.C3-Tat/Hiv-Luc vector, whereas the activity was slightly increased in the Ad5.IL-
1/IL-6-Luc-injected joints. No differences between induction of luciferase was found
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Figure 7 Comparative in vitro study of the LPS
response in three different promoter systems. RAW
macrophages (105 cells) were transfected with Ad5.
CMV-Luc, Ad5.IL-1/IL-6-Luc or Ad5.C3-Tat/HIV-
Luc at an MOI of 10. After 24 h, cells were stimula-
ted with LPS at a concentration of 2 µg/ml or not
stimulated. The luciferase expression was measured
24 h later and was expressed as RLU. The fold induc-
tion by LPS as compared to the unstimulated cells is
depicted as white numbers in the black bars. The
LPS-induced stimulation of Luc. activity was statisti-
cally significant with all three promoter systems.
*
Figure 8 In vivo response of the C3-Tat/HIV two-
component expression system in gene knockout
mice. Wild-type, IL-6-/- and IL-1a/b-/- double
knockout mice were injected intra-articularly with
106 ffu Ad5.C3-Tat/HIV-Luc virus into both knee
joints. After 3 days, the right knees received 180 µg
of zymosan material by an intra-articular injection
(black bars). At 1 day thereafter, the luciferase acti-
vity was measured in the synovial tissue lysates. A
significant induction (P<0.001) of luciferase
expression (white numbers in the black bars) by
the zymosan injection was observed in all mouse
strains. Note the significant (*P<0.001) reduction
in the zymosan-induced luciferase expression in
the IL-6 gene knockout mice.
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between both disease-regulatable promoter systems in the IL-1α/β-deficient mice. Next,
the expression of the C3-Tat/HIV and IL-1/IL-6 promoters was studied during the
course of SCW arthritis. Intra-articular injection of SCW material caused a transient
acute joint inflammation, which lasted for 7 days.20 Adenoviruses were injected into
both knee joints 1 day before induction of arthritis in the right knee joint, and the left
naive joint served as a within-animal control of basal transgene expression. The expres-
sion of Luc was higher in the naive joints infected with Ad5.IL-1/IL-6-Luc at day 1 of
arthritis, but much lower at days 7 and 14 as compared to the Ad5.C3-Tat/Hiv-Luc-
infected naive joints (Figure 9a and b). Injection of SCW material resulted in an acute
joint inflammation, with infiltration and exudation of neutrophils. This immediately
resulted in upregulation of the IL-1/IL-6 (Figure 9a) and C3-Tat/HIV (Figure 9b) pro-
moter activity. At day 14, the acute joint inflammation had subsided and a second SCW
injection immediately exacerbated the smouldering joint inflammation (inflammation
flared from 0.3±0.1 up to 1.2±0.3). The second SCW injection upregulated both pro-
moters, resulting in approximately the same luciferase expression (Figure 9). This sug-
gests that the adenoviral DNA was neither lost nor silenced during the 2-week in vivo
period. Because the background level of the IL-1/IL-6 promoter was lower, a higher stim-
ulation index was found at days 7 and 14 of SCW arthritis.
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Figure 9 Transgene expression during the course of SCW arthritis. Mice received an intra-articular
injection with 106 ffu of either Ad5.IL-1/IL-6- Luc (a) or Ad5.C3-Tat/HIV-Luc (b) into both knee
joints. After 1, arthritis was induced in the right knee joint by an intra-articular injection of 25 µg
SCW material; the left knee served as a within-animal control of the background transgene expres-
sion. At days 1, 7 and 14, histology was taken and joint inflammation (infiltration into synovium and
exudation of neutrophils into joint cavity on a 0-3 scale) was 1.5±0.1, 0.7±0.3 and 0.3±0.1, respective-
ly. A second SCW injection caused a flare-up of the inflammation resulting in a score of 1.2±0.3. The
luciferase activity in the synovial tissue was assessed at days 1, 7 and 14 of arthritis and is expressed as
RLU. At day 13, one group of animals received a second intraarticular injection of 25 µg SCW mate-
rial to reactivate the smouldering inflammation and the transgene promoter. The fold induction of
luciferase activity by arthritis is depicted in the bars.
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Discussion
Several groups have shown the feasibility of viral gene transfer of the inflamed joint for
treatment of arthritis in a large number of publications. The major challenge is to obtain
a tailor-made expression of therapeutic genes following the variable disease activity of
spontaneous remissions and exacerbations in RA. For this, we developed a hybrid pro-
moter system consisting of the human IL-1 enhancer sequence in front of the human IL-
6 promoter to allow autoregulation of the transgene during arthritis.
The IL-6 promoter region ( -163 to +12) alone showed little to no responsiveness in the
absence of the IL-1 enhancer region ( -3690 to  -2720) (Figure 1). We found that in the
murine macrophage cell line RAW 264,7, the LPS-induced upregulation of luciferase was
higher with the IL-1/IL-6 promoter than with the CMV promoter (Figure 2). Blocking IL-
1 with either IL-1 receptor antagonist protein or using neutralizing rabbit anti-IL-1 anti-
bodies had no effect on the LPS-induced promoter activation although it blocked the LPS-
induced NO production completely (data not shown). Murine recombinant IL-1a or IL-
1b had no effect on the IL-1/IL-6 promoter nor did it induce NO release in these cells (data
not shown). Kim and Son21 showed that neither IL-1, IL-2, IL-6 nor TNFα could induce
NO in RAW cells, but that NO was highly upregulated by LPS in the presence of IFNγ. Our
results suggest that for full activation by recombinant proteins these RAW cells probably
additionally need IFNγ. In the murine immortalized chondrocyte cell line (H4), the hybrid
promoter, however, responded to a wide range of cell stimuli as LPS and the cytokines IL-
1, IL-6, IL-17, IL-18, and TNFα (Figure 3a). Unexpectedly, the conventional CMV pro-
moter also showed the same responsiveness for IL-1a, TNFα and LPS (Figure 3b and c).
Moreover, the CMV immediate-early promoter has previously been shown to be regulat-
ed by various cytokines. It has been shown in monocytic and endothelial cells that the
human CMV promoter can be induced by PGE2, TNFα and IL-1β,22-24 probably in part
via NF-κB activation.25,26 TNFα has also been shown to negatively regulate the CMV
immediate-early promoter depending on the cell type studied.27,28 Based on our in vitro
studies and that of others, the human CMV immediate-early promoter may behave like the
IL-1/IL-6 enhancer-promoter construct. The difference found between the IL-1/IL-6
hybrid and CMV promoter in response to LPS in RAW cells suggests that we cannot
exclude that both promoters may respond differently in other target cells. We showed that
the endogenous iNOS gene was differently regulated than the IL-1/IL-6 promoter or the
CMV promoter in our chondrocyte cell line (Figure 3).
Our study confirmed the general problem encountered with the conventional CMV
promoter: high basal activity, transient and soon after nonresponsive probably due to
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promoter silencing in vivo (Figures 2, 3 and 5). The high background activity of CMV
was evident in both in vitro and in vivo situations. Furthermore, the amount of aden-
oviruses injected into the knee joint cavity only elicited a marginal joint inflammation.
Therefore, a significant contribution of viral-related inflammation on the basal CMV
activity was not likely to occur. The  cytokines, interferon-gamma and TNFα, can inhib-
it transgene expression controlled by most viral promoter/enhancers delivered by aden-
oviral, retroviral or plasmids in vitro.28 A specific transcriptional block as a result of
DNA methylation or chromatin condensation can silence viral promoters. Evidence is
emerging that the methyl-CpG-binding protein 2 (MeCP2) links DNA methylation with
histone deacetylases to form a transcriptional repression multiprotein complex.29,30 The
CMV-ie promoter has five palindromic CpG motifs that are potential sites of DNA
methylation and promoter silencing.31 We found that the histone deacetylase inhibitor
trichostatin A (TSA) can only partly reactivate the silenced CMV promoter in the syn-
ovial tissue ex vivo (manuscript in preparation). This showed that the silencing of the
CMV promoter is probably far more complex than CpG methylation alone.
The most important difference between the conventional CMV promoter and our IL-
1/IL-6 promoter is that the latter promoter was not silenced in vitro nor in vivo (Figures
2d, 5 and 9). This was illustrated by the rapid induction of the IL-1/IL-6-regulated Luc
expression by evoking SCW-mediated joint inflammation for a long period after trans-
duction Figure 5). Furthermore, Figures 2d and 9 show that the IL-1/IL-6 promoter was
not silenced irreversibly by an initial activation period and remained at least as respon-
sive for a second activation trigger. Only three short (6 bp sequence) palindromic CpG-
like sequences are present in our IL-1/IL-6 hybrid promoter, but either they did not
become methylated or are in a nonrelevant area of the promoter as we found no evidence
of promoter silencing. The reduced response at day 21 after infection with the Ad5.IL-
1/IL-6.Luc was related to the 80% loss of viral DNA.
It is possible that elimination of the adenoviral vector/ transfected cells contributed to
the loss of CMV-regulated transgene expression in mice. Recent studies showed that
TNFα plays an important role in the onset of an inflammatory response against aden-
oviruses and in eliciting an immune response against adenoviral and transgene prod-
ucts.32-34 Inhibition of TNFα in mice markedly prolonged adenoviral-mediated trans-
gene expression in mice.34,35 The CMV promoter gives a high constitutive expression,
and this might initiate an antiluciferase response thus eliminating the Ad5.CMV-Luc
transfected cells. This is less likely to happen with Ad5.IL-1/IL-6-Luc, as this promoter
exerts a low basal luciferase expression without stimulation. We found that at day 15 the
adenoviral DNA content in the murine knee joint was reduced to 40% of that measured
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at 1 day after infection, whereas the luciferase activity declined to 22% over that same
time period (Figure 6). The loss of viral DNA could be the result of immune response
against the transfected cells, but this cannot explain the complete unresponsiveness of
the CMV promoter in vivo (Figure 5). Unexpectedly, the CMV promoter seemed to per-
form quite well in the LPS-induced arthritis model in the rat.36,37 In these studies, the rat
synovium was stably transfected with an adeno-associated viral (AAV) vector. The CMV
promoter in AAV-transfected liver was, however, poorly inducible by LPS.38 As the AAV
genome integrates into host genome, it is possible that it undergoes position effect and
that enhancer elements from nearby promoter sites in the host genome crosstalk with the
CMV promoter in the AAV construct. So far, the evidence that the CMV promoter in an
AAV vector can be used for physiologically responsive gene therapy in other more rele-
vant arthritis models is lacking.
We previously achieved a disease-inducible transgene expression in experimental
arthritis using the two-component system described by Varley et al.16 This system was
developed to treat acute inflammatory diseases (eg sepsis) and was designed to give low
basal and induced short-term transgene expression.39 In this system, the viral HIV-LTR
promoter is also vulnerable to silencing by CpG methylation, but the transactivator of
transcription (Tat) protein can overcome the HIV-LTR promoter inactivation although
it was unable to demethylate both CpG sites in this promoter.40 In comparative studies,
we found that the IL-1/IL-6 hybrid promoter performed equally well as the C3-
Tat/HIVLTR two-component system and both systems responded to intra-articular
injections of LPS, SCW and zymosan (Figures 7-9). However, only the two-component
system was strongly dependent on the endogenous IL-6 activity in vivo (Figure 8). This
was expected as the complement C3 upregulation in response to an immunogen was
completely absent in the IL-6-/- mice41,42 and was probably regulated at the level of com-
plement C3 promoter activation.43,44 It is known that the TAT protein can transactivate
inflammatory host genes,45 including the IL-6 gene.46 It is plausible that the transactiva-
tion of IL-6 gene causes activation of the C3 promoter, which can explain the higher
background levels found with the C3-Tat/HIV two-component system as compared to
our IL-1/IL-6 construct (Figures 7 and 9). It must be emphasized that the basal transgene
levels and the fold induction using the C3-Tat/HIV two-component system were far bet-
ter in adenoviral-transfected HepG2 cells and in primary rat synovial fibroblasts.16,18 A
major difference was the 24-h serum (0.5% FBS) starvation used in these studies where-
as we performed our experiments in 5% FCS. Different batches of fetal calf serum may
contain varying amounts of growth factors, cytokines (IL-6) or traces of endotoxin, and
the C3-Tat/HIV two-component promoter system is extremely responsive to stimula-
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tion. In a recent pilot experiment, serum starvation of RAWcells (in an identical experi-
mental setup) did not affect both basal or the fold induction of Luc. activity by LPS.
Another important difference between both disease-inducible promoters is that the
Tat protein in the C3-Tat/ HIV-LTR system is a foreign immunogenic protein. Both the
IL-6 dependency and foreign Tat protein make the C3-Tat/HIV-LTR system in compar-
ison to the IL-1/IL-6 hybrid promoter less suitable for in the therapeutic approach of
gene transfer in RA.
There is circumstantial evidence (Figure 9) that with the IL-1/IL-6 hybrid promoter
but not the C3-Tat/HIVLTR system we experienced a contralateral effect on the activa-
tion of the promoter by the arthritic joint. The ‘contralateral effect’, that is the adminis-
tration of the expression vector in one joint to suppress arthritis in distal or contralater-
al joints, has been reported by many laboratories.47-52 This study, which shows activa-
tion of the IL-1/IL-6 enhancer-promoter in the contralateral joints by signals derived
from the arthritic joint, suggests that there is crosstalk between joints. Treatment of one
joint may interfere with this crosstalk and by this suppresses arthritis in the other con-
tralateral joint.
We demonstrated that our IL-1/IL-6 hybrid promoter upregulates transgene expres-
sion in response to a wide range of cytokines in vitro and during an acute joint inflam-
mation. The latter was induced by either zymosan (heat-inactivated yeast) or SCW
(Gram-positive bacterial cell walls) material, and both stimuli activate cells via dimeriza-
tion of toll-like receptors (TLR)-2 and TLR-6.53 The TLR-2/6 and TLR-4 (LPS receptor)
all can induce NF-κB activation and by this directly stimulate the IL-1/IL-6 receptor. For
this, we also investigated the IL-1/IL-6 promoter in an immune-mediated inflammation,
that of collagen-induced arthritis (CIA), and found that the IL-1/IL-6 promoter was
upregulated at the onset of CIA and that the amount of transgene (luciferase) correlated
with the severity of the joint inflammation (preliminary data).
In this study, we demonstrated that the IL-1/IL-6 promoter fulfills the criteria of a dis-
ease-inducible promoter: low basal activity and high during the acute inflammatory
response. This promoter might be feasible for auto-regulated protein drug treatment of
RA using adenoviral gene therapy.
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Materials and methods
Animals
For this study, C57Bl/6 male mice were obtained from Charles River (Sulzfeld, Germany).
Breeding pairs of IL-1α/β-deficient mice54 (a kind gift of Dr Y Iwakura, Center of
Experimental Medicine, University of Tokyo, Japan, who studied in conjunction with Dr
MG Netea, University Medical Center Nijmegen, The Netherlands) and IL-6 gene knock-
out55 (a kind gift of Dr M Kopf, Molecular Biomedicine, Swiss Federal Institute of
Technology Zurich, Zurich, Switzerland) were backcrossed into C57Bl/6 mice. The mice
were housed in filter-top cages. Mice were kept in low-pressure isolators and used between
10 and 12 weeks of age. They were fed a standard diet and tap water ad libitum. All in vivo
studies complied with national legislation and were approved by the local authorities
according to the ‘Care of Use of Animals’, with related codes of practice.
Construction of IL-1/IL-6 hybrid promoter
The human IL-6 promoter sequence ( -179/+12) was excised out of the PGL2 luciferase
reporter construct (kindly provided by Kishimoto56) and inserted into the SacI/XhoI
restriction sites of the PGL3 basic luciferase reporter vector (Promega). The human IL-1
gene region ( -3690/ -2720) with marked promoter enhancer activities57 was prepared by
the PCR method using human genomic DNA as a template and the oligonucleotide
primers (Eurogentec) — human IL-1β forward primer 5’-CTA CCC GCC ATC CAA
GAG GGA GAA GAA-3’, and the reverse primer 5’’-TAC CAT GGC TCG AGG GAA
ATT TTG GA-3’ — and blunt ligated into the Srf I site of the pCR-Script-SK(+) cloning
kit (Stratagene). The IL-1 enhancer sequence was inserted in the KpnI/SacI sites
upstream of the IL-6 promoter in the PGL3 basic luciferase reporter vector.
Adenoviral vectors and transduction
The IL-1/IL6 luciferase in PGL3 basic luciferase reporter vector was excised with SalI and
ligated into pShuttle (AdEasy system). Replication-deficient adenoviruses (E1 and E3
deleted) were prepared as described.58 Viral particles (v.p.) were measured spectropho-
tometrically by the method of Mittereded et al.59 To determine the titer of infectious
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viral particles (ffu), the vector stock was titrated on 911 cells (kind gift of Hoeben,
LUMC, the Netherlands60) and the viral capsid was detected 20 h after transduction by
immunohistochemistry.61 The v.p. and ffu per ml of the adenoviral vector stocks were
Ad5.CMV-Luc 1.5 x 1012 v.p., 1.2 x 1010 ffu, Ad5.IL-1/IL-6-Luc 5.4 x 1011 v.p., 9 x 109
ffu and Ad5.C3-Tat/HIV-Luc 2.9 x 1011 v.p., 6 x 109 ffu (kind gift of Munford, UT
Southwestern Medical Center, Dallas, TX, USA16).
In vitro transduction experiments
HIG-82 (rabbit synoviocyte cell line, ATCC), RAW 264,7 (murine macrophage cell line,
ATCC) and H4 (murine chondrocyte cell line62) were used in the transduction experi-
ments. Cells (5 x 105) were plated on a six-well culture plate (Costar), and transfected
with Lipofectamin 2000 (Invitrogene). After 24 h, cells were washed and thereafter stim-
ulated for 18 h. Cell culture supernatant was kept for nitrite measurement and cells were
harvested and cell lysate was obtained by osmotic and mechanical disruption. Protein
content and luciferase activity were assessed as described below.
Cells were plated in 96-well flat-bottom plates (1 x 105 cells/well) and 24 h later trans-
fected with adenoviruses at different MOI as indicated in the figures. In case of the RAW
cells, a CARex-Fc fusion protein (kindly provided by Hemmi, University of Z rich,
Switzerland) was used during infection (50 ng/107 ffu) for selective targeting of the ade-
novirus to the Fc-γ receptor type I (CD64), which will enhance the transduction up to
250-fold.63 After 2-3 h, cells were rinsed to reduce the number of free adenoviruses in
culture, and acclimated. After 20 h, cells were stimulated and their luciferase content was
measured 24 h later. Conditioned culture supernatants were stored at  -80°C until fur-
ther analysis for their nitrite content.
In vivo transduction experiments
Endotoxin-free stocks of the adenoviral vectors were diluted in physiological saline and
105-107 ffu in 6 ml was injected into the knee joint cavity.
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ZIA model
A homogeneous suspension of 300 µg of zymosan A (from Saccharomyces cerevisiae;
Sigma, St Louis, MO, USA), dissolved in 10 ml of endotoxin-free saline, was obtained by
repeated boiling, followed by sonic emulsification. The suspension was autoclaved and
stored in 0.5 ml aliquots at  -20°C. Arthritis was induced by intraarticular injection of
180 µg of zymosan through the suprapatellar ligament into the joint cavity. In all, 107 ffu
of the adenoviral vectors was intra-articularly injected 4 weeks after ZIA induction.
Streptococcus cell wall model
Cell walls from Streptococcus pyogenes were prepared as described previously.64
Unilateral arthritis was induced by intra-articular injection of 24 µg SCW in 6 µl PBS
into the right knee joint of C57/Bl6 mice.
Luciferase measurements
In vitro transduction experiments. To cell lysates in bidest Bright Glo (Bright Glot
luciferase assay system, Promega) was added and luciferase activity was measured
according to the manufacturer’s protocol.
In vivo transduction experiments. Patellae with surrounding tissue were dissected, put in
250 µl cell culture lysis buffer (Promega) and snap frozen in liquid nitrogen. Samples
were thawed, vortexed for 2 min, and centrifuged for 1 min at 10 000 g. We measured
luciferase in 10 µl of the supernatant with the luciferase assay system (Promega) accord-
ing to the manufacturer’s protocol in a luminometer (Polarstar galaxy, BMG, Germany).
Total protein concentration in the supernatant was determined with the Coomassie
Protein Assay Reagent (Pierce, Illinois, USA). The luciferase activity was expressed as rel-
ative light units (RLU) and normalized to total protein content of the cell/tissue extracts.
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Nitrite measurements 
The medium concentration of NO2 (a stable breakdown product of NO) was deter-
mined by Griess reaction using NaNO2 standards. The Griess reagent consisted of 0.1%
naphthylethylene diamine dihydrochloride, 1:1 diluted with 1.0% sulfanilamide in 5%
H3PO4. Briefly, 100 µl of the conditioned medium was mixed with 100 µl Griess reagent
in a flat-bottom microtiter plate, and adsorbance was read at 545 nm using an ELISA
plate reader.
Assessment of intra-articular adenoviral DNA
To determine the adenoviral DNA content in the synovial tissue, adenoviral DNA was
isolated by Hirt extraction, detected by PCR and analyzed on ethidium bromide-stained
agarose gel.65 Briefly, the synovial tissue was grinded in a mortar at 4°C in TE buffer.
Proteinase K was added and incubated for 1 h at 37°C. NaCl (5 M) was added and the
suspension was incubated overnight at 4°C and centrifuged at 4°C for 15 min at 15 000
g. In later experiments, sodium dodecyl sulfate (SDS) was used to inactivate proteins.
The adenoviral DNA in the supernatant was detected by PCR using the forward primer
(H1) 5’-GCC GCA GTG GTC TTA CAT GCA CAT C-3’ and the reverse primer (H2) 5’-
CAG CAC GCC GCG GAT GTC AAA GT-3’.66 Samples (5 µl) were taken at increasing
cycle numbers at five cycle intervals. The PCR products were analyzed on a 1.5% agarose
gel containing ethidium bromide. DNA was isolated from the gel and measured with
picogreen.
Statistical analysis 
Means ± sd of the various groups were determined and potential differences between the
groups were tested using the Mann-Whitney rank-sum test for all data.
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CHAPTER 8
________________________________________________________________
Summary and final considerations
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Joint disorders like osteoarthritis and rheumatoid arthritis can have great and long last-
ing effects on patients suffering from these diseases. In the affected joints elevated levels
of cytokines have been found. Depending on the type of cytokine these molecules can
have either negative or positive influences on disease progression and joint integrity. One
of the cytokines that is found to be elevated in joints of RA en OA patients is interleukin-
6. The existence of animal models for RA and OA and modern techniques like gene
knock out mice and viral overexpression systems have contributed to a huge amount of
knowledge on the role of cytokines in joint diseases. In the present thesis the role of IL6
in murine arthritis and osteoarthritis was investigated. 
In chapter 2 we started with a comparison of wild type and IL6 deficient mice in spon-
taneous and experimental osteoarthritis. Just as in humans, mice developed signs of OA
upon aging. In our study we found more spontaneous OA in old male IL6-/- mice than
in the wt controls. Old IL6-/- male mice showed the most severe cartilage loss, subchon-
dral bone sclerosis and proteoglycan (PG) deposition/bone formation in the ligaments.
OA development was studied in more detail in male mice. Cartilage PG synthesis and
breakdown were reduced in one year old IL6-/- mice. Total cartilage PG content, howev-
er, was not affected in old IL-6-/- mice. Also the bones were affected by IL6 deficiency as
we measured a lower bone mineral density of the total knee joint in old IL6-/- mice.
Collagenase injections in the knee joint led to severe signs of OA in both strains. This
suggests that one way of protection by IL-6 could be in regulating joint instability.
Together our results suggest a protective role for IL6 in OA and do not make it a likely
therapeutic target in this disease. 
In chapter 3 wt and IL6-/- mice were compared in different arthritis models.  Equal
inflammation in both strains was found in the short lasting immune-complex induced
arthritis. In the antigen-induced arthritis (AIA) we found that IL6-/- mice developed an
acute inflammatory reaction but the cellular infiltrate declined rapidly and IL6-/- joints
appeared non -inflamed by day 7 of AIA. WT mice, in contrast, developed a chronic
arthritis that lasted for more than 3 weeks. Gene expression for several important pro-
inflammatory cytokines, chemokines and adhesion-molecules were upregulated in the
synovial tissue during the first two days of the AIA and were indistinguishable between
the IL6-/- and wt mice. Immunized IL6-/- mice had lower antigen-specific IgG2a and
IgG2b titres as wt mice, but equal IgG1 titres. Lowering the amount of antigen during
immunization in wt mice reduced the IgG2A titres to levels that were found in IL6-/-
mice sensitised with the normal high amount of antigen. This, however, did not prevent
normal development of inflammation in these wt mice. Comparison of cytokine expres-
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sion in T cells indicated a shift to the Th1 subtype in wt mice and to the Th2 subtype in
IL6-/- mice. Transfer of antigen-specific wt lymph node cells to IL6-/- mice increased the
acute inflammation and cartilage damage but did not lead to development of a chronic
inflammation. Similar to our results in the AIA, we found that IL6-/- mice developed an
acute inflammation in the irritant induced zymosan-induced arthritis (ZIA) that failed
to proceed to the chronic phase. Taken together these different arthritis models showed
that IL6 played an important role in propagation of joint inflammation, potentially inde-
pendent of its role in immunity.
Signal Transducer and Activator of Transcription (STAT) molecules play an impor-
tant role in cytokine signaling. IL-6 can signal through activated STAT1 and STAT3.
Intra-cellular inhibition of signaling molecules in the synovium could be a good way to
inhibit the pro-inflammatory effects of IL-6 but to preserve the beneficial effects in car-
tilage. Therefore, in chapter 4, activation of STAT1 and STAT3 was investigated in the
joints of wt and IL6-/- mice during the acute and chronic phase of ZIA. STAT 3 was acti-
vated continuously during both acute and chronic inflammation in wt mice and this was
IL6 dependent. STAT 1, in contrast, became only activated in wt mice during the chron-
ic phase. The influx of PMN- and macrophages occurred in both strains and this exclud-
ed absence of these cells to be the cause of the impaired STAT activation in IL-6-/- mice.
Expression of the STAT-inhibitors SOCS-1 and -3 showed increased SOCS 3 expression
during both phases and increased SOCS 1 expression only during the chronic phase. In
STAT1-/- mice exacerbation of chronic joint inflammation occurred. In these mice STAT
3 was activated and SOCS 3 expression increased to the same extent as in the wt mice.
The expression of SOCS 1, however, was markedly reduced in the STAT1-/- mice.
Together these results suggest that IL6 could play a role in chronic joint inflammation
through STAT 3 activation, making it a likely target for inhibition. An opposed inflam-
mation-controlling role is proposed for STAT 1. 
The IL-6 family member Oncostatin M (OSM) is also expressed in the inflamed joints
of RA patients and might become an additional therapeutic target for STAT inhibition
because it also signals through the JAK-STAT pathway. Similar to IL-6, OSM has also
been described as a cytokine with both pro- and anti-inflammatory properties.
Therefore, the effects of OSM on the different components of the joint need to be inves-
tigated. In chapter 5 we investigated murine Oncostatin M induced joint pathology, with
an emphasis on inflammation and bone pathology, in wt and IL6-/- mice. Adenoviral
OSM gene transfer in the knee induced a pronounced joint inflammation that developed
also in the absence of IL6. In both strains OSM overexpression resulted in activation of
the periosteum leading to periosteal bone apposition. OSM, but not IL-6, could enhance
Summary and final considerations 157
bw-de hooge\50  30-08-2004  15:45  Pagina 157
the BMP-2 induced alkaline phosphatase expression/activity in C2C12 cells in vitro. This
suggests that OSM can stimulate bone formation by enhancing the activity of bone form-
ing factors. Bone formation occurred in vivo despite the expression of osteoclast activat-
ing RANKL and its receptor RANK in the synovium and periosteum.  Expression of the
RANKL antagonist osteoprotegerin (OPG) could shift the balance towards bone forma-
tion instead of resorption during the OSM-induced joint inflammation.
In chapter 6 OSM-induced joint pathology was further investigated in mice deficient
in IL1α/β, IL6, TNFα or INOS. At day 7, joint inflammation and cartilage PG depletion
were significantly reduced in IL1α/β-/- but not in the other mouse strains. By day 14,
inflammation, PG depletion and bone apposition did not differ between these strains.
OSM overexpression was found to affect growth plate integrity and PG content during
the first week in all except the IL1α/β-/- mice. Growth plate damage can occur in juve-
nile idiopathic arthritis (JIA) and we found that OSM protein is present in the synovial
fluid of children with JIA. Together these results show IL-1 dependence of OSM-induced
joint pathology and suggest that OSM could not only be important for joint pathology
in RA but also in JIA. 
In chapter 7 we made use of the data acquired from previous studies on the cytokine
expression profiles in our murine models of arthritis for the design of a disease-inducible
transgene expression cassette. An adenoviral vector was constructed containing the
human IL-6 promoter and the human IL1β enhancer region. Expression of the luciferase
reporter gene was rapidly silenced in vivo when the constitutively active viral CMV pro-
moter was used. In sharp contrast, the hybrid IL-1/IL-6 promoter showed a low basal
activity but high activity during the acute phase of arthritis. Furthermore, it could be
reactivated by a flare-up of the disease. By this study we showed feasibility of the IL-1/IL-
6 promoter construct to achieve disease regulated transgene expression that can be used
for tailor-made treatment of arthritis reducing the risk of side-effects that is expected
with the conventional uncontrolled expression systems.
Final considerations
IL-6, good or bad guy in RA? With this question, the research described in this thesis
started. Both pro- and anti-inflammatory properties had been described for IL-6.
Previous research in our lab had shown that IL-6 had a cartilage protective effect during
onset of zymosan-induced arthritis (ZIA) 1. Our present results in murine osteoarthritis
(OA) (chapter 2) further point towards this cartilage protective role for IL-6. 
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The role of IL-6 has been less studied in OA than in RA. In our study, cartilage loss
was increased in IL-6-/- mice. Also ex vivo PG synthesis and breakdown were reduced in
these mice. These effects of IL-6 deficiency could not only be important in OA but also
in RA. Although the net cartilage PG density was not affected, old IL-6-/- mice might be
more vulnerable to arthritic cartilage damage due to their reduced PG synthesis. This
could mean that previous studies, using young mice, might have underestimated the car-
tilage protective role of IL-6. Future experimental arthritis studies in older IL-6-/- mice
would therefore be very interesting. Based on our present and previous results IL-6 plays,
with regard to cartilage damage, a role as good guy in joint pathologies like RA and OA. 
A multifunctional cytokine like IL-6, however, also has properties that put it in a bad
perspective for RA. Previous studie2-4 mainly pointed at reduced antigen-specific immu-
nity in IL-6-/- mice during experimental RA. Our present results confirmed these data
but also showed that not only reduced immunity is involved in preventing development
of chronic arthritis in these mice (chapter 3). Similarly, Nowell et al. recently found that
injection of a IL-6/ soluble IL-6 receptor fusion protein enhanced joint inflammation in
IL-6-/- mice to wt levels at day 3 of AIA without enhancing antigen-specific immunity5. 
What are the roles that IL-6 plays in the arthritic joint? Circumstantial evidence shows
that IL-6 plays a role in orchestrating the switch from PMN- to monocyte/macrophage-
influx. In this way IL-6 could then contribute to development of chronic arthritis. Most
evidence was obtained using a peritonitis model in IL-6-/- mice6. Our present results sug-
gest that IL-6 plays a different role in joint inflammation. Synovial gene expression for
chemokines, adhesion-molecules and other pro-inflammatory cytokines was equally
induced in wt and IL-6-/- mice during onset of antigen-induced arthritis (AIA) (chapter
3). Immunohistochemistry of ZIA even showed that macrophages could enter the joint
in IL-6-/- mice (chapter 4). IL-6 therefore does not seem to be necessary for mono-
cyte/macrophage influx in this model and might be involved in other aspects of joint
inflammation.
Our results on STAT activation during ZIA could point at a different role for IL-6.
Lack of STAT1/3 phosphorylation despite presence of PMN’s, macrophages and syn-
oviocytes in the joints of IL-6-/- mice (chapter 4) could mean that these cells are not acti-
vated properly or that certain pro-inflammatory pathways are blocked in these mice.
Possible examples could be pathways related to apoptosis/anti-apoptosis, cell cycling and
proliferation. One way to address this could be large-scale gene comparison between wt
and IL-6-/- mice with for example micro-arrays.
Based on our results one could say that IL-6 plays a protective role with regard to car-
tilage but a pro-inflammatory role in the synovium. Future anti-IL-6 therapies should be
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developed in a way that they inhibit its actions in the synovium but preserve them in car-
tilage. There are several possibilities to inhibit IL-6 in RA. Administrating antibodies
against IL-6 or the IL-6 receptor is an option that is now showing positive effects in first
clinical trials7. Alternatives are biologicals like soluble GP130, mutated IL-6 or soluble
IL-6 receptor molecules5;8. It remains, however, to be determined if the IL-6 produced
in the cartilage itself is enough to have a protective effect or that additional IL-6 from the
synovium is necessary. This would have consequences for IL-6 inhibitory therapies in the
synovium. Based on our results in chapter 4, selective inhibition of STAT3 signaling
could be a way to restrict anti-IL-6 therapies to the synovium. Either introducing or
enhancing expression of dominant-negative STATs or of other inhibitors like the SOCS
and PIAS proteins in the synovium could be a way to accomplish this selective inhibi-
tion. Alternatively, enhancement of STAT1 signaling could also have anti-inflammatory
effects.
Gene therapy would be an option to achieve overexpression of e.g. SOCS proteins in
the synovium. Previously Shouda et al.9 showed that adenoviral gene transfer of SOCS3
could inhibit collagen-induced arthritis (CIA). In their study, however, the virus was
injected peri-articular in the ankle. Intra-articular gene delivery in contrast is more dif-
ficult. Intra-articular injection of an adenoviral SOCS3 vector in the knee joint did not
inhibit CIA in our hands (manuscript in preparation). We showed previously that stan-
dard adenoviral vectors were limited in their way to penetrate the synovium and that
modifications of the adenoviral fiberknob could enhance gene transfection in this tis-
sue10. Further development of these vectors must therefore take place to make gene ther-
apy a practical option for treatment of RA.
One such improvement is shown in chapter 7. The IL-6 promoter was used to con-
struct an adenoviral vector with a disease-inducible promoter. Expression of a therapeu-
tic gene cannot only be locally but also temporally restricted with this vector. Controlled
expression of anti-IL-6 molecules would be desirable since long term cytokine blocking
could lead to problems with infections. This occurs, for example, in part of the patients
on anti-TNF-α therapy11. Furthermore, complete and long-term suppression of IL-6
could have adverse effects for cartilage or bone as shown in chapter 2. Our IL-1/IL-6 pro-
moter construct could become a good tool towards local, disease-inducible anti-IL-6
therapy in the synovium.
Another member of the IL-6 family that is expressed in the inflamed joints of RA
patients is Oncostatin M. In chapters 5 and 6 we show that overexpression of murine
OSM can induce joint inflammation in naive mice. This was independent of IL-6 but
dependent on IL-1. OSM, like IL-6, can activate STAT3. Therapies aimed at inhibiting
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signaling by the GP130/JAK/STAT route could therefore have a broader range than just
inhibition of IL-6. The observed periosteal bone apposition in the inflamed joints (chap-
ter 5) illustrates that OSM, like IL-6, can both be a good (anabolic factor for bone) and
a bad guy (inducing joint inflammation and cartilage damage) during joint pathology. 
One interesting effect of OSM overexpression was that the growth plates became
affected. This raised our interest to investigate OSM expression in juvenile idiopathic
arthritis (JIA). We could indeed measure OSM expression in most of the synovial JIA flu-
ids that we tested. Research is under way to screen a larger JIA patient population for
OSM expression. OSM expression in our JIA group was lower than the expression that is
reported for RA12. For possible anti-OSM therapies in JIA this could be an advantage. Its
synergistic effect on other proinflammatory cytokines might lead to an even broader
therapeutic effect of anti-OSM treatment. This synergistic effect on other cytokines has
for example been demonstrated for IL-112 and was also found by us for BMP-2.
To generally conclude this thesis we propose that IL-6 plays a protective role in
osteoarthritis and should not be inhibited in this disease. With regard to arthritis, IL-6 is
a good guy related to cartilage but a bad guy related to inflammation of the synovium.
We furthermore propose that specific inhibition of IL-6 signaling in the synovium might
be a way to prevent this pro-inflammatory role of IL-6.
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Samenvatting
Reumatoïde artritis (RA) is de bekendste vorm van reumatische gewrichtsaandoeningen.
Het is een immunologische ziekte waarbij de eigen afweercellen zich richten tegen
lichaamseigen structuren in de gewrichten. Dit leidt tot een chronische ontsteking die het
kraakbeen en bot aantast. In het ontstoken gewricht worden veel verschillende cytokines
gemaakt. Dit zijn zgn. boodschappereiwitten die een rol spelen bij de communicatie tussen
cellen. Deze cytokines kunnen positieve als ook negatieve effecten hebben op de cellen in
het ontstoken gewricht. Een cytokine dat veel gemaakt wordt in ontstoken gewrichten, is
interleukine-6 (IL-6). IL-6 heeft eigenschappen die het zowel gunstig als ongunstig maken
voor de reuma patiënt. In dit proefschrift is de rol van IL-6 in gewrichtsaandoeningen
nader onderzocht in muizenmodellen met normale (IL-6+/+) en IL-6 knock-out (IL-6-/-)
muizen. Deze laatste stam mist het IL-6 gen en maakt daardoor geen IL-6.
Eerder onderzoek op ons lab had aangetoond dat IL-6 een beschermende rol heeft voor
het gewrichtskraakbeen tijdens het begin van de ontsteking. De vraag of  IL-6 onafhanke-
lijk van een ontsteking kraakbeen kan beschermen is niet alleen relevant voor artritis maar
ook voor  artrose (osteoarthritis of OA), een zeer veel voorkomende gewrichtsziekte waar-
bij kraakbeenschade optreedt maar waarbij ontsteking een minder belangrijke rol speelt. In
hoofdstuk 2 is de rol van IL-6 in relatie tot kraakbeenschade nader onderzocht in oude
IL6+/+ en IL-6-/- muizen. Hierbij werd gevonden dat oude IL-6-/- mannetjes muizen meer
en ernstiger artrose hadden dan oude IL-6+/+ mannetjes. Naast meer verlies van kraakbeen
hadden de oude IL-6-/- mannetjes meer verbening van de kniebanden en meer verdichting
van het bot onder het kraakbeen. Tijdens de veroudering nam tevens de synthese van
bepaalde kraakbeen componenten af en verloor het bot meer mineralen in IL-6-/- manne-
tjes. Dit suggereert een belangrijke beschermende rol voor IL-6 tijdens artrose. Tevens ver-
sterkt deze uitkomst de kraakbeenbeschermende rol in het gewricht die wij eerder vonden
tijdens arthritis.
In hoofdstuk 3 en 4 werd de rol van IL-6 in het ontstekingsproces nader onderzocht. In
hoofdstuk 3 werden IL-6+/+ en IL6-/- muizen vergeleken in verschillende reuma modellen.
In al deze modellen ontwikkelen IL-6-/- muizen wel een acute ontsteking. Deze gaat echter
niet over in een chronische ontsteking. In de immunologische modellen vonden wij dat IL-
6 een rol speelt bij de productie van zowel antilichamen als T cellen die specifiek gericht
zijn tegen een eiwit waarmee de ontsteking werd uitgelokt. Hierbij speelde een verandering
in het type T cellen dat gemaakt werd in de IL6-/- muizen de grootste rol. Transplantatie
van normale T cellen maakte de ontsteking in IL-6-/- muizen echter niet chronisch.
Aangezien de ontsteking ook niet chronisch werd bij een niet-immunologisch model sug-
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gereert dit dat IL-6 belangrijk is voor immuniteit maar ook op een andere manier een
belangrijke rol speelt bij het ontstaan van chronische ontsteking in gewrichten.
In hoofdstuk 4 is gekeken naar de signaaloverdracht van IL-6. IL-6 bindt aan specifieke
receptoren aan de buitenkant van de cel. Hierna worden in de cel zgn. STAT eiwitten geac-
tiveerd. Dit zijn STAT1 en STAT3. Na activatie kunnen deze STAT’s aan elkaar binden en
naar de celkern verhuizen. In de celkern kunnen zij specifiek bepaalde genen in het DNA
aanzetten. In het niet-immunologische zymosan model (gistdeeltjes inspuiten in de knie)
vonden wij continue activatie van STAT3 in het ontstoken gewricht. STAT1 activatie kwam
alleen tijdens de chronische fase van de ontsteking voor. Deze STAT activatie ontbrak in
IL-6-/- muizen. De betekenis van de STAT1 activatie werd onderzocht in STAT1-/- muizen.
Deze muizen lieten een verergering van de ontsteking zien. STAT3 activatie was normaal
in deze muizen. Dit suggereert dat IL-6 via STAT3 een pro-inflammatoire rol speelt en dat
STAT1 ontstekingremmend werkt. 
In hoofdstuk 5 en 6 is de rol van een familielid van IL-6, oncostatine M (OSM), in ge-
wrichtsontsteking onderzocht. In hoofdstuk 5 werd een adenovirus gebruikt als drager om
het muizen OSM gen in de knie van IL-6+/+ en IL-6-/- muizen te brengen en actief te ma-
ken. OSM kan in de knie een ontsteking starten, ook zonder IL-6. OSM productie leidde
echter ondanks de ontsteking ook tot vorming van nieuw bot. Dit laatste zou een positief
effect kunnen zijn van OSM. In hoofdstuk 6 is de afhankelijkheid van de OSM-geïndu-
ceerde ontsteking van andere cytokines onderzocht. Naast ontsteking en botvorming treedt
ook kraakbeenschade op onafhankelijk van IL-6 en TNF-a. De afwezigheid van IL-1 daar-
entegen had wel een remmend effect op schade en ontsteking. Opvallend was dat OSM ook
de groeischijf aantastte. Groeischijven zijn nog actief bij kinderen en OSM zou daarom een
rol kunnen spelen bij schade aan de groeischijf bij jeugdreuma. In vocht van ontstoken
gewrichten van kinderen met jeugdreuma konden wij productie van OSM aantonen.
De voorafgaande hoofdstukken toonden aan dat IL-6 en OSM zowel positieve als nega-
tieve effecten hebben in ontstoken gewrichten. Vooral in het ontstoken gewrichtskapsel
zou het goed zijn om IL-6 te remmen. Met remmers van STAT3 (hoofdstuk 4) zou men
daar lokaal  het effect van IL-6 kunnen remmen terwijl de positieve werking op kraakbeen
behouden blijft. In hoofdstuk 7 beschrijven wij een adenovirus dat gebruikt kan worden
om zulke remmers of andere therapeutische eiwitten lokaal te laten maken in het gewricht.
In dit virus is de productie van het therapeutische eiwit afhankelijk van prikkels die de IL-
6 productie stimuleren. Deze zgn. ontstekingsafhankelijke vector kan op momenten van
actieve ziekte de productie van therapeutische eiwitten sterk verhogen. Hiermee zou het in
de toekomst mogelijk moeten worden om in het gewricht en afhankelijk van de ziekte-acti-
viteit IL-6 en andere pro-inflammatoire cytokines te remmen.
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